0001144204-13-008541.txt : 20130214 0001144204-13-008541.hdr.sgml : 20130214 20130214093213 ACCESSION NUMBER: 0001144204-13-008541 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20121231 FILED AS OF DATE: 20130214 DATE AS OF CHANGE: 20130214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China YCT International Group, Inc. CENTRAL INDEX KEY: 0000847464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 652954561 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53600 FILM NUMBER: 13606869 BUSINESS ADDRESS: STREET 1: GUCHENG ROAD SICHUI COUNTY STREET 2: SHANDONG PROVINCE CITY: SICHUI STATE: F4 ZIP: 273200 BUSINESS PHONE: 86-537-4268278 MAIL ADDRESS: STREET 1: GUCHENG ROAD SICHUI COUNTY STREET 2: SHANDONG PROVINCE CITY: SICHUI STATE: F4 ZIP: 273200 FORMER COMPANY: FORMER CONFORMED NAME: itLinkz Group, Inc. DATE OF NAME CHANGE: 20070406 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL TECHNOLOGY & INNOVATIONS INC /FL/ DATE OF NAME CHANGE: 19960118 FORMER COMPANY: FORMER CONFORMED NAME: SOUTHSTAR PRODUCTIONS INC DATE OF NAME CHANGE: 19960118 10-Q 1 v334341_10q.htm FORM 10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

xQUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2012

 

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to _____________

 

Commission file number: 0-53600

 

CHINA YCT INTERNATIONAL GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 65-2954561
(State or other jurisdiction of incorporation or (IRS Employer Identification No.)
organization)  
   
c/o Shandong Spring Pharmaceutical Co., Ltd Economic  
Development Zone. 273200
Gucheng Road Sishui County Shandong Province PR China  
   
(Address of principal executive offices) (Zip Code)

 

Issuer's telephone number: 406-282-3188

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x   No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer                           Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)  Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

 

The number of shares outstanding of the issuer’s common stock on February 11, 2013 was 29,575,523.

 

 
 

 

CHINA YCT INTERNATIONAL GROUP, INC.

FORM 10-Q

QUARTERLY PERIOD ENDED DECEMBER 30, 2012

 

INDEX

TABLE OF CONTENTS

 

        Page
         
    PART I - FINANCIAL INFORMATION    
         
Item 1:   Financial Statements   3
         
Item 2:   Management's Discussion and Analysis of Financial Condition and Results of Operations   15
         
Item 3:   Quantitative and Qualitative Disclosures About Market Risk   22
         
Item 4:   Controls and Procedures   22
         
    PART II - OTHER INFORMATION    
         
Item 1:   Legal Proceedings   23
         
Item 1A:   Risk Factors   23
         
Item 2:   Unregistered Sales of Equity Securities and Use of Proceeds   23
         
Item 3:   Defaults Upon Senior Securities   23
         
Item 4:   Removed and Reserved   23
         
Item 5:   Other Information   23
         
Item 6:   Exhibits   23

 

1
 

 

Item 1. Financial Statement

 

CHINA YCT INTERNATIONAL GROUP, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED DECEMBER 31, 2012 AND 2011 (UNAUDITED)

 

Table of Contents

 

    Page
     
Consolidated Balance Sheets as of December 31, 2012 (Unaudited) and March 31, 2012   4
     
Consolidated Statements of Income for the three and nine months ended December 31, 2012 and 2011 (Unaudited)   5
     
Condensed Consolidated Statements of Stockholders' Equity for the three and nine months Ended December 31, 2012 (Unaudited) and March 31, 2012   6
     
Consolidated Statements of Cash Flows for the nine months Ended December 31, 2012 and 2011 (Unaudited)   7
     
Notes to Consolidated Financial Statement   8-16

 

2
 

 

CHINA YCT INTERNATIONAL GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

 

       UNIT: USD$ 
   December 31, 2012   March 31, 2012 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalent  $27,314,507   $22,146,240 
Accounts receivable   -    115,938 
Prepaid accounts   20,916    20,887 
Inventory   2,561,052    1,978,488 
Total current assets   29,896,475    24,261,553 
Plant, property and equipment, net   9,495,483    9,663,338 
Construction in progress   220,291    219,983 
Intangible assets, net   17,927,772    18,863,510 
Total assets   57,540,021    53,008,384 
           
Liabilities and Stockholders’ Equity (Deficit)          
Liabilities:          
Current liabilities:          
Tax payable   424,872    1,018,543 
Other payable   2,042,279    4,766,952 
Total current liabilities   2,467,151    5,785,495 
Derivative liabilities   -    5,531,892 
Total liabilities   2,467,151    11,317,387 
           
Stockholders’ Equity          
Preferred stock, par value $500.00 per share; 45 shares authorized and issued at September 30, 2012 and March 31, 2012   22,500    22,500 
Common stock, par value $0.001 per share; 100,000,000 shares authorized, 29,575,523 shares issued and outstanding at December 31, 2012; and 73,780,610 shares issued and outstanding at March 31, 2012, respectively   29,575    73,780 
Additional paid-in capital   4,180,183    36,879,643 
Statutory reserve   956,633    956,633 
Retained earnings   46,237,617    417,285 
Accumulated other comprehensive income   3,646,362    3,341,156 
Total stockholders’ equity   55,072,870    41,690,997 
Total liabilities and stockholders’ equity  $57,540,021   $53,008,384 

 

3
 

 

CHINA YCT INTERNATIONAL GROUP, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)

 

UNIT: USD$ 

   FOR THE THREE MONTHS ENDED   FOR THE NINE MONTHS ENDED 
   December 31, 2012   December 31, 2011   December 31, 2012   December 31, 2011 
                 
Sales Revenue  $6,922,363   $10,112,489   $23,521,007   $26,477,760 
Cost of Goods Sold   3,450,065    4,712,730    11,367,854    11,894,299 
Gross Profit   3,472,298    5,399,759    12,153,153    14,583,461 
Selling Expenses   552,318    713,694    2,216,642    2,505,249 
G&A Expense   1,184,227    1,570,674    2,387,125    4,028,897 
R&D Expenses   723,790    183,693    1,272,490    577,514 
Total expense   2,460,335    2,468,061    5,876,257    7,111,660 
Income from operation   1,011,963    2,931,698    6,276,896    7,471,801 
Interest income (Expense)   23,346    65,818    82,138    209,953 
Other income (Expense)   3,872,370    (3,319,135)   8,297,884    (3,319,135)
Profit before tax   4,907,679    (321,619)   14,656,918    4,362,619 
Income tax   258,827    1,112,777    1,585,251    2,283,837 
Net income   4,648,852    (1,434,396)   13,071,667    2,078,782 
Other comprehensive income                    
Foreign currency translation adjustment   474,863    (1,724)   305,206    847,925 
Comprehensive income  $5,123,715   $(1,436,120)  $13,376,873   $2,926,707 
Basic and diluted income per common share                    
Basic and Diluted   0.11    0.00    0.22    0.03 
                     
Weighted average number of common shares outstanding                    
Basic and Diluted   43,029,245    73,780,610    60,029,581    73,780,610 

 

4
 

 

CHINA YCT INTERNATIONAL GROUP, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

UNIT: USD$ 

   Preferred Stock
Series A
   Common shares   Additional
   Statutory   Accumulated   Retained    
   Shares   Amount   Shares   Amount   paid-in capital   Reserve   OCI    Earnings   Total 
Balance - March 31, 2012   45   $22,500    73,780,610   $73,780   $36,879,643   $956,633    3,341,156   $417,285   $41,690,997 
Issuance of common shares to independent directors             50,000    50    4,950                   5,000 
Net income for the year                                      2,252,710    2,252,710 
Foreign currency translation adjustment                                 (40,878)        (40,878)
                                              
Balance - June 30, 2012   45   $22,500    73,830,610   $73,830   $36,884,593   $956,633    3,300,278   $2,669,995   $43,907,829 
Net income for the year                                      6,170,105    6,170,105 
Foreign currency translation adjustment                                 (128,779)        (128,779)
                                              
Balance - September 30, 2012   45   $22,500    73,830,610   $73,830   $36,884,593   $956,633   $3,171,499   $8,840,100   $49,949,155 
Cancellation of issued stock for return of patent             (44,255,087)   (44,255)   (32,704,410)             32,746,665    - 
Net income for the year                                      4,648,852    (3,649,032)
Foreign currency translation adjustment                                 474,863         474,863 
                                              
Balance - December 31, 2012   45   $22,500    29,575,523   $29,575   $4,180,183   $956,633   $3,646,363   $46,237,617   $55,072,870 

 

5
 

 

CHINA YCT INTERNATIONAL GROUP, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW
(Unaudited)

 

UNIT: USD$ 

   NINE MONTHS ENDED 
   December 31, 2012   December 31, 2011 
Cash Flows From Operating Activities:          
Net income  $13,071,667   $2,078,782 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   1,225,386    3,693,018 
Common stock cancellation pursuant to the Termination Agreement   (2,765,993)   - 
Unrealized gain on fair value of derivative   (5,531,892)   - 
Issue of common shares as compensation   5,000    - 
Changes in operating assets and liabilities:          
Inventory   (582,564)   (2,424,798)
Accounts receivable   115,938    - 
Taxes payable   (593,671)   (248,678)
Accrued expenses and other payables   41,319    7,620,588 
Net cash provided by (used in) operating activities   4,985,291    10,718,912 
Cash flows from investing activities:          
Addition to plant and equipment   (73,502)   (14,704,423)
Prepayment/(deposit) to Jining Tianruitong for purchase of patents   -    15,534,631 
Net cash provided by (used in) investing activities   (73,502)   830,208 
Effect of exchange rate changes on cash and cash equivalents   256,578    847,926 
Net increase (decrease) in cash and cash equivalents   5,168,267    12,397,046 
Cash and cash equivalents at beginning of period   22,146,240    6,046,804 
Cash and cash equivalents at ending of period   27,314,507   $18,443,850 
Supplemental disclosures of cash flow information:          
Cash paid during the periods for:          
Interest  $82,138.00    - 
Income taxes  $2,178,922   $2,178,687 
Non-cash financing activities:          
Stock issued for services   50,000      
Stock cancelled for return of patent   44,255,087    - 

 

6
 

 

NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES

 

China YCT International Group, Inc. (“China YCT”) was incorporated in the State of Florida, in the United States of America (the “USA”) in January 1989, and reincorporated in the State of Delaware on April 4, 2007.   China YCT principally operates through directly owned subsidiaries: Landway Nano Bio-Tech, Inc. (100% owned), incorporated in Delaware, and Shandong Spring Pharmaceutical Co., Ltd. (“Shandong Spring”), (100% owned), incorporated in the People’s Republic of China (“PRC”). China YCT International Group, Inc. and its subsidiaries are collectively referred to as the “Company.”

 

China YCT, through its wholly owned subsidiary, Shandong Spring, is engaged in the business of developing, manufacturing and selling its own medicine from gingko extract, and other dietary supplement products in the P.R. China.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

 

Principles of consolidation

 

The consolidated financial statements include the financial statements of China YCT, Landway Nano and its wholly owned subsidiary, Shandong Spring.  All inter-company transactions and balances are eliminated in consolidation.

 

Use of estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.

 

Cash and cash equivalents

 

For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Inventory

 

Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of cost or market with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.

 

Property and equipment

 

Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:

 

Building 30-35 years
   
Machinery, equipment and automobiles 7-15 years
   
Furniture and fixtures 7-10 years

 

Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.

 

7
 

 

Intangible Assets

 

(i)   Land Use Rights:

 

All land in the PRC is owned by the government and cannot be sold to any individual or company.  However, the government may grant a “land use right” for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.

 

(ii)   Patents:

 

In March 2010, the Company purchased one patent from Shandong YCT Corp.  The patent is the Company’s exclusive right to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.  The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.

 

In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are “Treatment to ischemic encephalopathy and its preparation method” (ZL200510045001.9) and “Chinese herbal medicine compound to treat renal insufficiency and its preparation” (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.

 

Revenue recognition

 

The Company’s revenue recognition policies are in compliance with Staff Accounting Bulletin (“SAB”) 104, included in the Codification as ASC 605, Revenue Recognition. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.

 

Impairment of long-lived assets

 

The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Per ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Per ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).

 

Income taxes

 

The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (”SFAS”) No. 109, “ Accounting for Income Taxes ”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred Income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2012 and March 31, 2012.

 

China YCT International, Inc. is a holding company of Shandong Spring Pharmaceutical Co., Ltd and does not have any operating activities. Although the contract for the acquisition of the US patent acquired in February 2011 from LY Research Corp. was executed by the holding company, in substance, the patent was acquired by the Company’s operating entity in China. Therefore, the patent related income or expense does not result in any US income tax liabilities.

 

Value-added tax

 

Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (“VAT”). All of the Company’s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.

 

8
 

 

The Company recorded net VAT Payable in amount of $369,944 and $225,223 as of December 31, 2012 and March 31, 2012, respectively.

 

Research and development

 

Research and development costs relate to the Company’s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.

 

The research and development expense for the three months ended December 31, 2012 and 2011 was $723,790 and $183,693, respectively.

 

The research and development expense for the nine months ended December 31, 2012 and 2011 was $1,272,490 and $577,514, respectively.

 

Advertising costs

 

Advertising costs for newspaper and television are expensed as incurred.

 

The Company incurred advertising costs of $158,750 and $157,712 for the three months ended December 31, 2012 and 2011, respectively.

 

The Company incurred advertising costs of $759,866 and $390,452 for the nine months ended December 31, 2012 and 2011, respectively.

 

Mailing and handling costs

 

The Company accounts for mailing and handling fees in accordance with the FASB ASC 605-45 (Emerging Issues Task Force ( EITF ) Issue No . 00-10 , Accounting for Shipping and Handling Fees and Costs ). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.

 

For the three months ended December 31, 2012 and 2011, the Company incurred $218,820 and $1,475 mailing and handling costs, respectively.

 

For the nine months ended December 31, 2012 and 2011, the Company incurred $765,413 and $662,629 mailing and handling costs, respectively.

 

Stock Based Compensation

 

The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.  The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.

 

Net income (loss) per share (“EPS”)

 

Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.

 

There are nil and 31,610,679 common stock equivalents available for dilution purposes as of December 31, 2012 and 2011, respectively.

 

9
 

 

Risks and uncertainties

 

The Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

As of December 31, 2012, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.

 

Foreign currency translation

 

The accounts of the Company’s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (“ASC”) Topic 830 “Foreign Currency Matters,” with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders’ equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, “Comprehensive Income.” Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.

 

Translation adjustments resulting from this process amounted to $3,646,363 and $3,341,156 as of December 31, 2012 and March 31, 2012, respectively.

 

The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:

 

   December 31,
2012
   March 31,
2012
   December 31,
2011
 
Quarter End RMB Exchange Rate (RMB/USD$)   6.2855    6.2943    6.3009 
Quarterly Average RMB Exchange Rate (RMB/USD$)   6.2992    6.3933    6.3403 

 

Recent accounting pronouncements

 

In July 2012, FASB issued an amendment to the FASB Codification Topic 350 – Testing Indefinite-Lived Intangible Assets for Impairment. The objective of the amendments in this Update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-lived asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles – Goodwill and Other – General Intangibles Other than Goodwill. The more likely-than-not threshold is defined as having a likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company decided to adopt the amendment for the year starting with April 1, 2013. The Company does not expect the adoption of this pronouncement to have a significant impact on its financial condition or results of operations.

 

NOTE 3 – PREPAID ACCOUNTS

 

The prepaid account is a prepayment to Shandong YCT for purchase of its health products. The amount is $20,916 and $20,887 as of December 31, 2012 and March 31, 2012, respectively.

 

10
 

 

NOTE 4 - INVENTORY

 

Inventory consists of finished goods, work-in-process, and raw materials. No allowance for inventory was made for the three months and nine months ended December 31, 2012 and 2011. The components of inventories were as follows:

 

   Period Ended 
   December 31,
2012
   March 31,
2012
 
Raw materials  $1,112,873   $272,873 
Work-in-progress   668,309    414,390 
Finished goods   779,870    1,291,225 
Total Inventories  $2,561,052   $1,978,488 

 

NOTE 5 – PLANT, PROPERTY AND EQUIPMENT, NET

 

The components of property and equipment were as follows:

 

   Period Ended 
   December 31,
2012
   March 31,
2012
 
Machinery & Equipment  $617,363   $538,461 
Furniture & Fixture   164,767    164,536 
Building   10,123,714    10,109,560 
Subtotal   10,905,844    10,812,557 
Less: Accumulated Depreciation   (1,410,361)   (1,149,219)
Total plant, property and equipment, net  $9,495,483   $9,663,338 

 

The depreciation expense for the three months ended December 31, 2012 and 2011 was $84,813 and $27,885, respectively.

 

The depreciation expense for the nine months ended December 31, 2012 and 2011 was $261,143 and $155,283, respectively.

 

NOTE 6 – CONSTRUCTION IN PROGRESS

 

Construction in progress represents direct costs of construction or acquisition and design fees incurred for the Company’s new plant and equipment. Capitalization of these costs ceases and the construction in progress is transferred to plant and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is made until construction is completed and put into use.

 

NOTE 7 - MAJOR CUSTOMER AND VENDOR

 

In the three and nine months ended December 31, 2012, the Company mainly sold products to individual retail customers through nine major distributors.

 

For the three months ended December 31, 2012, the purchases from four major vendors was $1,802,900, representing 80% of the Company’s total purchases for the quarter.

 

For the nine months ended December 31, 2012, the purchases from four major vendors was $9,445,424, representing 75% of the Company’s total purchases for the period.

 

NOTE 8 - INTANGIBLE ASSETS, NET

 

The intangible assets of the Company consist of land use right and purchased patents.

 

11
 

 

Net land use right and purchased patents were as follows:

 

       Amortization   As of 
     Period   December 31, 2012   March 31, 2012 
Land use right   50 years   $1,614,510   $1,612,252 
Less: Accumulated amortization        (202,597)   (178,052)
Land use right, net        1,411,913    1,434,200 
Patent 1   16.5 years    7,318,430    7,308,199 
Patent (non-US No. ZL200510045001.9)   13.75 years    9,863,973    9,850,182 
Patent (non-US No. ZL200710013301.8)   14.95 years    1,590,963    1,588,739 
Less: Accumulated amortization        (2,257,508)   (1,317,810))
Patents, net       $16,515,858   $17,429,310 

 

The amortization expense of land use right for the three months ended December 31, 2012 and 2011 was $9,831 and $9,439, respectively.  The amortization expense of patents for the three months ended December 31, 2012 and 2011 was $330,933 and $1,419,727, respectively.

 

The amortization expense of land use right for the nine months ended December 31, 2012 and 2011 was $24,545 and $29,856, respectively.  The amortization expense of patents for the nine months ended December 31, 2012 and 2011 was $939,698 and $3,315,517, respectively.

 

NOTE 9 - TAX PAYABLE

 

Tax payable as of December 31, 2012 and March 31, 2012 were as follows:

 

   As of 
   December 31,
2012
   March 31,
2012
 
         
Corporate Income Tax  $25,502   $774,423 
Value-Added Tax   369,944    225,223 
Other Tax & Fees   29,426    18,897 
           
Total Tax Payable  $424,872   $1,018,543 

 

NOTE 10 - INCOME TAXES

 

Shandong Spring Pharmaceutical Co., Ltd. is subject to the Enterprise income tax (“EIT”) at a statutory rate of 25%.

 

The expense associated with the recognition of a contingent obligation under ASC 480-10-25-8, is not tax deductible in China. Per ASC 740-10-25-3A, “An excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary or a foreign corporate joint venture that is essentially permanent in duration. ” Therefore, the tax difference in the amount of $1,382,973 ($5,531,892 x 25% tax rate) caused by expense recognized on our book but not in the Chinese tax purpose at March 31, 2012 will be a permanent difference.

 

On February 28, 2011, the Company purchased a patent (the “US Patent”) pursuant to the terms of a purchase agreement with L.Y. Research Corp., a New Jersey corporation (“LY Research”), which purchase agreement was amended and restated on August 15, 2011 and amended on October 21, 2011 (the “Purchase Agreement), On October 29, 2012, due to the fact that the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a termination agreement to formally terminate the Purchase Agreement, and return the US Patent and the shares to LY Research and the Company, respectively. Prior to termination of the purchase agreement, the Company had conducted an impairment analysis with respect to the US Patent and concluded that an impairment was warranted. The loss from impairment of the US patent is not tax deductible in China. Therefore, the tax difference in the amount of $7,920,122 ($31,680,487 x 25%) caused by loss recognized on our book but not for the Chinese tax purpose at March 31, 2012 was a permanent difference. However, upon the return of the US Patent back to LY Research, the permanent tax differences associated with the recognition of the contingent obligation and the loss from impairment were reversed and there was no permanent tax difference at December 31, 2012.

 

12
 

 

For the three months ended December 31, 2012 and 2011, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $258,827 and $1,112,777, respectively.

 

For the nine months ended December 31, 2012 and 2011, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $1,585,251 and $2,283,837, respectively.

 

NOTE 11 – OTHER LIABILITY

 

On February 28, 2011, the Company entered into the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Company acquired a patent (the “LY Patent”) from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research Corp., in exchange for 44,254,952 shares of the Company’s common stock at inception date. In addition, there were two contingent considerations of a total of 31,610,544 shares to be issued upon the occurrences of some pre-determined events. The first contingent consideration of 11,063,968 shares was required to be issued upon the Company’s stock being listed on OTCBB or OTCQB.

 

Because the obligation to issue additional shares to LY Research was contingent upon the occurrence of certain predetermined events, the liability was to be recognized when the contingencies were resolved. On September 9, 2011, LY Research became entitled to the issuance of 11,063,968 shares of common stock upon the occurrence of the quotation of the Company’s common stock on the OTCQB. Therefore, the liability to issue 11,063,968 shares of common stock should be recorded for the quarter ended September 30, 2011 and forward.

 

The amount of the liability is calculated by multiplying the 11,063,968 shares of stock by the quoted average stock price on September 9, 2011. The stock price per share on September 9, 2011 was $0.25. The calculation of the liability to issue 11,063,968 shares of the common stock is as followed:

 

Other Liability $2,765,992 = 11,063,968 shares x $0.25

 

We recognized $2,765,992 as an “Other Liability” and an addition to the US patent, for the quarter ended September 30, 2011 and forward. As of March 31, 2012, the Patent was written-off due to impairment.

 

As of October 21, 2012, because the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a termination agreement on October 29, 2012 to formally terminate the Purchase Agreement, and return the Patent and the shares to LY Research and the Company, respectively. As a result, the “Other Liability” of $2,765,992 was reversed as of December 31, 2012.

 

NOTE 12 – DERIVATIVE LIABILITY AND UNREALIZED GAIN

 

On February 28, 2011, the Company entered into the Purchase Agreement with LY Research; and the Purchase Agreement was amended and restated on August 15, 2011. Pursuant to the terms of the Purchase Agreement, the Company acquired the LY Patent from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research corp., in exchange for 44,254,952 shares of common stock at the acquisition date. In addition, 11,063,968 shares of common stock will be issued to the seller upon the occurrence of the quotation of the Company’s common stock on the OTCQB or OTCBB; and 20,546,711 shares will be issued to the seller upon the receipt by the Company of a minimum of $20,000,000 in gross proceeds from a debt or equity financing, or a series of debt and/or equity financings (the “Financing”); or upon the quotation of its common stock on NASDAQ or a major stock exchange located outside of the United States (collectively, “Events”). On September 9, 2011, the Company’s stock became quoted at OTCQB; therefore, 11,063,968 shares of common stock became issuable.

 

As of October 21, 2011, the Purchase Agreement was further amended to state that if either of the Events should not occur within one year from October 21, 2011; the shares issued pursuant to the Purchase Agreement shall be returned to the Company and the LY Patent shall be returned to LY Research and the Purchase Agreement, as amended, shall be cancelled and of no further force or effect. Because the Company is required to acquire the issued shares by returning the US patent if the predetermined financing event is not met, the term meets the definition under the ASC 480-10-25-8, “Obligations to Repurchase Issuer’s Equity Shares by Transferring Assets”. Per ASC 480-10-25-8, the obligation to repurchase an issuer’s own shares by transferring asset should be recognized as a liability at inception.

 

In addition, because the acquisition was not a certain future event as of October 21, 2011 and forwards, the Company considers the contingent obligation to repurchase its own shares as a written put option. Per ASC 480-10-30-7, all financial instruments, recognized under the guidance in Section 480-10-25, other than certain physically settled forward purchase contracts, shall be measured initially at fair value.

 

13
 

 

The fair value of the obligation on October 21, 2011 should be the market price of the shares that the company is obligated to repurchase if the financing is failing and weighted by the probability of the Company failing to meet the financing target of $20,000,000 or achieving the listing on NASDAQ or a major foreign stock exchange. On October 21, 2011, the company had issued and was obligated to issue 55,318,920 common shares to Dr. Liu. Therefore, the number of potential shares needed to repurchase was 55,318,920 on October 21, 2011.

 

Determination of the market price of the shares:

 

Per ASC 820-10-20 “Readily Determinable Fair Value”, “ The fair value of an equity security is readily determinable if sales prices or bid-and-asked quotations are currently available on a securities exchange registered with the U.S. Securities and Exchange Commission (SEC) or in the over-the-counter market, provided that those prices or quotations for the over-the-counter market are publicly reported by the National Association of Securities Dealers Automated Quotations systems or by Pink Sheets LLC. Restricted stock meets that definition if the restriction terminates within one year. ” Because the sales price of the company’s common stock shares was currently available in the over-the-counter market, the fair value of the company’s stock is readily determinable and is the sales price of the stock on October 21, 2011. Because the company’s common stock was not traded on October 21, 2011, the closest quotations were the prices on October 23, 2011, which was $0.40/share; therefore, the fair values per share for were $0.40 for October 21, 2011. As of September 30, 2012, the most recent quoted CYIG stock price was $0.02 (at September 28, 2012).

 

Determination of the probability of the Company failing to meet the predetermined event:

 

The Company determined that on October 21, 2011, the chance that the final contingency would not be met, thereby triggering our obligation to repurchase those shares, was around 15% based on the reasons described in its amended 10Q for the quarter ended December 31, 2011. Therefore, the Company recognized $3,319,135 as a derivative liability as of December 31, 2011.

 

However, as of March 31, 2012, the Company was informed by its placement agent that it was highly unlikely to achieve the $20M financing by October 21, 2012. Therefore, the Company reassessed the probability of failing to achieve the financing target by October 21, 2012 to be 100% as of March 31, 2012 and forwards.

 

The fair value of the derivative obligation was calculated as follows:

$1,106,378 = 55,318,920 x $0.02/share x 100% at September 30, 2012, and

$5,531,892 = 55,318,920 x $0.10/share x 100% at March 31, 2012.

 

The fair value of the derivative obligation was decreased by $4,425,514 at September 30, 2012 as a result of the CYIG stock price change. The decrease was recognized as unrealized gain reflecting a non-cash adjustment for changes in fair value of the Company’s derivative liability.

 

On October 29, 2012, because the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into the Termination Agreement to formally terminate the Purchase Agreement, and return the Patent and the shares to LY Research and the Company, respectively. As a result, the derivative obligation and the unrealized gain were reversed by the carrying amount of $1,106,378 and $4,425,514, respectively.

 

NOTE 13 - STOCKHOLDERS’ EQUITY

 

Stock Issued to Independent Directors

 

The total amount of the compensation in the form of issuing shares of common stock to the independent directors was $50 and $22,222 for the periods ended December 31, 2012 and March 31, 2012, respectively.

 

Stock Cancelled for Return of Patent

 

On February 28, 2011, the Company issued 44,254,952 shares of common stock, as a partial of total considerations to acquire a U.S. patent No. 6,475,531 B1 titled “Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function” from L.Y. Research Corp., a New Jersey Corporation.   The shares of the common stock were valued at the average closing market price on February 28, 2011 in the amount of $32,748,665.

 

On October 29, 2012, because the conditions set in the Purchase Agreement with L.Y. Research Corp. were not fulfilled, the Company and LY Research entered into a termination agreement to formally terminate the Purchase Agreement, and returned the patent and the shares to LY Research and the Company, respectively. Subsequently, the Company cancelled the returned shares of the Company’s common stock. As a result of this cancellation, “Additional paid-in capital” and “Retained earnings” decreased by $32,704,410 and $32,748,664, respectively.

 

14
 

 

Statutory Reserve

 

Subsidiaries incorporated in China are required to make appropriations to reserve funds, based on after-tax net income determined in accordance with generally accepted accounting principles of the People’s Republic of China (“PRC GAAP”).  Effective January 1, 2006, the Company is only required to contribute to one statutory reserve fund at 10% of net income after tax per annum, and any contributions are not to exceed 50% of the respective companies’ registered capital.

 

As of December 31, 2012, the Company appropriated $956,633 to the statutory reserve.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Result of Operations

 

You should read the following discussion together with our consolidated financial statements and the related notes included elsewhere in this Form 10-Q and our audited financial statements included in our Annual Report on Form 10-K. This discussion contains forward-looking statements. These forward-looking statements are based on information available at the time the statements are made and/or management’s belief as of that time with respect to future events and involve risks and uncertainties that could cause actual results and outcomes to be materially different. Important factors that could cause such differences include but are not limited to: competitive factors, general economic conditions, customer relations, relationships with vendors, the interest rate environment, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein and in other filings made by the company with the Securities and Exchange Commission. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, and therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date this Form 10-Q is filed with the Securities and Exchange Commission.

 

Overview

 

China YCT International Group, Inc. (“CYIG”) was incorporated in the State of Florida in January 1989, and reincorporated in the State of Delaware on April 4, 2007. China YCT principally operates through two of its wholly-owned subsidiaries: Landway Nano Bio-Tech, Inc., incorporated in Delaware, and Shandong Spring Pharmaceutical Co., Ltd. (“Shandong Spring”), incorporated in the People’s Republic of China (the “PRC”). China YCT International Group, Inc. and its subsidiaries are collectively referred to as the “Company” or CYIG. CYIG, through its wholly-owned subsidiary, Shandong Spring, is engaged in the business of developing, manufacturing and marketing gingko and distributing other dietary supplement products in the PRC.

 

Recent Event

 

On February 28, 2011, the Company entered into a purchase agreement with L.Y. Research Corp., a New Jersey corporation (“LY Research”); and the purchase agreement was amended and restated on August 15, 2011 (the “Purchase Agreement”). Pursuant to the terms of the Purchase Agreement, the Company acquired a patent (the “LY Patent”) from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research corp., in exchange for 44,254,952 shares of common stock at the acquisition date. In addition, 11,063,968 shares of common stock will be issued to the seller upon the occurrence of the quotation of the Company’s common stock on the OTCQB or OTCBB; and 20,546,711 shares will be issued to the seller upon the receipt by the Company of a minimum of $20,000,000 in gross proceeds from a debt or equity financing, or a series of debt and/or equity financings (the “Financing”); or upon the quotation of its common stock on NASDAQ or a major stock exchange located outside of the United States (collectively, “Events”). On September 9, 2011, the Company’s stock became quoted at OTCQB; therefore, 11,063,968 shares of common stock became issuable.

As of October 21, 2011, the Purchase Agreement was further amended to state that if either of the Events should not occur within one year from October 21, 2011; the shares issued pursuant to the Purchase Agreement shall be returned to the Company and the LY Patent shall be returned to LY Research and the Purchase Agreement, as amended, shall be cancelled and of no further force or effect.

On October 29, 2012, because the Events set in the Purchase Agreement were not fulfilled, the Company and L.Y. Research entered into a termination agreement to formally terminate the Purchase Agreement, and return the Patent and the shares to L.Y. Research and the Company, respectively (“Termination Agreement”). The returned shares were subsequently cancelled.

 

15
 

 

Results of Operations – for the Three Months ended December 31, 2012 and 2011:

 

The following table sets forth information from our statements of operations for the three months ended December 31, 2012 and 2011, in dollars:

 

   Three Months Ended         
   December 31   $   % 
   2012   2011   Change   Change 
Revenues   6,922,363    10,112,489    (3,190,126)   -31.5%
                     
Cost of Sales   (3,450,065)   (4,712,730)   1,262,665    -26.8%
                     
Gross Profit   3,472,298    5,399,759    (1,927,461)   -35.7%
                     
Operating Expenses   (2,460,335)   (2,468,061)   7,726    -0.3%
                     
Operating Income   1,011,963    2,931,698    (1,919,735)   -65.5%
                     
Interest Income, net   23,346    65,818    (42,472)   -64.5%
                     
Other Income (Expense)   3,872,370    (3,319,135)   7,191,505    -216.7%
                     
Income Tax Provision   (258,827)   (1,112,777)   853,950    -76.7%
                     
Net Income   4,648,852    (1,434,396)   6,083,248    -424.1%
                     
Comprehensive Income (Loss)   5,123,715    (1,436,120)   6,559,835    -456.8%

 

 

Net sales

 

During the three months ended December 31, 2012, we had net sales of $6,922,363, as compared with net sales of $10,112,489 for the same period in 2011, a decrease of $3,190,126, or 31.5%. The decrease was primarily due to the recent market concerns over the toxic capsules used in health products in China. Although we conducted independent quality check and our capsules do not have any quality issue, our sales of encapsulated Huoliyuan and healthcare supplements were adversely affected.

 

We entered into a purchase and sale contract with Shandong Yong Chun Tang (“Shandong YCT”) on December 26, 2006 (the “Purchase and Sale Contract”), which sets forth the wholesale price that we pay to Shandong YCT for distributing their products. On February 9, 2010, we renewed the Purchase and Sale Contract with Shandong YCT for a term of five years ending on February 28, 2015. Pursuant to the renewed contract, we can purchase 10 types of health care supplement products from Shandong YCT on a fixed price, which were selected according to their sales volume and profit margin. For the three months ended December 31, 2012, 38.1% of our revenue was from the sale of the health care supplement products, compared to 33.6% in the same period in 2011.

 

Since September 2009, we started to engage in the production and distribution of our own non-prescription drug, Huoliyuan Capsule, which is patented in China, and developed distribution channels for the drug. Our sales have increased since September 2009 as a result of the establishment of our manufacturing and distribution channels of Huoliyuan Capsule. Since July 2010, the Company changed from being solely a distributor of Shandong YCT to both a manufacturer and distributor of our own products, the Huoliyuan Capsules. As a result, we obtained new customers and expanded our sales of Huoliyuan Capsules. The Huoliyuan Capsule product accounted for 59.6% of our revenue for the three months ended December 31, 2012, compared to 61.2% for the same period in 2011.

 

16
 

 

The following table presents the breakdown of revenues by product mix:

 

   Three Months Ended
December 31, 2012
   Three Months Ended
December 31, 2011
         
      2011   Change   2012 
Sales from:                    
Health care supplements   2,634,748    3,398,462    (763,714)   -22.5%
Drugs   4,124,795    6,192,876    (2,068,081)   -33.4%
Others   162,821    521,151    (358,330)   -68.8%
Total   6,922,363    10,112,489    (3,190,126)   -31.5%

 

Cost of Sales

 

Our costs of revenue were comprised primarily of the cost of finished goods we purchased from Shandong YCT, the manufacturing cost of Huoliyuan Capsules, and the raw materials we purchased from third party vendors. During the three months ended December 31, 2012, we had cost of sales of $3,450,065 as compared with cost of sales of $4,712,730 during the same period in 2011, a decrease of approximately $1,262,665, or 26.8%. The percentage of the costs of sales to total revenues increased to 49.8% from 46.6% as compared to the same period in 2011, primarily due to an increase in the market price of raw materials.

 

Gross Profit

 

As a result of the changes in sales and costs, gross profit during the three months ended December 31, 2012 was $3,472,298, a decrease of $1,927,461 or 35.7% as compared to the same period in the previous year. Our gross margin decreased to 50.2% during the three months ended December 31, 2012 from 53.4% during the three months ended December 31, 2011.

 

The following table sets forth a breakdown of our gross profits of different products during the three months ended December 31, 2012 and 2011:

 

   Three Months
Ended
Dec 31, 2012
   Three Months
Ended
Dec 31, 2011
   Change in $   Variance 
Health care supplements   1,415,724    1,842,896    (427,172)   -23.2%
Margin (%)   53.7%   54.2%          
Drugs   1,968,013    3,169,387    (1,201,374)   -37.9%
Margin (%)   47.7%   51.2%          
Others   88,561    387,476    (298,915)   -77.1%
Total   3,472,298    5,399,759    (1,927,461)   -35.7%

 

Selling Expenses

 

Our selling expenses decreased by $161,376 or 22.6% to $552,318 for the three months ended December 31, 2012, from $713,694 for the same period of 2011. As a percentage of sales, selling expenses increased to 8.0% for the three months ended December 31, 2012 from 7.1% for the same period in 2011. The increase of selling expenses as a percentage of sales was primarily due to increase in advertising and promotion expenses related to marketing and promotional activities in our Huoliyuan Capsule markets.

 

General and Administrative Expenses

 

Our general and administrative expenses were $1,184,227 during the three months ended December 31, 2012, compared with $1,570,674 during the three months ended December 31, 2011, a decrease of $386,447 or approximately 24.6%. The decrease in general and administrative expenses was principally due to the amortization expense accrued for the acquired US Patent (U.S. No. 6,475,531 B1) in 2011. During the three months ended December 31, 2011, the amortization expense of this patent was $935,517. The US patent was written-off as of March 31, 2012 due to impairment and returned pursuant to the Termination Agreement entered on October 29, 2012. Therefore, no such amortization expense occurred for the three months ended December 31, 2012. The decrease was reduced by other additional expenses. During the three months ended December 31, 2012, the General and Administration Expenses include additional training expenses of $317,501 for adopting the new GMP (Good Manufacturing Practice) Standards and additional retirement plan expenses of $283,452.

 

17
 

 

Research and Development Expenses

 

Research and development expenses were $723,790 during the three months ended December 31, 2012 compared with $183,693 during the three months ended December 31, 2011, an increase of $540,097 or 294.0%, reflecting the increased expenses related to investments in developing technologies and products that can be utilized to refine and extract the beneficial compounds from plants, primarily gingko.

 

Interest Income (Expense), Net

 

Interest income was $23,346 for the three months ended December 31, 2012, decreased by $42,472 or 64.5%, compared to the three months ended December 31, 2011. There were favorable interest arrangements offered by our banks for the three months ended December 31, 2011. However, these arrangements were no longer available for the three months ended December 31, 2012. There was no interest expense as we did not have outstanding loans from banks or other parties.

 

Other Income (Expense)

 

Pursuant to the Termination Agreement, derivative and other liabilities were reversed with other income of $8,297,884 recognized in the three months ended December 31, 2012. The income was decreased by the reversing of unrealized gain on derivative in the amount of $4,425,514. For the three months ended December 31, 2011, other expense included the adjustment on derivative in the amount of $3,319,135.

 

Income Tax

 

Income tax was $258,827 during the three months ended December 31, 2012, as compared to $1,112,777 for the same period in 2011, a decrease of $853,950 or approximately 76.7%. The decrease was primarily due to the decreased taxable income (excluding other expenses related to the derivative) during the three months ended December 31, 2012.

 

Net Income

 

As a result of the above factors, we had a net income of $4,648,852 during the three months ended December 31, 2012, compared with a net loss of $1,434,396 during the three months ended December 31, 2011.

 

Other Comprehensive Income

 

As a result of the currency translation adjustment, we had other comprehensive income of $474,863 during the quarter ended December 31, 2012, compared with other comprehensive loss of $1,724 during the quarter ended December 31, 2011 due to exchange rate fluctuations from Chinese RMB, the functional currency used in our Chinese subsidiary, to US dollar, our reporting currency.

 

Results of Operations – for the Nine Months ended December 31, 2012 and 2011:

 

The following table sets forth information from our statements of operations for the nine months ended December 31, 2012 and 2011, in dollars:

 

   Nine Months Ended         
   December 31   $   % 
   2012   2011   Change   Change 
Revenues   23,521,007    26,477,760    (2,956,753)   -11.2%
                     
Cost of Sales   (11,367,854)   (11,894,299)   526,445    -4.4%
                     
Gross Profit   12,153,153    14,583,461    (2,430,308)   -16.7%
                     
Operating Expenses   (5,876,257)   (7,111,660)   1,235,403    -17.4%
                     
Operating Income   6,276,896    7,471,801    (1,194,905)   -16.0%
                     
Interest Income, net   82,138    209,953    (127,815)   -60.9%
                     
Other Income (Expense)   8,297,884    (3,319,135)   11,617,019    350.0%
                     
Income Tax Provision   (1,585,251)   (2,283,837)   698,586    -30.6%
                     
Net Income   13,071,667    2,078,782    10,992,885    528.8%
                     
Comprehensive Income (Loss)   13,376,873    2,926,707    10,450,166    357.1%

 

 

Net sales

 

18
 

 

During the nine months ended December 31, 2012, we had net sales of $23,521,007, as compared with net sales of $26,477,760 during the same period in 2011, a decrease of $2,956,753 or 11.2%. The decrease was primarily due to the recent market concerns over the toxic capsules used in health products in China. Although we conducted an independent quality check and our capsules do not have any adverse quality issue, our sales of encapsulated Huoliyuan and healthcare supplements were adversely affected.

 

For the nine months ended December 31, 2012, 33.8% of our revenue was from the sale of the 10 products distributed for Shandong YCT, compared to 34.9% in the nine months ended December 31, 2011. The Huoliyuan Capsule products accounted for 61.4% of our revenue for the nine months ended December 31, 2012, compared to 59.0% for the same period in 2011.

 

The following table presents the breakdown of revenues by product mix:

 

   Three Months Ended         
  Dec 31, 2012   Dec 31, 2011   Change in $   Change in % 
Sales from:                    
Health care supplements   7,940,511    9,249,105    (1,308,594)   -14.1%
Drugs   14,444,389    15,615,134    (1,170,745)   -7.5%
Others   1,136,108    1,613,521    (477,413)   -29.6%
Total   23,521,007    26,477,760    (2,956,753)   -11.2%

 

Cost of Sales and Gross Margin

 

During the nine months ended September 30, 2012, we had cost of sales of $11,367,854, as compared with cost of sales of $11,894,299 during the same period in 2011, a decrease of approximately $526,445, or 4.4%, reflecting the decrease in net sales and the increase in raw material price.

 

The gross profit declined to $12,153,153 for the nine months ended December 31, 2012, or a 16.7% decrease compared with $14,583,461 during the same period in 2011 as a result of the increase in raw material price. Our gross margin decreased to 51.7% during the nine months ended December 31, 2012 from 55.1% during the nine months ended December 31, 2011.  The percentage of our cost of sales over the sales of distributing Shandong YCT products increased to 46.3% for the nine months ended December 31, 2012 from 45.8% for the same period in previous year. The percentage of our cost of sales over the sales for Huoliyuan Capsules was up to 52.3% for the nine months ended December 31, 2012 from 48.8% for the same period in 2011 because of raw material cost increase.  In addition, beginning with the fiscal year of 2011, we obtained new contracts from external customers to process and package their semi-finished products.  The gross margin from sales of these products were relatively high, approximately 69.4% for the nine months ended December 31, 2012.

 

Selling Expenses

 

Our selling expenses decreased by $288,607, or 11.5%, to $2,216,642 for the nine months ended December 31, 2012, from $2,505,249 for the same period in 2011. As a percentage of sales, selling expenses decreased slightly from 9.5% for the nine months ended December 31, 2011 to 9.4% for the same period of 2012.

 

19
 

 

General and Administrative Expenses

 

Our general and administrative expenses were $2,387,125 during the nine months ended December 31, 2012, compared with $4,028,897 during the nine months ended December 31, 2011, a decrease of $1,641,772 or approximately 40.8%. The decrease in general and administrative expenses was principally due to the amortization expense recorded for the acquired US Patent (U.S. No. 6,475,531 B1) in 2011. During the nine months ended December 31, 2011, the amortization expense of this patent was $2,898,608. The US Patent was written-off as of March 31, 2012 due to impairment. Therefore, there was no amortization for the nine months ended December 31, 2012.

 

Research and Development Expenses

 

Research and development expenses were $1,272,490 during the nine months ended December 31, 2012 compared with $577,514 during the nine months ended December 31, 2011, an increase of $694,976, or 120.3%, reflecting the increased expenses related to investments in developing new technologies and products that can be utilized to refine and extract the beneficial components from plants, primarily gingko.

 

Interest Income

 

Interest income was $82,138 for the nine months ended December 31, 2012, decreased by $127,815 or 60.9%, compared to $209,953 for the nine months ended December 31, 2011. There were favorable interest arrangements offered by our banks for the nine months ended December 31, 2011. However, these arrangements were no longer available for 2012.

 

Other Expense

 

Pursuant to the Termination Agreement, derivative and other liabilities were reversed, with other income of $8,297,884 recognized for the nine months ended December 31, 2012. For the nine months ended December 31, 2011, other expense included the adjustment on derivative in the amount of $3,319,135.

 

Income Tax

 

Income tax was $1,585,251 during the nine months ended December 31, 2012, as compared to $2,283,837 for the same period of 2011, a decrease of $698,586, or approximately 30.6%. The decrease was primarily due to decreased taxable income (excluding other expense related to derivative) during the nine months ended December 31, 2012.

 

Net Income

 

As a result of the factors described above, we generated net income of $13,071,667 during the nine months ended December 31, 2012, as compared with net income of $2,078,782 during the nine months ended December 31, 2011.

 

Other Comprehensive Income

 

As a result of a currency translation adjustment, other comprehensive income was $305,206 during the nine months ended December 31, 2012, compared with other comprehensive income of $847,925 during the nine months ended December 31, 2011; which is mainly attributable to the exchange rate fluctuations from Chinese RMB, the functional currency used in our Chinese subsidiary, to US dollar, our reporting currency.

 

Liquidity and Capital Resources

 

Our principal source of liquidity was generated from our operations during the nine months ended December 31, 2012. As of December 31, 2012, we had $27,429,324 in working capital, an increase of $8,953,266, or 48%, as compared to $18,476,058 in working capital at March 31, 2012. The increase was due in part to our reduction of the level of inventory by consuming existing raw materials and decreasing purchases. The decrease in tax payable also contributed to the increase in working capital.

 

Based on our current operating plan, we believe that existing cash and cash equivalents balances, and the funds to be generated by operations will be sufficient to meet our working capital and capital requirements for our current operations for at least the next 12 months. Our operations produced positive cash flow of $4,985,291 during the nine months ended December 31, 2012. We did not have accounts receivable outstanding as of December 31, 2012 as there were no products shipped where payments have not been rendered We expect our marketing activities to continue to help generate positive cash flow.  The operations of our own manufacturing since fiscal year 2010 has put some pressure on our cash flow. We may be required to seek additional capital and reduce certain spending as needed on an on-going basis. There can be no assurance that the additional financing will be available on acceptable terms.

 

20
 

 

The following table sets forth a summary of our cash flows for the period as indicated:

 

   Nine months ended         
   Dec 31, 2012   Dec 31, 2011   Change in $   % 
Net cash provided by operating activities  $4,985,291   $10,718,912    (5,733,721)   -53.5%
Net cash provided by (used in) investing activities  $(73,502)  $830,208    (903,710)   -108.9%
Net cash provided by financing activities  $-   $-    -    - 
Effect of exchange rate change on cash and cash equivalents  $256,578   $847,926    (591,348)   -69.7%
Net increase in cash and cash equivalents  $5,168,267   $12,397,046    (7,228,779)   -58.3%
Cash and cash equivalents, beginning balance  $22,146,240   $6,046,804    16,099,436    266.2%
Cash and cash equivalents, ending balance  $27,314,507   $18,443,850    8,870,657    48.1%

 

 

Operating Activities

 

For the nine months ended December 31, 2012, net cash provided by operating activities was $4,985,291, compared to $10,718,912 for the same period in 2011. The primary reason for the change was mainly the result of the increased net income, off-set by the non-cash items and the decrease in tax and other payables.

 

Investing Activities

 

Net cash used in investing activities was $73,502 for the nine months ended December 31, 2012 as compared to cash provided by investing activities of $830,208 for the nine months ended December 31, 2011 as we received a refund of $15.5M from Jining Tianruitong Technology Development Limited Company, the owner of the patents, during the nine months ended December 31, 2011.

 

Financing Activities

 

There were no financing activities for the nine months ended December 31, 2012 and 2011.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on their financial condition or results of operations.

 

Critical Accounting Policies

 

This section should be read together with the Summary of Significant Accounting Policies included as Note 2 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2012 and our Quarterly Report on Form 10-Q for the period ended December 31, 2012 filed with the SEC.

 

We prepare our financial statements in conformity with U.S. GAAP, which requires us to make estimates and assumptions that affect our reporting of, among other things, assets and liabilities, contingent liabilities and revenues and expenses. We continually evaluate these estimates and assumptions based on the most recently available information, our own historical experiences and other factors that we believe to be relevant under the circumstances. Since our financial reporting process inherently relies on the use of estimates and assumptions, our actual results could differ from our expectations. This is especially true with some accounting policies that require higher degrees of judgment than others in their application. We consider the policies discussed below to be critical to an understanding of our audited and unaudited consolidated financial statements because they involve the greatest reliance on our management’s judgment.

 

Principles of consolidation

 

The consolidated financial statements for the nine months ended December 31, 2012 and 2011 include the accounts of China YCT International Group, Inc and Shandong Spring Pharmaceutical Company. Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).  All significant inter-company balances and transactions are eliminated in consolidation.

 

21
 

 

Revenue recognition

 

Our revenue recognition policies are in compliance with Staff Accounting Bulletin (“SAB”) 104, included in the Codification as ASC 605, Revenue Recognition. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.

 

Inventories

 

Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of cost or market with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.

 

Stock Based Compensation

 

The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.  The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.

 

Recent Accounting Pronouncements

 

In July 2012, FASB issued an amendment to the FASB Codification Topic 350 – Testing Indefinite-Lived Intangible Assets for Impairment. The objective of the amendments in this Update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-lived asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles – Goodwill and Other – General Intangibles Other than Goodwill. The more likely-than-not threshold is defined as having a likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company decided to adopt the amendment for the year starting with April 1, 2013. The Company does not expect the adoption of this pronouncement to have a significant impact on its financial condition or results of operations.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures.

 

The term “disclosure controls and procedures” (defined in SEC Rule 13a-15(e)) refers to the controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within required time periods. The Company’s management, with the participation of the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q (the “Evaluation Date”). Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, such controls and procedures were effective.

 

Changes in internal controls.

 

The term “internal control over financial reporting” (defined in SEC Rule 13a-15(f)) refers to the process of a company that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s management, with the participation of the Chief Executive Officer and Chief Financial Officer, has evaluated any changes in the Company’s internal control over financial reporting that occurred during the quarter ended December 31, 2012, and they have concluded that there was no change to the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

22
 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There are no material pending legal proceedings to which the Company is a party.

 

Item 1A. Risk Factors

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4. Removed and Reserved

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

10.1 Termination Agreement, dated as of October 29, 2012, by China YCT International Group, Inc. and L.Y. Research Corporation, filed as an exhibit to the Company’s Current Report on Form 8-K on January 16, 2013
31.1 Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer
31.2 Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer
32.1 Section 1350 Certification of Chief Executive Officer
32.2 Section 1350 Certification of Chief Financial Officer

 

XBRL Exhibit

101.INS XBRL Instance Document.

101.SCH XBRL Taxonomy Extension Schema Document.

101.CALXBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB XBRL Taxonomy Extension Label Linkbase Document.

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.

 

23
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

CHINA YCT INTERNATIONAL GROUP, LTD.  
   
Date: February 13, 2013  
/s/ Yan Tinghe  
Yan Tinghe Chief Executive Officer  
(Principal Executive Officer)  
   
/s/ Li Chuanmin  
Li Chuanmin Chief Financial Officer  
(Principal Financial Officer)  

 

24

EX-31.1 2 v334341_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1: Rule 13a-14(a) Certification

 

I, Yan Tinghe, certify that:

 

1.  I have reviewed this quarterly report on Form 10-Q of China YCT International Group, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 13, 2013      
       
  By:  /s/ Yan Tinghe  
    Yan Tinghe, Chief Executive Officer  

 

 

EX-31.2 3 v334341_ex31-2.htm EXHIBIT 31.2

 

EXHIBIT 31.2: Rule 13a-14(a) Certification

 

I, Li Chuanmin, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of China YCT International Group, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February13 , 2013 By: /s/ Li Chuanmin  
    Li Chuanmin, Chief Financial Officer  

 

 

EX-32 4 v334341_ex32.htm EXHIBIT 32

 

EXHIBIT 32: Rule 13a-14(b) Certification

 

In connection with the Quarterly Report of China YCT International Group, Inc. (the “Company”) on Form 10-Q for the period ending December 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

February 13, 2013  By: /s/ Yan Tinghe  
  Yan Tinghe, Chief Executive Officer  
     
February13, 2013  By: /s/ Li Chuanmin  
  Li Chuanmin, Chief Financial Officer  

 

A signed original of this written statement required by Section 906 has been provided to China YCT International Group, Inc. and will be retained by China YCT International Group, Inc. and furnished to the Securities and Exchange Commission or its staff upon request

 

 

 

EX-101.INS 5 cyig-20121231.xml XBRL INSTANCE DOCUMENT 0000847464 2005-12-02 2006-01-01 0000847464 cyig:PatentOneMember cyig:ShandongYctCorpMember 2010-03-01 2010-03-31 0000847464 2011-02-28 0000847464 cyig:PatentFourMember cyig:LyHongKongBiotechLimitedMember 2011-02-28 0000847464 cyig:PatentFourMember cyig:LyHongKongBiotechLimitedMember cyig:ScenarioTwoMember 2011-02-28 0000847464 cyig:PatentFourMember cyig:LyHongKongBiotechLimitedMember cyig:ScenarioOneMember 2011-02-28 0000847464 2011-02-01 2011-02-28 0000847464 cyig:PatentFourMember cyig:LyHongKongBiotechLimitedMember 2011-02-01 2011-02-28 0000847464 cyig:PatentFourMember 2011-02-01 2011-02-28 0000847464 cyig:PatentFourMember cyig:LyHongKongBiotechLimitedMember us-gaap:MinimumMember 2011-02-01 2011-02-28 0000847464 2011-03-31 0000847464 2011-06-30 0000847464 2011-08-16 2011-09-09 0000847464 cyig:PatentFourMember cyig:LyHongKongBiotechLimitedMember 2011-08-16 2011-09-09 0000847464 cyig:PatentFourMember 2011-08-16 2011-09-09 0000847464 2011-09-30 0000847464 2011-10-01 2011-10-21 0000847464 cyig:PatentThreeMember 2011-10-01 2011-10-31 0000847464 cyig:PatentTwoMember 2011-10-01 2011-10-31 0000847464 2011-10-01 2011-12-30 0000847464 cyig:LandUseRightsMember 2011-10-01 2011-12-30 0000847464 us-gaap:PatentsMember 2011-10-01 2011-12-30 0000847464 2011-12-30 0000847464 2011-04-01 2011-12-31 0000847464 cyig:LandUseRightsMember 2011-04-01 2011-12-31 0000847464 us-gaap:PatentsMember 2011-04-01 2011-12-31 0000847464 2011-12-31 0000847464 2012-02-29 0000847464 2011-04-01 2012-03-31 0000847464 country:CN 2011-04-01 2012-03-31 0000847464 cyig:IndependentDirectorsMember 2011-04-01 2012-03-31 0000847464 2012-03-31 0000847464 cyig:PatentThreeMember 2012-03-31 0000847464 cyig:PatentTwoMember 2012-03-31 0000847464 cyig:PatentOneMember 2012-03-31 0000847464 cyig:LandUseRightsMember 2012-03-31 0000847464 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0000847464 us-gaap:CommonStockMember 2012-03-31 0000847464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-03-31 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-03-31 0000847464 us-gaap:PatentsMember 2012-03-31 0000847464 us-gaap:RetainedEarningsAppropriatedMember 2012-03-31 0000847464 us-gaap:SeriesAPreferredStockMember 2012-03-31 0000847464 cyig:ShandongYctCorpMember 2012-03-31 0000847464 2012-06-30 0000847464 us-gaap:AdditionalPaidInCapitalMember 2012-06-30 0000847464 us-gaap:CommonStockMember 2012-06-30 0000847464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-06-30 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-06-30 0000847464 us-gaap:RetainedEarningsAppropriatedMember 2012-06-30 0000847464 us-gaap:SeriesAPreferredStockMember 2012-06-30 0000847464 us-gaap:AdditionalPaidInCapitalMember 2012-04-01 2012-06-30 0000847464 us-gaap:CommonStockMember 2012-04-01 2012-06-30 0000847464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-04-01 2012-06-30 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-04-01 2012-06-30 0000847464 2012-07-01 2012-09-30 0000847464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-07-01 2012-09-30 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-07-01 2012-09-30 0000847464 cyig:IndependentDirectorsMember 2011-10-01 2012-09-30 0000847464 2012-09-30 0000847464 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000847464 us-gaap:CommonStockMember 2012-09-30 0000847464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-09-30 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-09-30 0000847464 us-gaap:RetainedEarningsAppropriatedMember 2012-09-30 0000847464 us-gaap:SeriesAPreferredStockMember 2012-09-30 0000847464 country:CN 2012-03-01 2012-09-30 0000847464 cyig:LandwayNanoBiotechIncMember 2012-03-01 2012-09-30 0000847464 cyig:ShandongSpringPharmaceuticalCoLtdMember 2012-03-01 2012-09-30 0000847464 2012-10-01 2012-12-31 0000847464 cyig:PatentThreeMember 2012-10-01 2012-12-31 0000847464 cyig:PatentTwoMember 2012-10-01 2012-12-31 0000847464 cyig:LandUseRightsMember 2012-10-01 2012-12-31 0000847464 us-gaap:PatentsMember 2012-10-01 2012-12-31 0000847464 cyig:PatentOneMember 2012-10-01 2012-12-31 0000847464 us-gaap:AdditionalPaidInCapitalMember 2012-10-01 2012-12-31 0000847464 us-gaap:CommonStockMember 2012-10-01 2012-12-31 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-10-01 2012-12-31 0000847464 cyig:ShandongSpringPharmaceuticalMember 2012-10-01 2012-12-31 0000847464 us-gaap:SupplierConcentrationRiskMember 2012-10-01 2012-12-31 0000847464 cyig:LyHongKongBiotechLimitedMember 2012-10-01 2012-12-31 0000847464 us-gaap:AdditionalPaidInCapitalMember cyig:LyHongKongBiotechLimitedMember 2012-10-01 2012-12-31 0000847464 us-gaap:RetainedEarningsMember cyig:LyHongKongBiotechLimitedMember 2012-10-01 2012-12-31 0000847464 2012-04-01 2012-12-31 0000847464 cyig:LandUseRightsMember 2012-04-01 2012-12-31 0000847464 us-gaap:PatentsMember 2012-04-01 2012-12-31 0000847464 us-gaap:SupplierConcentrationRiskMember 2012-04-01 2012-12-31 0000847464 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2012-04-01 2012-12-31 0000847464 us-gaap:BuildingMember us-gaap:MaximumMember 2012-04-01 2012-12-31 0000847464 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2012-04-01 2012-12-31 0000847464 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2012-04-01 2012-12-31 0000847464 us-gaap:BuildingMember us-gaap:MinimumMember 2012-04-01 2012-12-31 0000847464 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2012-04-01 2012-12-31 0000847464 2012-12-31 0000847464 cyig:PatentThreeMember 2012-12-31 0000847464 cyig:PatentTwoMember 2012-12-31 0000847464 cyig:PatentOneMember 2012-12-31 0000847464 cyig:LandUseRightsMember 2012-12-31 0000847464 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000847464 us-gaap:CommonStockMember 2012-12-31 0000847464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0000847464 us-gaap:RetainedEarningsUnappropriatedMember 2012-12-31 0000847464 us-gaap:PatentsMember 2012-12-31 0000847464 us-gaap:RetainedEarningsAppropriatedMember 2012-12-31 0000847464 us-gaap:SeriesAPreferredStockMember 2012-12-31 0000847464 cyig:ShandongYctCorpMember 2012-12-31 0000847464 us-gaap:SupplierConcentrationRiskMember 2012-12-31 0000847464 cyig:PatentFourMember 2012-12-31 0000847464 2013-02-11 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure 10-Q false 2012-12-31 2013 Q3 CYIG CHINA YCT INTERNATIONAL GROUP, INC. 0000847464 --03-31 Smaller Reporting Company 29575523 6046804 16316460 16316460 19697004 18443850 22146240 22146240 27314507 22146240 115938 0 20887 20887 20916 20916 1978488 2561052 24261553 29896475 9663338 9495483 219983 220291 18863510 1434200 17429310 17927772 1411913 16515858 53008384 57540021 1018543 424872 4766952 2042279 5785495 2467151 3319135 5531892 0 11317387 2467151 22500 22500 73780 29575 36879643 4180183 956633 956633 417285 46237617 3341156 3646362 41690997 36879643 73780 3341156 417285 956633 22500 43907829 36884593 73830 3300278 2669995 956633 22500 49949155 36884593 73830 3171499 8840100 956633 22500 55072870 4180183 29575 3646363 46237617 956633 22500 53008384 57540021 500.00 500.00 45 45 45 45 0.001 0.001 100000000 100000000 73780610 29575523 73780610 29575523 10112489 26477760 6922363 23521007 4712730 11894299 3450065 11367854 5399759 14583461 3472298 12153153 713694 2505249 552318 2216642 1570674 4028897 1184227 2387125 183693 577514 723790 1272490 2468061 7111660 2460335 5876257 2931698 7471801 1011963 6276896 65818 209953 23346 82138 -3319135 -3319135 3872370 8297884 -321619 4362619 4907679 14656918 1112777 2283837 258827 1585251 -1434396 2078782 2252710 6170105 6170105 4648852 13071667 -1724 847925 -40878 -128779 -128779 474863 305206 -1436120 2926707 5123715 13376873 0.00 0.03 0.11 0.22 73780610 73780610 43029245 60029581 73780610 45 73780610 45 73780610 45 29575523 45 55318920 50000 4950 -32704410 -44255 32746665 0 -44255087 32748664 32704410 32748664 3693018 1225386 0 -2765993 0 0 4425514 1106378 -5531892 0 5000 -2424798 -582564 0 115938 -248678 -593671 7620588 41319 10718912 4985291 14704423 73502 -15534631 0 830208 -73502 847926 256578 12397046 5168267 0 82138.00 2178687 2178922 50000 0 44255087 <div><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 1 - ORGANIZATION AND&#160;PRINCIPAL ACTIVITIES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">China YCT International Group, Inc. (&#8220;China YCT&#8221;) was incorporated in the State of Florida, in the United States of America (the &#8220;USA&#8221;) in January 1989, and reincorporated in the State of Delaware on April 4, 2007.&#160;&#160; China YCT principally operates through directly owned subsidiaries: Landway Nano Bio-Tech, Inc. (100% owned), incorporated in Delaware, and Shandong Spring Pharmaceutical Co., Ltd. (&#8220;Shandong Spring&#8221;), (100% owned), incorporated in the People&#8217;s Republic of China (&#8220;PRC&#8221;). China YCT International Group, Inc. and its subsidiaries are collectively referred to as the &#8220;Company.&#8221;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">China YCT, through its wholly owned subsidiary, Shandong Spring, is engaged in the business of developing, manufacturing and selling its own medicine from gingko extract, and other dietary supplement products in the P.R. China.</div></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Basis of presentation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Principles of consolidation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The consolidated financial statements include the financial statements of China YCT, Landway Nano and its wholly owned subsidiary, Shandong Spring.&#160;&#160;All inter-company transactions and balances are eliminated in consolidation.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Use of estimates</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company&#8217;s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and cash equivalents</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Inventory</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of cost or market with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Property and equipment</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 1in; width: 60%;">Building</td><td style="width: 40%;">30-35 years</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">Machinery, equipment and automobiles</td><td>7-15 years</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">Furniture and fixtures</td><td>7-10 years</td></tr></table><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Intangible Assets</i></b></div><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: right; font-style: italic; width: 9%;"><i>(i)&#160;&#160;</i></td><td style="text-align: justify; font-style: italic; width: 91%;"><i>Land Use Rights:</i></td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">All land in the PRC is owned by the government and cannot be sold to any individual or company.&#160;&#160;However, the government may grant a &#8220;land use right&#8221; for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: right; font-style: italic; width: 9%;"><i>(ii)&#160;&#160;</i></td><td style="text-align: justify; font-style: italic; width: 91%;"><i>Patents:</i></td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In March 2010, the Company purchased one patent from Shandong YCT Corp.&#160;&#160;The patent is the Company&#8217;s exclusive right to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.&#160;&#160;The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are &#8220;Treatment to ischemic encephalopathy and its preparation method&#8221; (ZL200510045001.9) and &#8220;Chinese herbal medicine compound to treat renal insufficiency and its preparation&#8221; (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Revenue recognition</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s revenue recognition policies are in compliance with Staff Accounting Bulletin (&#8220;SAB&#8221;) 104, included in the Codification as ASC 605, <i>Revenue Recognition</i>. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Impairment of long-lived assets</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Per ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Per ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Income taxes</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (&#8221;SFAS&#8221;) No. 109, &#8220; Accounting for Income Taxes &#8221;, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred Income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2012 and March 31, 2012.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">China YCT International, Inc. is a holding company of Shandong Spring Pharmaceutical Co., Ltd and does not have any operating activities. Although the contract for the acquisition of the US patent acquired in February 2011 from LY Research Corp. was executed by the holding company, in substance, the patent was acquired by the Company&#8217;s operating entity in China. Therefore, the patent related income or expense does not result in any US income tax liabilities.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Value-added tax</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (&#8220;VAT&#8221;). All of the Company&#8217;s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company recorded net VAT Payable in amount of $369,944 and $225,223 as of December 31, 2012 and March 31, 2012, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and development</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Research and development costs relate to the Company&#8217;s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The research and development expense for the three months ended December 31, 2012 and 2011 was $723,790 and $183,693, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The research and development expense for the nine months ended December 31, 2012 and 2011 was $1,272,490 and $577,514, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Advertising costs</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Advertising costs for newspaper and television are expensed as incurred.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company incurred advertising costs of $158,750 and $157,712 for the three months ended December 31, 2012 and 2011, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company incurred advertising costs of $759,866 and $390,452 for the nine months ended December 31, 2012 and 2011, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Mailing and handling costs</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company accounts for mailing and handling fees in accordance with the <i>FASB ASC</i> 605-45 (<i>Emerging Issues Task Force</i> ( <i>EITF</i> ) <i>Issue No</i> . <i>00-10</i> , <i>Accounting for Shipping and Handling Fees and Costs</i> ). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the three months ended December 31, 2012 and 2011, the Company incurred $218,820 and $1,475 mailing and handling costs, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the nine months ended December 31, 2012 and 2011, the Company incurred $765,413 and $662,629 mailing and handling costs, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock Based Compensation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.&#160;&#160;The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company&#8217;s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Net income (loss) per share (&#8220;EPS&#8221;)</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">There are nil and 31,610,679 common stock equivalents available for dilution purposes as of December 31, 2012 and 2011, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Risks and uncertainties</i></b></div><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s operations are carried out in the PRC. Accordingly, the Company&#8217;s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, and by the general state of the PRC&#8217;s economy. The Company&#8217;s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company&#8217;s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times,"><b><i>Fair Value of Financial Instruments</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Foreign currency translation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accounts of the Company&#8217;s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 830 &#8220;Foreign Currency Matters,&#8221; with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders&#8217; equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, &#8220;Comprehensive Income.&#8221; Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Translation adjustments resulting from this process amounted to $3,646,363 and $3,341,156 as of December 31, 2012 and March 31, 2012, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following exchange rates were adopted to translate the amounts from RMB into United States dollars (&#8220;USD$&#8221;) for the respective periods:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; width: 61%;">Quarter End RMB Exchange Rate (RMB/USD$)</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.2855</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.2943</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.3009</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Quarterly Average RMB Exchange Rate (RMB/USD$)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.2992</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.3933</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.3403</td><td style="text-align: left;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Recent accounting pronouncements</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In July 2012, FASB issued an amendment to the FASB Codification Topic 350 &#8211; Testing Indefinite-Lived Intangible Assets for Impairment. The objective of the amendments in this Update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-lived asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles &#8211; Goodwill and Other &#8211; General Intangibles Other than Goodwill. The more likely-than-not threshold is defined as having a likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company decided to adopt the amendment for the year starting with April 1, 2013. The Company does not expect the adoption of this pronouncement to have a significant impact on its financial condition or results of operations.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-family: times new roman,times;" size="2"><b>NOTE 3 &#8211; PREPAID ACCOUNTS</b></font></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-family: times new roman,times;" size="2">&#160;</font></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-family: times new roman,times;" size="2">The prepaid account is a prepayment to Shandong YCT for purchase of its health products. The amount is $20,916 and $20,887 as of December 31, 2012 and March 31, 2012, respectively.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 4 -&#160;INVENTORY</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Inventory consists of finished goods, work-in-process, and raw materials. No allowance for inventory was made for the three months and nine months ended December 31, 2012 and 2011.<font style="font-size: 10pt;"></font>The components of inventories were as follows:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Period&#160;Ended</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December&#160;31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March&#160;31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 74%;">Raw materials</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">1,112,873</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">272,873</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Work-in-progress</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">668,309</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">414,390</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left;">Finished goods</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">779,870</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,291,225</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; font-weight: bold;">Total Inventories</td><td style="font-weight: bold;">&#160;</td><td style="text-align: left; font-weight: bold;">$</td><td style="text-align: right; font-weight: bold;">2,561,052</td><td style="text-align: left; font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: left; font-weight: bold;">$</td><td style="text-align: right; font-weight: bold;">1,978,488</td><td style="text-align: left; font-weight: bold;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 5 &#8211; PLANT, PROPERTY AND EQUIPMENT, NET</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The components of property and equipment were as follows:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap">Period Ended</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 74%;">Machinery &amp; Equipment</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">617,363</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">538,461</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Furniture &amp; Fixture</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">164,767</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">164,536</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Building</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">10,123,714</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">10,109,560</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Subtotal</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10,905,844</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10,812,557</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated Depreciation</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,410,361</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,149,219</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;">Total plant, property and equipment, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">9,495,483</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">9,663,338</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The depreciation expense for the three months ended December 31, 2012 and 2011 was $84,813 and $27,885, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The depreciation expense for the nine months ended December 31, 2012 and 2011 was $261,143 and $155,283, respectively.</p> <div><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 6 &#8211; CONSTRUCTION IN PROGRESS</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Construction in progress represents direct costs of construction or acquisition and design fees incurred for the Company&#8217;s new plant and equipment. Capitalization of these costs ceases and the construction in progress is transferred to plant and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is made until construction is completed and put into use.</div></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 7 - MAJOR CUSTOMER AND VENDOR</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In the three and nine months ended December 31, 2012, the Company mainly sold products to individual retail customers through nine major distributors.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the three months ended December 31, 2012, the purchases from four major vendors was $1,802,900, representing 80% of the Company&#8217;s total purchases for the quarter.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the nine months ended December 31, 2012, the purchases from four major vendors was $9,445,424, representing 75% of the Company&#8217;s total purchases for the period.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 8 - INTANGIBLE ASSETS, NET</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The intangible assets of the Company consist of land use right and purchased patents.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Net land use right and purchased patents were as follows:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: left;" nowrap="nowrap">Amortization</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="6" nowrap="nowrap">As&#160;of</td><td nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td colspan="2" nowrap="nowrap">&#160;</td><td style="text-align: left;" nowrap="nowrap">Period</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">December 31,&#160;2012</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,&#160;2012</td><td nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 61%;">Land use right</td><td style="width: 1%;">&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left; width: 10%;">50 years</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">1,614,510</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">1,612,252</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(202,597</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(178,052</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt;">Land use right, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,411,913</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,434,200</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Patent 1</td><td>&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left;">16.5 years</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7,318,430</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7,308,199</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left;">Patent (non-US No. ZL200510045001.9)</td><td>&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left;">13.75 years</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9,863,973</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9,850,182</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Patent (non-US No. ZL200710013301.8)</td><td>&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left;">14.95 years</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,590,963</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,588,739</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(2,257,508</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,317,810</td><td style="text-align: left; padding-bottom: 1pt;">))</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt;">Patents, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">16,515,858</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">17,429,310</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The amortization expense of land use right for the three months ended December 31, 2012 and 2011 was $9,831 and $9,439, respectively.&#160;&#160;The amortization expense of patents for the three months ended December 31, 2012 and 2011 was $330,933 and $1,419,727, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The amortization expense of land use right for the nine months ended December 31, 2012 and 2011 was $24,545 and $29,856, respectively.&#160;&#160;The amortization expense of patents for the nine months ended December 31, 2012 and 2011 was $939,698 and $3,315,517, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 9 - TAX PAYABLE</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Tax payable as of December 31, 2012 and March 31, 2012 were as follows:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="font-weight: bold;" nowrap="nowrap">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">As of</td><td style="font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 74%; font-weight: bold;">Corporate Income Tax</td><td style="width: 1%; font-weight: bold;">&#160;</td><td style="text-align: left; width: 1%; font-weight: bold;">$</td><td style="text-align: right; width: 10%; font-weight: bold;">25,502</td><td style="text-align: left; width: 1%; font-weight: bold;">&#160;</td><td style="width: 1%; font-weight: bold;">&#160;</td><td style="text-align: left; width: 1%; font-weight: bold;">$</td><td style="text-align: right; width: 10%; font-weight: bold;">774,423</td><td style="text-align: left; width: 1%; font-weight: bold;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="font-weight: bold;">Value-Added Tax</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">369,944</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">225,223</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; font-weight: bold;">Other Tax &amp; Fees</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">29,426</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">18,897</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;">Total Tax Payable</td><td style="padding-bottom: 2.5pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold;">424,872</td><td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold;">1,018,543</td><td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 10 - INCOME TAXES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Shandong Spring Pharmaceutical Co., Ltd. is subject to the Enterprise income tax (&#8220;EIT&#8221;) at a statutory rate of 25%.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The expense associated with the recognition of a contingent obligation under ASC 480-10-25-8, is not tax deductible in China. Per ASC 740-10-25-3A, &#8220;An excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary or a foreign corporate joint venture that is essentially permanent in duration. &#8221; Therefore, the tax difference in the amount of $1,382,973 ($5,531,892 x 25% tax rate) caused by expense recognized on our book but not in the Chinese tax purpose at March 31, 2012 will be a permanent difference.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 28, 2011, the Company purchased a patent (the &#8220;US Patent&#8221;) pursuant to the terms of a purchase agreement with L.Y. Research Corp., a New Jersey corporation (&#8220;LY Research&#8221;), which purchase agreement was amended and restated on August 15, 2011 and amended on October 21, 2011 (the &#8220;Purchase Agreement), On October 29, 2012, due to the fact that the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a termination agreement to formally terminate the Purchase Agreement, and return the US Patent and the shares to LY Research and the Company, respectively. Prior to termination of the purchase agreement, the Company had conducted an impairment analysis with respect to the US Patent and concluded that an impairment was warranted. The loss from impairment of the US patent is not tax deductible in China. Therefore, the tax difference in the amount of $7,920,122 ($31,680,487 x 25%) caused by loss recognized on our book but not for the Chinese tax purpose at March 31, 2012 was a permanent difference. However, upon the return of the US Patent back to LY Research, the permanent tax differences associated with the recognition of the contingent obligation and the loss from impairment were reversed and there was no permanent tax difference at December 31, 2012.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the three months ended December 31, 2012 and 2011, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $258,827 and $1,112,777, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the nine months ended December 31, 2012 and 2011, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $1,585,251 and $2,283,837, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 11 &#8211; OTHER LIABILITY</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 28, 2011, the Company entered into the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Company acquired a patent (the &#8220;LY Patent&#8221;) from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research Corp., in exchange for 44,254,952 shares of the Company&#8217;s common stock at inception date. In addition, there were two contingent considerations of a total of 31,610,544 shares to be issued upon the occurrences of some pre-determined events. The first contingent consideration of 11,063,968 shares was required to be issued upon the Company&#8217;s stock being listed on OTCBB or OTCQB.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Because the obligation to issue additional shares to LY Research was contingent upon the occurrence of certain predetermined events, the liability was to be recognized when the contingencies were resolved. On September 9, 2011, LY Research became entitled to the issuance of 11,063,968 shares of common stock upon the occurrence of the quotation of the Company&#8217;s common stock on the OTCQB. Therefore, the liability to issue 11,063,968 shares of common stock should be recorded for the quarter ended September 30, 2011 and forward.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The amount of the liability is calculated by multiplying the 11,063,968 shares of stock by the quoted average stock price on September 9, 2011. The stock price per share on September 9, 2011 was $0.25. The calculation of the liability to issue 11,063,968 shares of the common stock is as followed:</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">Other Liability $2,765,992 = 11,063,968 shares x $0.25</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognized $2,765,992 as an &#8220;Other Liability&#8221; and an addition to the US patent, for the quarter ended September 30, 2011 and forward. As of March 31, 2012, the Patent was written-off due to impairment.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of October 21, 2012, because the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a termination agreement on October 29, 2012 to formally terminate the Purchase Agreement, and return the Patent and the shares to LY Research and the Company, respectively. As a result, the &#8220;Other Liability&#8221; of $2,765,992 was reversed as of December 31, 2012.</p> <div><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 12 &#8211; DERIVATIVE LIABILITY AND UNREALIZED GAIN</b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 28, 2011, the Company entered into the Purchase Agreement with LY Research; and the Purchase Agreement was amended and restated on August 15, 2011. Pursuant to the terms of the Purchase Agreement, the Company acquired the LY Patent from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research corp., in exchange for 44,254,952 shares of common stock at the acquisition date. In addition, 11,063,968 shares of common stock will be issued to the seller upon the occurrence of the quotation of the Company&#8217;s common stock on the OTCQB or OTCBB; and 20,546,711 shares will be issued to the seller upon the receipt by the Company of a minimum of $20,000,000 in gross proceeds from a debt or equity financing, or a series of debt and/or equity financings (the &#8220;Financing&#8221;); or upon the quotation of its common stock on NASDAQ or a major stock exchange located outside of the United States (collectively, &#8220;Events&#8221;). On September 9, 2011, the Company&#8217;s stock became quoted at OTCQB; therefore, 11,063,968 shares of common stock became issuable.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of October 21, 2011, the Purchase Agreement was further amended to state that if either of the Events should not occur within one year from October 21, 2011; the shares issued pursuant to the Purchase Agreement shall be returned to the Company and the LY Patent shall be returned to LY Research and the Purchase Agreement, as amended, shall be cancelled and of no further force or effect. Because the Company is required to acquire the issued shares by returning the US patent if the predetermined financing event is not met, the term meets the definition under the ASC 480-10-25-8, &#8220;Obligations to Repurchase Issuer&#8217;s Equity Shares by Transferring Assets&#8221;. Per ASC 480-10-25-8, the obligation to repurchase an issuer&#8217;s own shares by transferring asset should be recognized as a liability at inception.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In addition, because the acquisition was not a certain future event as of October 21, 2011 and forwards, the Company considers the contingent obligation to repurchase its own shares as a written put option. Per ASC 480-10-30-7, all <font style="color: windowtext;">financial instruments</font>, recognized under the guidance in Section <font style="color: windowtext;">480-10-25</font>, other than certain physically settled forward purchase contracts, shall be measured initially at fair value.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of the obligation on October 21, 2011 should be the market price of the shares that the company is obligated to repurchase if the financing is failing and weighted by the probability of the Company failing to meet the financing target of $20,000,000 or achieving the listing on NASDAQ or a major foreign stock exchange. On October 21, 2011, the company had issued and was obligated to issue 55,318,920 common shares to Dr. Liu. Therefore, the number of potential shares needed to repurchase was 55,318,920 on October 21, 2011.</div><div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</div><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>Determination of the market price of the shares:</u></i></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Per ASC 820-10-20 &#8220;Readily Determinable Fair Value&#8221;, &#8220;&#160;The fair value of an equity security is readily determinable if sales prices or bid-and-asked quotations are currently available on a securities exchange registered with the U.S. Securities and Exchange Commission (SEC) or in the over-the-counter market, provided that those prices or quotations for the over-the-counter market are publicly reported by the National Association of Securities Dealers Automated Quotations systems or by Pink Sheets LLC. Restricted stock meets that definition if the restriction terminates within one year. &#8221; Because the sales price of the company&#8217;s common stock shares was currently available in the over-the-counter market, the fair value of the company&#8217;s stock is readily determinable and is the sales price of the stock on October 21, 2011. Because the company&#8217;s common stock was not traded on October 21, 2011, the closest quotations were the prices on October 23, 2011, which was $0.40/share; therefore, the fair values per share for were $0.40 for October 21, 2011. As of September 30, 2012, the most recent quoted CYIG stock price was $0.02 (at September 28, 2012).</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i><u>Determination of the probability of the Company failing to meet the predetermined event:</u></i></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company determined that on October 21, 2011, the chance that the final contingency would not be met, thereby triggering our obligation to repurchase those shares, was around 15% based on the reasons described in its amended 10Q for the quarter ended December 31, 2011. Therefore, the Company recognized $3,319,135 as a derivative liability as of December 31, 2011.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">However, as of March 31, 2012, the Company was informed by its placement agent that it was highly unlikely to achieve the $20M financing by October 21, 2012. Therefore, the Company reassessed the probability of failing to achieve the financing target by October 21, 2012 to be 100% as of March 31, 2012 and forwards.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of the derivative obligation was calculated as follows:</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">$1,106,378 = 55,318,920 x $0.02/share x 100% at September 30, 2012, and</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">$5,531,892 = 55,318,920 x $0.10/share x 100% at March 31, 2012.</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of the derivative obligation was decreased by $4,425,514 at September 30, 2012 as a result of the CYIG stock price change. The decrease was recognized as unrealized gain reflecting a non-cash adjustment for changes in fair value of the Company&#8217;s derivative liability.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On October 29, 2012, because the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into the Termination Agreement to formally terminate the Purchase Agreement, and return the Patent and the shares to LY Research and the Company, respectively. As a result, the derivative obligation and the unrealized gain were reversed by the carrying amount of $1,106,378 and $4,425,514, respectively.</div></div> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 13 - STOCKHOLDERS&#8217; EQUITY</b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Stock Issued to Independent Directors</i></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The total amount of the compensation in the form of issuing shares of common stock to the independent directors was $50 and $22,222 for the periods ended December 31, 2012 and March 31, 2012, respectively.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Stock Cancelled for Return of Patent</i></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On February 28, 2011, the Company issued 44,254,952 shares of common stock, as a partial of total considerations to acquire a U.S. patent No. 6,475,531 B1 titled &#8220;Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function&#8221; from L.Y. Research Corp., a New Jersey Corporation.&#160;&#160; The shares of the common stock were valued at the average closing market price on February 28, 2011 in the amount of $32,748,665.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On October 29, 2012, because the conditions set in the Purchase Agreement with L.Y. Research Corp. were not fulfilled, the Company and LY Research entered into a termination agreement to formally terminate the Purchase Agreement, and returned the patent and the shares to LY Research and the Company, respectively. Subsequently, the Company cancelled the returned shares of the Company&#8217;s common stock. As a result of this cancellation, &#8220;Additional paid-in capital&#8221; and &#8220;Retained earnings&#8221; decreased by $32,704,410 and $32,748,664, respectively.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Statutory Reserve</i></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Subsidiaries incorporated in China are required to make appropriations to reserve funds, based on after-tax net income determined in accordance with generally accepted accounting principles of the People&#8217;s Republic of China (&#8220;PRC GAAP&#8221;).&#160;&#160;Effective January 1, 2006, the Company is only required to contribute to one statutory reserve fund at 10% of net income after tax per annum, and any contributions are not to exceed 50% of the respective companies&#8217; registered capital.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, the Company appropriated $956,633 to the statutory reserve.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Basis of presentation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Principles of consolidation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The consolidated financial statements include the financial statements of China YCT, Landway Nano and its wholly owned subsidiary, Shandong Spring.&#160;&#160;All inter-company transactions and balances are eliminated in consolidation.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Use of estimates</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of financial statements in conformity with US&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company&#8217;s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and cash equivalents</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Inventory</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of cost or market with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Property and equipment</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 1in; width: 60%;">Building</td><td style="width: 40%;">30-35 years</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">Machinery, equipment and automobiles</td><td>7-15 years</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">Furniture and fixtures</td><td>7-10 years</td></tr></table><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Intangible Assets</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: right; font-style: italic; width: 9%;"><i>(i)&#160;&#160;</i></td><td style="text-align: justify; font-style: italic; width: 91%;"><i>Land Use Rights:</i></td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">All land in the PRC is owned by the government and cannot be sold to any individual or company.&#160;&#160;However, the government may grant a &#8220;land use right&#8221; for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: right; font-style: italic; width: 9%;"><i>(ii)&#160;&#160;</i></td><td style="text-align: justify; font-style: italic; width: 91%;"><i>Patents:</i></td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In March 2010, the Company purchased one patent from Shandong YCT Corp.&#160;&#160;The patent is the Company&#8217;s exclusive right to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.&#160;&#160;The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are &#8220;Treatment to ischemic encephalopathy and its preparation method&#8221; (ZL200510045001.9) and &#8220;Chinese herbal medicine compound to treat renal insufficiency and its preparation&#8221; (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Revenue recognition</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s revenue recognition policies are in compliance with Staff Accounting Bulletin (&#8220;SAB&#8221;) 104, included in the Codification as ASC 605, <i>Revenue Recognition</i>. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Impairment of long-lived assets</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Per ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Per ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Income taxes</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (&#8221;SFAS&#8221;) No. 109, &#8220; Accounting for Income Taxes &#8221;, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred Income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2012 and March 31, 2012.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">China YCT International, Inc. is a holding company of Shandong Spring Pharmaceutical Co., Ltd and does not have any operating activities. Although the contract for the acquisition of the US patent acquired in February 2011 from LY Research Corp. was executed by the holding company, in substance, the patent was acquired by the Company&#8217;s operating entity in China. Therefore, the patent related income or expense does not result in any US income tax liabilities.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Value-added tax</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (&#8220;VAT&#8221;). All of the Company&#8217;s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company recorded net VAT Payable in amount of $369,944 and $225,223 as of December 31, 2012 and March 31, 2012, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and development</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Research and development costs relate to the Company&#8217;s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The research and development expense for the three months ended December 31, 2012 and 2011 was $723,790 and $183,693, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The research and development expense for the nine months ended December 31, 2012 and 2011 was $1,272,490 and $577,514, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Advertising costs</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Advertising costs for newspaper and television are expensed as incurred.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company incurred advertising costs of $158,750 and $157,712 for the three months ended December 31, 2012 and 2011, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company incurred advertising costs of $759,866 and $390,452 for the nine months ended December 31, 2012 and 2011, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Mailing and handling costs</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company accounts for mailing and handling fees in accordance with the <i>FASB ASC</i> 605-45 (<i>Emerging Issues Task Force</i> ( <i>EITF</i> ) <i>Issue No</i> . <i>00-10</i> , <i>Accounting for Shipping and Handling Fees and Costs</i> ). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the three months ended December 31, 2012 and 2011, the Company incurred $218,820 and $1,475 mailing and handling costs, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For the nine months ended December 31, 2012 and 2011, the Company incurred $765,413 and $662,629 mailing and handling costs, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock Based Compensation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.&#160;&#160;The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company&#8217;s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Net income (loss) per share (&#8220;EPS&#8221;)</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">There are nil and 31,610,679 common stock equivalents available for dilution purposes as of December 31, 2012 and 2011, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Risks and uncertainties</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s operations are carried out in the PRC. Accordingly, the Company&#8217;s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, and by the general state of the PRC&#8217;s economy. The Company&#8217;s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company&#8217;s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Foreign currency translation</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accounts of the Company&#8217;s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 830 &#8220;Foreign Currency Matters,&#8221; with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders&#8217; equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, &#8220;Comprehensive Income.&#8221; Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Translation adjustments resulting from this process amounted to $3,646,363 and $3,341,156 as of December 31, 2012 and March 31, 2012, respectively.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following exchange rates were adopted to translate the amounts from RMB into United States dollars (&#8220;USD$&#8221;) for the respective periods:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; width: 61%;">Quarter End RMB Exchange Rate (RMB/USD$)</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.2855</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.2943</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.3009</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Quarterly Average RMB Exchange Rate (RMB/USD$)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.2992</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.3933</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.3403</td><td style="text-align: left;"></td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Recent accounting pronouncements</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In July 2012, FASB issued an amendment to the FASB Codification Topic 350 &#8211; Testing Indefinite-Lived Intangible Assets for Impairment. The objective of the amendments in this Update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-lived asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles &#8211; Goodwill and Other &#8211; General Intangibles Other than Goodwill. The more likely-than-not threshold is defined as having a likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company decided to adopt the amendment for the year starting with April 1, 2013. The Company does not expect the adoption of this pronouncement to have a significant impact on its financial condition or results of operations.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 1in; width: 60%;">Building</td><td style="width: 40%;">30-35 years</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">Machinery, equipment and automobiles</td><td>7-15 years</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="padding-left: 1in;">Furniture and fixtures</td><td>7-10 years</td></tr></table><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following exchange rates were adopted to translate the amounts from RMB into United States dollars (&#8220;USD$&#8221;) for the respective periods:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; width: 61%;">Quarter End RMB Exchange Rate (RMB/USD$)</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.2855</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.2943</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td><td style="padding-bottom: 1pt; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">6.3009</td><td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Quarterly Average RMB Exchange Rate (RMB/USD$)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.2992</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.3933</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.3403</td><td style="text-align: left;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Inventory consists of finished goods, work-in-process, and raw materials. No allowance for inventory was made for the three months and nine months ended December 31, 2012 and 2011.<font style="font-size: 10pt;"></font>The components of inventories were as follows:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Period&#160;Ended</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December&#160;31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March&#160;31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 74%;">Raw materials</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">1,112,873</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">272,873</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Work-in-progress</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">668,309</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">414,390</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left;">Finished goods</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">779,870</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,291,225</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; font-weight: bold;">Total Inventories</td><td style="font-weight: bold;">&#160;</td><td style="text-align: left; font-weight: bold;">$</td><td style="text-align: right; font-weight: bold;">2,561,052</td><td style="text-align: left; font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: left; font-weight: bold;">$</td><td style="text-align: right; font-weight: bold;">1,978,488</td><td style="text-align: left; font-weight: bold;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The components of property and equipment were as follows:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap">Period Ended</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 74%;">Machinery &amp; Equipment</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">617,363</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">538,461</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Furniture &amp; Fixture</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">164,767</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">164,536</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Building</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">10,123,714</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">10,109,560</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Subtotal</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10,905,844</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">10,812,557</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated Depreciation</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,410,361</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,149,219</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;">Total plant, property and equipment, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">9,495,483</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">9,663,338</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Net land use right and purchased patents were as follows:</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: left;" nowrap="nowrap">Amortization</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="6" nowrap="nowrap">As&#160;of</td><td nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td colspan="2" nowrap="nowrap">&#160;</td><td style="text-align: left;" nowrap="nowrap">Period</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">December 31,&#160;2012</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,&#160;2012</td><td nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 61%;">Land use right</td><td style="width: 1%;">&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left; width: 10%;">50 years</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">1,614,510</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">1,612,252</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(202,597</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(178,052</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt;">Land use right, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,411,913</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,434,200</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Patent 1</td><td>&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left;">16.5 years</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7,318,430</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7,308,199</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left;">Patent (non-US No. ZL200510045001.9)</td><td>&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left;">13.75 years</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9,863,973</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9,850,182</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Patent (non-US No. ZL200710013301.8)</td><td>&#160;</td><td style="text-align: left;" colspan="2">&#160;</td><td style="text-align: left;">14.95 years</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,590,963</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,588,739</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated amortization</td><td style="padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(2,257,508</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,317,810</td><td style="text-align: left; padding-bottom: 1pt;">))</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt;">Patents, net</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;" colspan="2">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">16,515,858</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">17,429,310</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Tax payable as of December 31, 2012 and March 31, 2012 were as follows:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="font-weight: bold;" nowrap="nowrap">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">As of</td><td style="font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2012</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 74%; font-weight: bold;">Corporate Income Tax</td><td style="width: 1%; font-weight: bold;">&#160;</td><td style="text-align: left; width: 1%; font-weight: bold;">$</td><td style="text-align: right; width: 10%; font-weight: bold;">25,502</td><td style="text-align: left; width: 1%; font-weight: bold;">&#160;</td><td style="width: 1%; font-weight: bold;">&#160;</td><td style="text-align: left; width: 1%; font-weight: bold;">$</td><td style="text-align: right; width: 10%; font-weight: bold;">774,423</td><td style="text-align: left; width: 1%; font-weight: bold;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="font-weight: bold;">Value-Added Tax</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">369,944</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">225,223</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; font-weight: bold;">Other Tax &amp; Fees</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">29,426</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">18,897</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;">Total Tax Payable</td><td style="padding-bottom: 2.5pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold;">424,872</td><td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold;">1,018,543</td><td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold;">&#160;</td></tr></table> 1.00 1.00 P7Y P35Y P7Y P10Y P30Y P15Y P16Y6M P9Y10M24D P9Y10M24D P9Y10M24D P14Y11M12D P13Y9M P14Y11M12D P13Y9M P50Y P16Y6M 0.17 225223 369944 157712 390452 158750 759866 1475 662629 218820 765413 31610679 31610679 3341156 3646363 6.3549 6.3009 6.2943 6.2855 6.3403 6.3933 6.2992 272873 1112873 414390 668309 1291225 779870 538461 617363 164536 164767 10109560 10123714 10812557 10905844 1149219 1410361 27885 155283 84813 261143 9 4 1802900 9445424 0.80 0.75 1588739 9850182 7308199 1612252 1590963 9863973 7318430 1614510 178052 1317810 202597 2257508 9439 1419727 29856 3315517 9831 330933 24545 939698 774423 25502 225223 369944 18897 29426 0.25 0.25 0.25 0.25 0.25 1382973 1106378 5531892 4425514 1106378 7920122 31680487 44254952 44254952 2 31610544 31610544 20546711 11063968 0.74 0.74 0.25 0.25 2765992 20000000 20000000 20000000 20000000 P1Y 55318920 55318920 0.40 0.02 P1Y 0.15 1.00 1.00 2012-10-21 2012-10-21 22222 50 32748665 2765992 2765992 0.10 0.50 0000847464us-gaap:AccumulatedOtherComprehensiveIncomeMember2012-10-012012-12-31 474863 4648852 9 00008474642012-04-012012-06-30 5000 2252710 -40878 50 EX-101.CAL 6 cyig-20121231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 cyig-20121231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 cyig-20121231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 cyig-20121231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.SCH 10 cyig-20121231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - PREPAID ACCOUNTS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - INVENTORY link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT, NET link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - CONSTRUCTION IN PROGRESS link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - MAJOR CUSTOMER AND VENDOR link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - INTANGIBLE ASSETS, NET link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - TAX PAYABLE link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - OTHER LIABILITY link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - DERIVATIVE LIABILITY AND UNREALIZED GAIN link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - INVENTORY (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - PLANT, PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - TAX PAYABLE (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Useful Lives of Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars (Detail) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - PREPAID ACCOUNTS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Components of Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Components of Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - PLANT, PROPERTY AND EQUIPMENT, NET - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - MAJOR CUSTOMER AND VENDOR - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Net Land Use Right and Purchased Patent (Detail) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - INTANGIBLE ASSETS, NET - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Tax Payable (Detail) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - INCOME TAXES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - OTHER LIABILITY - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - DERIVATIVE LIABILITY AND UNREALIZED GAIN- Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
OTHER LIABILITY - Additional Information (Detail) (USD $)
1 Months Ended 1 Months Ended
Sep. 09, 2011
Feb. 28, 2011
Dec. 31, 2012
Patent (U.S. No. 6,475,531 B1)
Sep. 09, 2011
Patent (U.S. No. 6,475,531 B1)
L.Y. Hong Kong Biotech Limited
Feb. 28, 2011
Patent (U.S. No. 6,475,531 B1)
L.Y. Hong Kong Biotech Limited
Feb. 28, 2011
Patent (U.S. No. 6,475,531 B1)
L.Y. Hong Kong Biotech Limited
Scenario 1
Other Liabilities [Line Items]            
Common stock shares issued to acquire patent   44,254,952     44,254,952  
Number of contingent consideration         2  
Common stock, shares issuable   31,610,544     31,610,544 11,063,968
Common stock price, per share $ 0.25 $ 0.74   $ 0.25 $ 0.74  
Other Liability     $ 2,765,992      
XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
PLANT, PROPERTY AND EQUIPMENT, NET - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended
Dec. 31, 2012
Dec. 30, 2011
Dec. 31, 2012
Dec. 31, 2011
Property, Plant and Equipment [Line Items]        
Depreciation expense $ 84,813 $ 27,885 $ 261,143 $ 155,283
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
TAX PAYABLE (Tables)
9 Months Ended
Dec. 31, 2012
Tax Disclosure [Abstract]  
Tax Payable

Tax payable as of December 31, 2012 and March 31, 2012 were as follows:

 

  As of 
  December 31,
2012
  March 31,
2012
 
       
Corporate Income Tax $25,502  $774,423 
Value-Added Tax  369,944   225,223 
Other Tax & Fees  29,426   18,897 
         
Total Tax Payable $424,872  $1,018,543 
XML 15 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Tax Payable (Detail) (USD $)
Dec. 31, 2012
Mar. 31, 2012
Taxes [Line Items]    
Corporate Income Tax $ 25,502 $ 774,423
Value-Added Tax 369,944 225,223
Other Tax & Fees 29,426 18,897
Total Tax Payable $ 424,872 $ 1,018,543
XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
PREPAID ACCOUNTS
9 Months Ended
Dec. 31, 2012
Prepaid Expenses and Other Current Assets Disclosure [Abstract]  
PREPAID ACCOUNTS

NOTE 3 – PREPAID ACCOUNTS

 

The prepaid account is a prepayment to Shandong YCT for purchase of its health products. The amount is $20,916 and $20,887 as of December 31, 2012 and March 31, 2012, respectively.

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q M9F4P-3,U,&4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E1?3T9?4U1/ M0SPO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5$%.1TE"3$5?05-315137TY%5#PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E1!6%]005E!0DQ%/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!,04Y47U!23U!%4E197T%.1%]%455)4$U%3E1?3C$\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E5S M969U;%],:79E5]A;F1?13PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-!3E1? M04-#3U5.5#,\+W@Z3F%M93X-"B`@("`\>#I7;W)K&-H86YG95]2871E#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O6%B;&5?1&5T86EL/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+2$],1$524U]%455)5%E?061D:71I;VYA;#PO>#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V8V8C`P.&-D7V0P9#=?-&4P-5]B,#5B7S@R8S%F M93`U,S4P90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F-F(P,#AC M9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^0UE)1SQS<&%N/CPO'0^0TA)3D$@64-4($E.5$523D%4 M24].04P@1U)/55`L($E.0RX\2!#96YT3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#@T-S0V-#QS<&%N M/CPO'0^+2TP,RTS,3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F5D(&%N9"!I3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879AF5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XT-3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U M7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ+#$X-"PR,C<\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&=A:6X@;VX@9F%I'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S('!A>6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA6%B;&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XT,2PS,3D\2`H=7-E9"!I;BD@;W!E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6UE;G0O*&1E<&]S:70I('1O($II;FEN9R!4:6%N2`H=7-E9"!I M;BD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$W."PY,C(\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I M=CX\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M2`Q.3@Y+"!A;F0@2!O M<&5R871E2!.86YO($)I;RU496-H+"!);F,N("@Q,#`E(&]W;F5D*2P@:6YC M;W)P;W)A=&5D(&EN($1E;&%W87)E+"!A;F0@4VAA;F1O;F<@4W!R:6YG(%!H M87)M86-E=71I8V%L($-O+BP@3'1D+B`H)B,X,C(P.U-H86YD;VYG(%-P2!R969E2!O=VYE9"!S=6)S:61I87)Y+"!3:&%N9&]N M9R!3<')I;F'1R86-T+"!A;F0@;W1H97(@9&EE=&%R>2!S M=7!P;&5M96YT('!R;V1U8W1S(&EN('1H92!0+E(N($-H:6YA+CPO9&EV/CPO M9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`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`Q,#`E.R!B;W)D97(M8V]L;&%P6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UEF5D+CPO M<#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W=I9'1H.B`Q M,#`E.R!B;W)D97(M8V]L;&%P3L@9F]N M="US='EL93H@:71A;&EC.R!W:61T:#H@.3$E.R<^/&D^3&%N9"!52!T:&4@9V]V97)N;65N M="!A;F0@8V%N;F]T(&)E('-O;&0@=&\@86YY(&EN9&EV:61U86P@;W(@8V]M M<&%N>2XF(S$V,#LF(S$V,#M(;W=E=F5R+"!T:&4@9V]V97)N;65N="!M87D@ M9W)A;G0@82`F(S@R,C`[;&%N9"!U6QE/3-$ M)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE28C M.#(Q-SMS(&5X8VQU6-O;F4@='EP M92!A;F0@<'5R:69I8V%T:6]N(&UE=&AO9"!O9B!B:6]TF5D(&]V97(@=&AE('-H;W)T97(@;V8@:71S(')E;6%I;FEN9R!L96=A M;"!L:69E+"`Q-BXU('EE87)S+"!O3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE2!B87-E9"!O;B!A('!U2!D979E;&]P M;65N="!#;VUP86YY+"!,:6UI=&5D(&]N($]C=&]B97(@,C8L(#(P,3`[('=H M:6-H(&%R92`F(S@R,C`[5')E871M96YT('1O(&ES8VAE;6EC(&5N8V5P:&%L M;W!A=&AY(&%N9"!I=',@<')E<&%R871I;VX@;65T:&]D)B,X,C(Q.R`H6DPR M,#`U,3`P-#4P,#$N.2D@86YD("8C.#(R,#M#:&EN97-E(&AE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-EF5D(&%T('1H92!D871E(&]F('-H:7!M96YT('1O(&-U&5D(&]R(&1E=&5R;6EN86)L92P@=&AE(&1E;&EV97)Y(&ES M(&-O;7!L971E9"P@;F\@;W1H97(@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!R979I97=S(&%N9"!E=F%L M=6%T97,@=&AE(&YE="!C87)R>6EN9R!V86QU92!O9B!I=',@;&]N9RUL:79E M9"!A2!W:&5N979E&-E961S(&ET&-E961S('1H92!S=6T@ M;V8@=&AE('5N9&ES8V]U;G1E9"!C87-H(&9L;W=S(&5X<&5C=&5D('1O(')E M&5S/"]I M/CPO8CX\+W`^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!3=&%T96UE;G0@ M;V8@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A&5S("8C.#(R,3LL('=H:6-H(')E<75I"!A"!C;VYS97%U96YC97,@;V8@=&AE(&5V M96YT2!D:69F97)E;F-E"!A;F0@9FEN86YC:6%L('-T M871E;65N=',@8F%S97,@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE"!A2!T M:&%N(&YO="!T:&%T('-O;64@<&]R=&EO;B!O"!A3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2`R,#$Q(&9R;VT@3%D@ M4F5S96%R8V@@0V]R<"X@=V%S(&5X96-U=&5D(&)Y('1H92!H;VQD:6YG(&-O M;7!A;GDL(&EN('-U8G-T86YC92P@=&AE('!A=&5N="!W87,@86-Q=6ER960@ M8GD@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E28C.#(Q-SMS('!R;V1U8W1S('1H870@87)E('-O;&0@:6X@=&AE(%!20R!A M3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE'!E;G-E9"!A6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E'!E M;G-E(&9O6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE'!E;G-E9"!A6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2X\+W`^/'`@6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E2!H87,@8F5E;B!R96%C:&5D(&]R('1H M92!C;W5N=&5R<&%R='DF(S@R,3<[2!I;G-T6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!I&5R8VES960@;W(@8V]N=F5R=&5D(&EN=&\@8V]M;6]N('-T;V-K M+CPO<#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E28C.#(Q-SMS(&]P97)A=&EO;G,@:6X@=&AE(%!20R!A28C.#(Q-SMS(')E2!A9F9E8W1E9"!B M>2!C:&%N9V5S(&EN(&=O=F5R;FUE;G1A;"!P;VQI8VEE2!C;VYV97)S:6]N(&%N9"!R96UI='1A;F-E M(&%B&%T:6]N+"!A M;6]N9R!O=&AE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ#0H@:G5S=&EF>3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE2X\+W`^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE'0M86QI9VXZ(&-E;G1E M6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E M.R<^-BXR.#4U/"]T9#X\=&0@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-BXR.30S M/"]T9#X\=&0@'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-BXS,#`Y/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C8N M,CDY,CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^-BXS-#`S/"]T9#X\=&0@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE2!S:6UP;&EF>6EN9R!H;W<@86X@96YT:71Y M('1E2!I;B!I;7!A:7)M96YT('1E2UT:&%N+6YO M="!T:')E2!D;V5S(&YO="!E>'!E M8W0@=&AE(&%D;W!T:6]N(&]F('1H:7,@<')O;F]U;F-E;65N="!T;R!H879E M(&$@3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E M,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O M'0O:'1M M;#L@8VAA'0^/'`@3H@=&EM97,@ M;F5W(')O;6%N+'1I;65S.R<@3H@=&EM97,@;F5W(')O;6%N M+'1I;65S.R<@6UE;G0@=&\@4VAA;F1O;F<@64-4(&9O'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!W M87,@;6%D92!F;W(@=&AE('1H3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P M)3LG/C$L,3$R+#@W,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C(W,BPX-S,\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CPO M='(^/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#LG/C0Q-"PS.3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY&:6YI6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#LG/C6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PR.3$L,C(U/"]T9#X\=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT M+7=E:6=H=#H@8F]L9#LG/C$L.36QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T M9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U M,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D M-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2P@4&QA M;G0@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!A M;F0@97%U:7!M96YT('=E'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG M/C8Q-RPS-C,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,24[)SXD/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$V M-"PU,S8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X\+W1R/CQT6QE/3-$ M)W!A9&1I;F6QE M/3-$)W!A9&1I;F'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R<^,3`L M,3(S+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$P+#DP-2PX-#0\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,3`L.#$R+#4U M-SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`Q<'0@'0M86QI9VXZ(')I9VAT.R<^*#$L-#$P+#,V,3PO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\ M=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2X\+W`^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2X\+W`^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E M,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O M'0O:'1M M;#L@8VAA6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-EF%T M:6]N(&]F('1H97-E(&-O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!S;VQD('!R;V1U8W1S M('1O(&EN9&EV:61U86P@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E28C.#(Q-SMS('1O=&%L('!U3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)? M.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`V,24[)SY,86YD('5S92!R:6=H=#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!W:61T:#H@,3`E.R<^-3`@>65A6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`W,3`P,3,S,#$N."D\ M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<@8V]L6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L-3DP+#DV,SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^ M)B,Q-C`[/"]T9#X\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE2XF(S$V M,#LF(S$V,#M4:&4@86UOF%T:6]N(&5X<&5N2X\+W`^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE'!E;G-E(&]F('!A M=&5N=',@9F]R('1H92!N:6YE(&UO;G1H2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U M,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D M-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`Y-24[(&)O'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UW96EG M:'0Z(&)O;&0[)SXD/"]T9#X\=&0@6QE/3-$)W=I M9'1H.B`Q)3L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@,3`E.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C#PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#LG/C,V.2PY-#0\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,C(U+#(R,SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^ M/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`Q<'0@'0M86QI9VXZ(')I9VAT.R<^,CDL-#(V/"]T9#X\ M=&0@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R<^,3@L.#DW/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG M"!087EA M8FQE/"]T9#X\=&0@6QE/3-$)V)O M6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^)#PO=&0^/'1D('-T>6QE/3-$)V)O7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE"`H)B,X,C(P.T5)5"8C.#(R,3LI(&%T(&$@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&-E2!P97)M M86YE;G0@:6X@9'5R871I;VXN("8C.#(R,3L@5&AE"!R871E*2!C875S960@8GD@97AP96YS92!R96-O M9VYI>F5D(&]N(&]U2P@2!H860@8V]N9'5C=&5D(&%N(&EM<&%I"!D961U8W1I8FQE(&EN($-H:6YA+B!4:&5R969OF5D(&]N M(&]U"!P=7)P;W-E M(&%T($UA"!D:69F97)E M;F-E"!D:69F97)E;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$R+CPO<#X\<"!S M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E"!P6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!O M=VYE9"!C;VUP86YY(&)Y($PN62X@4F5S96%R8V@@0V]R<"XL(&EN(&5X8VAA M;F=E(&9O28C.#(Q M-SMS(&-O;6UO;B!S=&]C:R!A="!I;F-E<'1I;VX@9&%T92X@26X@861D:71I M;VXL('1H97)E('=E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!I2!T:&4@<75O=&5D(&%V97)A9V4@2!T;R!I"`P<'0@,"XU:6X[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UEF5D("0R+#28C.#(R,3L@86YD(&%N(&%D9&ET:6]N('1O('1H M92!54R!P871E;G0L(&9O3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!A;F0@3%D@ M4F5S96%R8V@@96YT97)E9"!I;G1O(&$@=&5R;6EN871I;VX@86=R965M96YT M(&]N($]C=&]B97(@,CDL(#(P,3(@=&\@9F]R;6%L;'D@=&5R;6EN871E('1H M92!0=7)C:&%S92!!9W)E96UE;G0L(&%N9"!R971U2X@07,@82!R97-U;'0L('1H92`F(S@R,C`[3W1H97(@ M3&EA8FEL:71Y)B,X,C(Q.R!O9B`D,BPW-C4L.3DR('=A3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U M8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA M3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE2`R."P@,C`Q,2P@=&AE($-O;7!A;GD@96YT M97)E9"!I;G1O('1H92!0=7)C:&%S92!!9W)E96UE;G0@=VET:"!,62!297-E M87)C:#L@86YD('1H92!0=7)C:&%S92!!9W)E96UE;G0@=V%S(&%M96YD960@ M86YD(')E2!O=VYE9"!C;VUP86YY(&)Y($PN62X@ M4F5S96%R8V@@8V]R<"XL(&EN(&5X8VAA;F=E(&9O3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!3:&%R97,@8GD@5')A;G-F97)R:6YG($%S2!T3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)V-O;&]R.B!W:6YD;W=T97AT.R<^9FEN86YC:6%L(&EN M2!A="!F86ER('9A;'5E+CPO<#X\ M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!T:&4@<')O8F%B:6QI='D@;V8@ M=&AE($-O;7!A;GD@9F%I;&EN9R!T;R!M965T('1H92!F:6YA;F-I;F<@=&%R M9V5T(&]F("0R,"PP,#`L,#`P(&]R(&%C:&EE=FEN9R!T:&4@;&ES=&EN9R!O M;B!.05-$05$@;W(@82!M86IO2!H860@:7-S=65D(&%N M9"!W87,@;V)L:6=A=&5D('1O(&ES3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!$971E M2!D M971E2!0:6YK(%-H965T65A28C.#(Q M-SMS(&-O;6UO;B!S=&]C:R!S:&%R97,@=V%S(&-U2!A=F%I;&%B M;&4@:6X@=&AE(&]V97(M=&AE+6-O=6YT97(@;6%R:V5T+"!T:&4@9F%I28C.#(Q-SMS('-T;V-K(&ES(')E861I;'D@ M9&5T97)M:6YA8FQE(&%N9"!I3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@=&5X="UI;F1E M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E"`D,"XP,B]S:&%R92!X(#$P,"4@870@4V5P=&5M M8F5R(#,P+"`R,#$R+"!A;F0\+W`^/'`@3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@@ M,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E"`D,"XQ,"]S:&%R M92!X(#$P,"4@870@36%R8V@@,S$L(#(P,3(N/"]P/CQP('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN M.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P="!T:6UE2X\+W`^/'`@3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E2P@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2X\ M+W`^/'`@3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE2`R."P@,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D(#0T M+#(U-"PY-3(@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE2!T97)M:6YA=&4@=&AE(%!U2P@=&AE($-O;7!A;GD@8V%N8V5L;&5D('1H92!R971U2`D,S(L-S`T+#0Q,"!A;F0@)#,R M+#2X\+W`^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!297-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E2!R97%U:7)E9"!T;R!C;VYT"!P97(@86YN=6TL(&%N9"!A;GD@8V]N=')I8G5T:6]N M6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5? M8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@ M8VAA3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!A6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE2!.86YO(&%N9"!I=',@ M=VAO;&QY(&]W;F5D('-U8G-I9&EA2!T'0^/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE'!E;G-E6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E2!C M;VUP;W-E9"!O9B!R87<@;6%T97)I86QS(&%N9"!P86-K:6YG(&UA=&5R:6%L M'0^/'`@6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!A;F0@ M97%U:7!M96YT(&%R92!S=&%T960@870@8V]S="X@5&AE(&-O6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!I=&%L:6,[('=I9'1H.B`Y)3LG/CQI M/BAI*28C,38P.R8C,38P.SPO:3X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!J=7-T:69Y.R!F;VYT+7-T>6QE.B!I=&%L:6,[('=I9'1H.B`Y,24[ M)SX\:3Y,86YD(%5S92!2:6=H=',Z/"]I/CPO=&0^/"]T6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!G6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!I=&%L:6,[('=I9'1H M.B`Y)3LG/CQI/BAI:2DF(S$V,#LF(S$V,#L\+VD^/"]T9#X\=&0@3L@9F]N="US='EL93H@:71A;&EC.R!W M:61T:#H@.3$E.R<^/&D^4&%T96YT6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE28C.#(Q-SMS(&5X8VQU6-O;F4@='EP92!A;F0@<'5R:69I8V%T:6]N(&UE=&AO9"!O9B!B M:6]TF5D(&]V97(@=&AE('-H;W)T97(@;V8@:71S M(')E;6%I;FEN9R!L96=A;"!L:69E+"`Q-BXU('EE87)S+"!O3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!B87-E9"!O;B!A('!U2!D979E;&]P;65N="!#;VUP86YY+"!,:6UI=&5D(&]N($]C=&]B M97(@,C8L(#(P,3`[('=H:6-H(&%R92`F(S@R,C`[5')E871M96YT('1O(&ES M8VAE;6EC(&5N8V5P:&%L;W!A=&AY(&%N9"!I=',@<')E<&%R871I;VX@;65T M:&]D)B,X,C(Q.R`H6DPR,#`U,3`P-#4P,#$N.2D@86YD("8C.#(R,#M#:&EN M97-E(&AE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M&ES M=',L('1H92!P2!I2!I6UE;G1S(')E8V5I=F5D M(&)E9F]R92!A;&P@;V8@=&AE(')E;&5V86YT(&-R:71E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2P@;W(@=7!O;B!T:&4@;V-C=7)R96YC92!O M9B!O=&AE6EN9R!A;6]U;G1S M(&UA>2!N;W0@8F4@2!N;W0@8F4@6EN9R!A;6]U;G0@;V8@=&AE(&QO M;F6EN9R!A M;6]U;G0@;V8@82!L;VYG+6QI=F5D(&%S&5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P M="`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`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E28C.#(Q-SMS(&1E=F5L;W!I;F<@:71S(&EN=&5L;&5C='5A;"!P M2X@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O'!E;G-E9"!A6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!I;F-U6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE2!A8V-O=6YT2!I;F-L M=61E2!T M:&4@0V]M<&%N>2!F;W(@9G)E:6=H="!A3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E2X\+W`^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE'0^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE'!E M;G-E(&9O65E('-T;V-K+6)A6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE2!I&5R8VES960@;W(@8V]N=F5R=&5D(&EN=&\@ M8V]M;6]N('-T;V-K+CPO<#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE28C.#(Q-SMS(&]P97)A=&EO;G,@87)E(&-A28C.#(Q-SMS M(&)U'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE28C.#(Q-SMS($-H:6YE M2!A2!W97)E('1R86YS;&%T960@:6YT;R!5 M4T0@:6X@86-C;W)D86YC92!W:71H($%C8V]U;G1I;F<@4W1A;F1A2!-871T97)S+"8C.#(R,3L@=VET:"!T:&4@ M4DU"(&%S('1H92!F=6YC=&EO;F%L(&-U2!T3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`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`[/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-BXS.3,S M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#LG/C8N,S0P,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE2!S:6UP;&EF>6EN9R!H;W<@ M86X@96YT:71Y('1E2!I;B!I;7!A:7)M96YT('1E2UT:&%N+6YO="!T:')E2!D M96-I9&5D('1O(&%D;W!T('1H92!A;65N9&UE;G0@9F]R('1H92!Y96%R('-T M87)T:6YG('=I=&@@07!R:6P@,2P@,C`Q,RX@5&AE($-O;7!A;GD@9&]E7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`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`[/"]T M9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M-BXS.3,S/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#LG/C8N,S0P,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X M,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B M,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA2!$:7-C;&]S=7)E M(%M!8G-T'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!W87,@;6%D92!F M;W(@=&AE('1H3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C$L,3$R M+#@W,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@ M=VED=&@Z(#$P)3LG/C(W,BPX-S,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T M>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#LG/C0Q-"PS.3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY&:6YI6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG M/C6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^,2PR.3$L,C(U/"]T9#X\=&0@6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)#PO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7=E:6=H=#H@ M8F]L9#LG/C$L.36QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X\+W1R/CPO M=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P M-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA2P@4&QA M;G0@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$ M)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG2`F M86UP.R!%<75I<&UE;G0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T M:#H@,24[)SXD/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-3,X+#0V,3PO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M,38T+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#LG/C$P+#@Q,BPU-3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R<^*#$L,30Y+#(Q M.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)V)O M6QE/3-$)V)O'1087)T7V8V8C`P.&-D7V0P M9#=?-&4P-5]B,#5B7S@R8S%F93`U,S4P90T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U M,&4O5V]R:W-H965T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`V,24[)SY,86YD('5S M92!R:6=H=#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!C;VQS<&%N/3-$ M,CXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,3`E.R<^-3`@>65A6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`W,3`P,3,S,#$N."D\+W1D/CQT9#XF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@8V]L6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!R:6=H=#LG/C$L-3DP+#DV,SPO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,38L-3$U+#@U.#PO=&0^/'1D M#0H@6QE/3-$)V)O3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E M,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'`@6%B;&4@87,@;V8@1&5C96UB97(@,S$L(#(P,3(@86YD($UA6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W'0M86QI9VXZ(&-E;G1E M6QE/3-$)W!A M9&1I;F6QE/3-$ M)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R!F;VYT+7=E M:6=H=#H@8F]L9#LG/C(U+#4P,CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#LG/C(R-2PR,C,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE M/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)#PO=&0^/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F'0M M86QI9VXZ(')I9VAT.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C$L,#$X+#4T,SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'1087)T7V8V8C`P.&-D7V0P9#=?-&4P-5]B,#5B7S@R8S%F93`U,S4P90T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F-F(P,#AC9%]D,&0W7S1E M,#5?8C`U8E\X,F,Q9F4P-3,U,&4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7V8V8C`P.&-D7V0P9#=?-&4P-5]B,#5B7S@R8S%F93`U,S4P M90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F-F(P,#AC9%]D,&0W M7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A;F0@97%U:7!M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS,"!Y96%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^,S4@>65A2P@97%U:7!M96YT(&%N9"!A=71O;6]B:6QE2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M65A2P@97%U:7!M96YT(&%N M9"!A=71O;6]B:6QE&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA M2P@4&QA;G0@86YD($5Q=6EP M;65N="!;3&EN92!)=&5M'1U'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^-R!Y96%R&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA M2P@4&QA;G0@86YD($5Q=6EP M;65N="!;3&EN92!)=&5M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)? M.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA'0^,3,@>65A'0^,30@>65A7,\65A7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-H86YG92!2871E&-H86YG92!2871E("A234(O55-$)"D\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)? M.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA'!E;G-E'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M M2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T* M("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2P@ M4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P M-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C9B,#`X8V1? M9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-3`@>65A'0^,3,@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#DL.#,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,S M,"PY,S,\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W M7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E M+U=O'0O M:'1M;#L@8VAA6%B;&4@*$1E=&%I;"D@*%531"`D M*3QB"!087EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#0R-"PX-S(\7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA"!A="!S=&%T=71O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!E;G-E(&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^,2!Y96%R/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^3V-T(#(Q+`T*"0DR,#$R/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3V-T(#(Q+`T*"0DR M,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F5D(&=A:6X@;VX@9F%I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ MF5D(&=A:6X@;VX@9F%I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W M7S1E,#5?8C`U8E\X,F,Q9F4P-3,U,&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C9B,#`X8V1?9#!D-U\T93`U7V(P-6)?.#)C,69E,#4S-3!E M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!R97-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&UL/@T*+2TM+2TM M/5].97AT4&%R=%]F-F(P,#AC9%]D,&0W7S1E,#5?8C`U8E\X,F,Q9F4P-3,U &,&4M+0T* ` end XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars (Detail)
3 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 30, 2011
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Foreign Currency Exchange Rate [Line Items]          
Quarter End RMB Exchange Rate (RMB/USD$) 6.2855   6.2943 6.3009 6.3549
Quarterly Average RMB Exchange Rate (RMB/USD$) 6.2992 6.3403 6.3933    
XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Feb. 28, 2011
Dec. 31, 2012
Dec. 30, 2011
Dec. 31, 2012
Dec. 31, 2011
Mar. 31, 2012
Dec. 31, 2012
Patent 1
Mar. 31, 2010
Patent 1
Shandong YCT
Oct. 31, 2011
Patents (non-US No. ZL200510045001.9)
Dec. 31, 2012
Patents (non-US No. ZL200510045001.9)
Oct. 31, 2011
Patents (non-US No. ZL200710013301.8)
Dec. 31, 2012
Patents (non-US No. ZL200710013301.8)
Dec. 31, 2012
Land use rights
Feb. 28, 2011
Patent (U.S. No. 6,475,531 B1)
Feb. 28, 2011
Patent (U.S. No. 6,475,531 B1)
L.Y. Hong Kong Biotech Limited
Accounting Policies [Line Items]                              
Useful life of intangible assets 9 years 10 months 24 days           16 years 6 months 16 years 6 months 13 years 9 months 13 years 9 months 14 years 11 months 12 days 14 years 11 months 12 days 50 years 9 years 10 months 24 days 9 years 10 months 24 days
Value-added tax rate   17.00%                          
Net VAT payable   $ 369,944   $ 369,944   $ 225,223                  
Research and development expense   723,790 183,693 1,272,490 577,514                    
Advertising costs   158,750 157,712 759,866 390,452                    
Mailing and handling costs   218,820 1,475 765,413 662,629                    
Shares used in computation of diluted earnings per share   31,610,679 31,610,679                        
Foreign currency transaction and translation adjustment   $ 3,646,363   $ 3,646,363   $ 3,341,156                  
XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
PREPAID ACCOUNTS - Additional Information (Detail) (USD $)
Dec. 31, 2012
Mar. 31, 2012
Prepaid Expenses [Line Items]    
Prepaid accounts $ 20,916 $ 20,887
Shandong YCT
   
Prepaid Expenses [Line Items]    
Prepaid accounts $ 20,916 $ 20,887
XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Components of Inventories (Detail) (USD $)
Dec. 31, 2012
Mar. 31, 2012
Inventory Disclosure [Line Items]    
Raw materials $ 1,112,873 $ 272,873
Work-in-progress 668,309 414,390
Finished goods 779,870 1,291,225
Total Inventories $ 2,561,052 $ 1,978,488
XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Dec. 31, 2012
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

 

Principles of consolidation

 

The consolidated financial statements include the financial statements of China YCT, Landway Nano and its wholly owned subsidiary, Shandong Spring.  All inter-company transactions and balances are eliminated in consolidation.

 

Use of estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.

 

Cash and cash equivalents

 

For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Inventory

 

Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of cost or market with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.

 

Property and equipment

 

Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:

 

Building30-35 years
  
Machinery, equipment and automobiles7-15 years
  
Furniture and fixtures7-10 years

 

Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.

 

Intangible Assets

 

(i)  Land Use Rights:

 

All land in the PRC is owned by the government and cannot be sold to any individual or company.  However, the government may grant a “land use right” for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.

 

(ii)  Patents:

 

In March 2010, the Company purchased one patent from Shandong YCT Corp.  The patent is the Company’s exclusive right to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.  The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.

 

In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are “Treatment to ischemic encephalopathy and its preparation method” (ZL200510045001.9) and “Chinese herbal medicine compound to treat renal insufficiency and its preparation” (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.

 

Revenue recognition

 

The Company’s revenue recognition policies are in compliance with Staff Accounting Bulletin (“SAB”) 104, included in the Codification as ASC 605, Revenue Recognition. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.

 

Impairment of long-lived assets

 

The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Per ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Per ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).

 

Income taxes

 

The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (”SFAS”) No. 109, “ Accounting for Income Taxes ”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred Income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2012 and March 31, 2012.

 

China YCT International, Inc. is a holding company of Shandong Spring Pharmaceutical Co., Ltd and does not have any operating activities. Although the contract for the acquisition of the US patent acquired in February 2011 from LY Research Corp. was executed by the holding company, in substance, the patent was acquired by the Company’s operating entity in China. Therefore, the patent related income or expense does not result in any US income tax liabilities.

 

Value-added tax

 

Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (“VAT”). All of the Company’s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.

 

The Company recorded net VAT Payable in amount of $369,944 and $225,223 as of December 31, 2012 and March 31, 2012, respectively.

 

Research and development

 

Research and development costs relate to the Company’s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.

 

The research and development expense for the three months ended December 31, 2012 and 2011 was $723,790 and $183,693, respectively.

 

The research and development expense for the nine months ended December 31, 2012 and 2011 was $1,272,490 and $577,514, respectively.

 

Advertising costs

 

Advertising costs for newspaper and television are expensed as incurred.

 

The Company incurred advertising costs of $158,750 and $157,712 for the three months ended December 31, 2012 and 2011, respectively.

 

The Company incurred advertising costs of $759,866 and $390,452 for the nine months ended December 31, 2012 and 2011, respectively.

 

Mailing and handling costs

 

The Company accounts for mailing and handling fees in accordance with the FASB ASC 605-45 (Emerging Issues Task Force ( EITF ) Issue No . 00-10 , Accounting for Shipping and Handling Fees and Costs ). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.

 

For the three months ended December 31, 2012 and 2011, the Company incurred $218,820 and $1,475 mailing and handling costs, respectively.

 

For the nine months ended December 31, 2012 and 2011, the Company incurred $765,413 and $662,629 mailing and handling costs, respectively.

 

Stock Based Compensation

 

The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.  The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.

 

Net income (loss) per share (“EPS”)

 

Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.

 

There are nil and 31,610,679 common stock equivalents available for dilution purposes as of December 31, 2012 and 2011, respectively.

 

Risks and uncertainties

 

The Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

As of December 31, 2012, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.

 

Foreign currency translation

 

The accounts of the Company’s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (“ASC”) Topic 830 “Foreign Currency Matters,” with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders’ equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, “Comprehensive Income.” Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.

 

Translation adjustments resulting from this process amounted to $3,646,363 and $3,341,156 as of December 31, 2012 and March 31, 2012, respectively.

 

The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:

 

  December 31,
2012
  March 31,
2012
  December 31,
2011
 
Quarter End RMB Exchange Rate (RMB/USD$)  6.2855   6.2943   6.3009 
Quarterly Average RMB Exchange Rate (RMB/USD$)  6.2992   6.3933   6.3403 

 

Recent accounting pronouncements

 

In July 2012, FASB issued an amendment to the FASB Codification Topic 350 – Testing Indefinite-Lived Intangible Assets for Impairment. The objective of the amendments in this Update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-lived asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles – Goodwill and Other – General Intangibles Other than Goodwill. The more likely-than-not threshold is defined as having a likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company decided to adopt the amendment for the year starting with April 1, 2013. The Company does not expect the adoption of this pronouncement to have a significant impact on its financial condition or results of operations.

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Components of Property and Equipment (Detail) (USD $)
Dec. 31, 2012
Mar. 31, 2012
Property, Plant and Equipment [Line Items]    
Machinery & Equipment $ 617,363 $ 538,461
Furniture & Fixture 164,767 164,536
Building 10,123,714 10,109,560
Subtotal 10,905,844 10,812,557
Less: Accumulated Depreciation (1,410,361) (1,149,219)
Total plant, property and equipment, net $ 9,495,483 $ 9,663,338
XML 24 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
DERIVATIVE LIABILITY AND UNREALIZED GAIN- Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 21, 2011
Sep. 09, 2011
Feb. 28, 2011
Dec. 31, 2012
Dec. 30, 2011
Dec. 31, 2012
Dec. 31, 2011
Mar. 31, 2012
Fair Value of Financial Instruments [Line Items]                
Common stock shares issued to acquire patent     44,254,952          
Common stock, shares issuable     31,610,544          
Minimum Proceeds from issuance of debt and/or equity in order to issue shares to sellers of patent   $ 20,000,000 $ 20,000,000          
Agreement cancellation period 1 year              
Number of shares issued 55,318,920              
Number of shares to be repurchased 55,318,920         55,318,920    
Fair value of price per share $ 0.40         $ 0.02    
Stock restriction period 1 year              
Percentage of shares to be repurchased       100.00%   100.00% 15.00% 100.00%
Derivative liability       0   0 3,319,135 5,531,892
Agreement expiration date       Oct. 21, 2012       Oct. 21, 2012
Unrealized gain on fair value of derivative       4,425,514 0 (5,531,892) 0  
L.Y. Hong Kong Biotech Limited
               
Fair Value of Financial Instruments [Line Items]                
Unrealized gain on fair value of derivative       1,106,378        
Patent (U.S. No. 6,475,531 B1)
               
Fair Value of Financial Instruments [Line Items]                
Minimum Proceeds from issuance of debt and/or equity in order to issue shares to sellers of patent   20,000,000            
Patent (U.S. No. 6,475,531 B1) | L.Y. Hong Kong Biotech Limited
               
Fair Value of Financial Instruments [Line Items]                
Common stock shares issued to acquire patent     44,254,952          
Common stock, shares issuable     31,610,544          
Patent (U.S. No. 6,475,531 B1) | L.Y. Hong Kong Biotech Limited | Minimum
               
Fair Value of Financial Instruments [Line Items]                
Minimum Proceeds from issuance of debt and/or equity in order to issue shares to sellers of patent     $ 20,000,000          
Patent (U.S. No. 6,475,531 B1) | L.Y. Hong Kong Biotech Limited | Scenario 1
               
Fair Value of Financial Instruments [Line Items]                
Common stock, shares issuable     11,063,968          
Patent (U.S. No. 6,475,531 B1) | L.Y. Hong Kong Biotech Limited | Scenario 2
               
Fair Value of Financial Instruments [Line Items]                
Common stock, shares issuable     20,546,711          
XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEET (USD $)
Dec. 31, 2012
Mar. 31, 2012
Current assets:    
Cash and cash equivalent $ 27,314,507 $ 22,146,240
Accounts receivable 0 115,938
Prepaid accounts 20,916 20,887
Inventory 2,561,052 1,978,488
Total current assets 29,896,475 24,261,553
Plant, property and equipment, net 9,495,483 9,663,338
Construction in progress 220,291 219,983
Intangible assets, net 17,927,772 18,863,510
Total assets 57,540,021 53,008,384
Current liabilities:    
Tax payable 424,872 1,018,543
Other payable 2,042,279 4,766,952
Total current liabilities 2,467,151 5,785,495
Derivative liabilities 0 5,531,892
Total liabilities 2,467,151 11,317,387
Stockholders' Equity    
Preferred stock, par value $500.00 per share; 45 shares authorized and issued at September 30, 2012 and March 31, 2012 22,500 22,500
Common stock, par value $0.001 per share; 100,000,000 shares authorized, 29,575,523 shares issued and outstanding at December 31, 2012; and 73,780,610 shares issued and outstanding at March 31, 2012, respectively 29,575 73,780
Additional paid-in capital 4,180,183 36,879,643
Statutory reserve 956,633 956,633
Retained earnings 46,237,617 417,285
Accumulated other comprehensive income 3,646,362 3,341,156
Total stockholders' equity 55,072,870 41,690,997
Total liabilities and stockholders' equity $ 57,540,021 $ 53,008,384
XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW (USD $)
9 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Cash Flows From Operating Activities:    
Net income $ 13,071,667 $ 2,078,782
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,225,386 3,693,018
Common stock cancellation pursuant to the Termination Agreement (2,765,993) 0
Unrealized gain on fair value of derivative (5,531,892) 0
Issue of common shares as compensation 5,000 0
Changes in operating assets and liabilities:    
Inventory (582,564) (2,424,798)
Accounts receivable 115,938 0
Taxes payable (593,671) (248,678)
Accrued expenses and other payables 41,319 7,620,588
Net cash provided by (used in) operating activities 4,985,291 10,718,912
Cash flows from investing activities:    
Addition to plant and equipment (73,502) (14,704,423)
Prepayment/(deposit) to Jining Tianruitong for purchase of patents 0 15,534,631
Net cash provided by (used in) investing activities (73,502) 830,208
Effect of exchange rate changes on cash and cash equivalents 256,578 847,926
Net increase (decrease) in cash and cash equivalents 5,168,267 12,397,046
Cash and cash equivalents at beginning of period 22,146,240 6,046,804
Cash and cash equivalents at ending of period 27,314,507 18,443,850
Cash paid during the periods for:    
Interest 82,138.00 0
Income taxes 2,178,922 2,178,687
Non-cash financing activities:    
Stock issued for services 50,000  
Stock cancelled for return of patent $ 44,255,087 $ 0
XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Land Use Right and Purchased Patent (Detail) (USD $)
1 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended
Feb. 28, 2011
Dec. 31, 2012
Mar. 31, 2012
Dec. 31, 2012
Land use rights
Mar. 31, 2012
Land use rights
Dec. 31, 2012
Patent 1
Mar. 31, 2012
Patent 1
Oct. 31, 2011
Patents (non-US No. ZL200510045001.9)
Dec. 31, 2012
Patents (non-US No. ZL200510045001.9)
Mar. 31, 2012
Patents (non-US No. ZL200510045001.9)
Oct. 31, 2011
Patents (non-US No. ZL200710013301.8)
Dec. 31, 2012
Patents (non-US No. ZL200710013301.8)
Mar. 31, 2012
Patents (non-US No. ZL200710013301.8)
Dec. 31, 2012
Patents
Mar. 31, 2012
Patents
Finite-Lived Intangible Assets [Line Items]                              
Amortization Period 9 years 10 months 24 days     50 years   16 years 6 months   13 years 9 months 13 years 9 months   14 years 11 months 12 days 14 years 11 months 12 days      
Intangible assets, gross       $ 1,614,510 $ 1,612,252 $ 7,318,430 $ 7,308,199   $ 9,863,973 $ 9,850,182   $ 1,590,963 $ 1,588,739    
Accumulated amortization       (202,597) (178,052)                 (2,257,508) (1,317,810)
Intangible assets, net   $ 17,927,772 $ 18,863,510 $ 1,411,913 $ 1,434,200                 $ 16,515,858 $ 17,429,310
XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORY (Tables)
9 Months Ended
Dec. 31, 2012
Inventory Disclosure [Abstract]  
Components of Inventories

Inventory consists of finished goods, work-in-process, and raw materials. No allowance for inventory was made for the three months and nine months ended December 31, 2012 and 2011.The components of inventories were as follows:

 

  Period Ended 
  December 31,
2012
  March 31,
2012
 
Raw materials $1,112,873  $272,873 
Work-in-progress  668,309   414,390 
Finished goods  779,870   1,291,225 
Total Inventories $2,561,052  $1,978,488 
XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
INTANGIBLE ASSETS, NET - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended
Dec. 31, 2012
Dec. 30, 2011
Dec. 31, 2012
Dec. 31, 2011
Land use rights
       
Finite-Lived Intangible Assets [Line Items]        
Amortization expense $ 9,831 $ 9,439 $ 24,545 $ 29,856
Patents
       
Finite-Lived Intangible Assets [Line Items]        
Amortization expense $ 330,933 $ 1,419,727 $ 939,698 $ 3,315,517
XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
INTANGIBLE ASSETS, NET (Tables)
9 Months Ended
Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]  
Net Land Use Right and Purchased Patent

Net land use right and purchased patents were as follows:

 

    Amortization  As of 
   Period  December 31, 2012  March 31, 2012 
Land use right  50 years  $1,614,510  $1,612,252 
Less: Accumulated amortization      (202,597)  (178,052)
Land use right, net      1,411,913   1,434,200 
Patent 1  16.5 years   7,318,430   7,308,199 
Patent (non-US No. ZL200510045001.9)  13.75 years   9,863,973   9,850,182 
Patent (non-US No. ZL200710013301.8)  14.95 years   1,590,963   1,588,739 
Less: Accumulated amortization      (2,257,508)  (1,317,810))
Patents, net     $16,515,858  $17,429,310 
XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PRINCIPAL ACTIVITIES
9 Months Ended
Dec. 31, 2012
Organization, Consolidation and Presentation Of Financial Statements [Abstract]  
ORGANIZATION AND PRINCIPAL ACTIVITIES

NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES

 

China YCT International Group, Inc. (“China YCT”) was incorporated in the State of Florida, in the United States of America (the “USA”) in January 1989, and reincorporated in the State of Delaware on April 4, 2007.   China YCT principally operates through directly owned subsidiaries: Landway Nano Bio-Tech, Inc. (100% owned), incorporated in Delaware, and Shandong Spring Pharmaceutical Co., Ltd. (“Shandong Spring”), (100% owned), incorporated in the People’s Republic of China (“PRC”). China YCT International Group, Inc. and its subsidiaries are collectively referred to as the “Company.”

 

China YCT, through its wholly owned subsidiary, Shandong Spring, is engaged in the business of developing, manufacturing and selling its own medicine from gingko extract, and other dietary supplement products in the P.R. China.
XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) (USD $)
Dec. 31, 2012
Mar. 31, 2012
Preferred stock, par value $ 500.00 $ 500.00
Preferred stock, shares authorized 45 45
Preferred stock, shares issued 45 45
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 29,575,523 73,780,610
Common stock, shares outstanding 29,575,523 73,780,610
XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
OTHER LIABILITY
9 Months Ended
Dec. 31, 2012
Other Liabilities Disclosure [Abstract]  
OTHER LIABILITY

NOTE 11 – OTHER LIABILITY

 

On February 28, 2011, the Company entered into the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Company acquired a patent (the “LY Patent”) from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research Corp., in exchange for 44,254,952 shares of the Company’s common stock at inception date. In addition, there were two contingent considerations of a total of 31,610,544 shares to be issued upon the occurrences of some pre-determined events. The first contingent consideration of 11,063,968 shares was required to be issued upon the Company’s stock being listed on OTCBB or OTCQB.

 

Because the obligation to issue additional shares to LY Research was contingent upon the occurrence of certain predetermined events, the liability was to be recognized when the contingencies were resolved. On September 9, 2011, LY Research became entitled to the issuance of 11,063,968 shares of common stock upon the occurrence of the quotation of the Company’s common stock on the OTCQB. Therefore, the liability to issue 11,063,968 shares of common stock should be recorded for the quarter ended September 30, 2011 and forward.

 

The amount of the liability is calculated by multiplying the 11,063,968 shares of stock by the quoted average stock price on September 9, 2011. The stock price per share on September 9, 2011 was $0.25. The calculation of the liability to issue 11,063,968 shares of the common stock is as followed:

 

Other Liability $2,765,992 = 11,063,968 shares x $0.25

 

We recognized $2,765,992 as an “Other Liability” and an addition to the US patent, for the quarter ended September 30, 2011 and forward. As of March 31, 2012, the Patent was written-off due to impairment.

 

As of October 21, 2012, because the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a termination agreement on October 29, 2012 to formally terminate the Purchase Agreement, and return the Patent and the shares to LY Research and the Company, respectively. As a result, the “Other Liability” of $2,765,992 was reversed as of December 31, 2012.

XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
9 Months Ended
Dec. 31, 2012
Feb. 11, 2013
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2012  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q3  
Trading Symbol CYIG  
Entity Registrant Name CHINA YCT INTERNATIONAL GROUP, INC.  
Entity Central Index Key 0000847464  
Current Fiscal Year End Date --03-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock Shares Outstanding   29,575,523
XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
DERIVATIVE LIABILITY AND UNREALIZED GAIN
9 Months Ended
Dec. 31, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE LIABILITY AND UNREALIZED GAIN

NOTE 12 – DERIVATIVE LIABILITY AND UNREALIZED GAIN

 

On February 28, 2011, the Company entered into the Purchase Agreement with LY Research; and the Purchase Agreement was amended and restated on August 15, 2011. Pursuant to the terms of the Purchase Agreement, the Company acquired the LY Patent from L.Y. (HK) Biotech Limited, a wholly owned company by L.Y. Research corp., in exchange for 44,254,952 shares of common stock at the acquisition date. In addition, 11,063,968 shares of common stock will be issued to the seller upon the occurrence of the quotation of the Company’s common stock on the OTCQB or OTCBB; and 20,546,711 shares will be issued to the seller upon the receipt by the Company of a minimum of $20,000,000 in gross proceeds from a debt or equity financing, or a series of debt and/or equity financings (the “Financing”); or upon the quotation of its common stock on NASDAQ or a major stock exchange located outside of the United States (collectively, “Events”). On September 9, 2011, the Company’s stock became quoted at OTCQB; therefore, 11,063,968 shares of common stock became issuable.

 

As of October 21, 2011, the Purchase Agreement was further amended to state that if either of the Events should not occur within one year from October 21, 2011; the shares issued pursuant to the Purchase Agreement shall be returned to the Company and the LY Patent shall be returned to LY Research and the Purchase Agreement, as amended, shall be cancelled and of no further force or effect. Because the Company is required to acquire the issued shares by returning the US patent if the predetermined financing event is not met, the term meets the definition under the ASC 480-10-25-8, “Obligations to Repurchase Issuer’s Equity Shares by Transferring Assets”. Per ASC 480-10-25-8, the obligation to repurchase an issuer’s own shares by transferring asset should be recognized as a liability at inception.

 

In addition, because the acquisition was not a certain future event as of October 21, 2011 and forwards, the Company considers the contingent obligation to repurchase its own shares as a written put option. Per ASC 480-10-30-7, all financial instruments, recognized under the guidance in Section 480-10-25, other than certain physically settled forward purchase contracts, shall be measured initially at fair value.

 

The fair value of the obligation on October 21, 2011 should be the market price of the shares that the company is obligated to repurchase if the financing is failing and weighted by the probability of the Company failing to meet the financing target of $20,000,000 or achieving the listing on NASDAQ or a major foreign stock exchange. On October 21, 2011, the company had issued and was obligated to issue 55,318,920 common shares to Dr. Liu. Therefore, the number of potential shares needed to repurchase was 55,318,920 on October 21, 2011.
 

Determination of the market price of the shares:

 

Per ASC 820-10-20 “Readily Determinable Fair Value”, “ The fair value of an equity security is readily determinable if sales prices or bid-and-asked quotations are currently available on a securities exchange registered with the U.S. Securities and Exchange Commission (SEC) or in the over-the-counter market, provided that those prices or quotations for the over-the-counter market are publicly reported by the National Association of Securities Dealers Automated Quotations systems or by Pink Sheets LLC. Restricted stock meets that definition if the restriction terminates within one year. ” Because the sales price of the company’s common stock shares was currently available in the over-the-counter market, the fair value of the company’s stock is readily determinable and is the sales price of the stock on October 21, 2011. Because the company’s common stock was not traded on October 21, 2011, the closest quotations were the prices on October 23, 2011, which was $0.40/share; therefore, the fair values per share for were $0.40 for October 21, 2011. As of September 30, 2012, the most recent quoted CYIG stock price was $0.02 (at September 28, 2012).

 

Determination of the probability of the Company failing to meet the predetermined event:

 

The Company determined that on October 21, 2011, the chance that the final contingency would not be met, thereby triggering our obligation to repurchase those shares, was around 15% based on the reasons described in its amended 10Q for the quarter ended December 31, 2011. Therefore, the Company recognized $3,319,135 as a derivative liability as of December 31, 2011.

 

However, as of March 31, 2012, the Company was informed by its placement agent that it was highly unlikely to achieve the $20M financing by October 21, 2012. Therefore, the Company reassessed the probability of failing to achieve the financing target by October 21, 2012 to be 100% as of March 31, 2012 and forwards.

 

The fair value of the derivative obligation was calculated as follows:

$1,106,378 = 55,318,920 x $0.02/share x 100% at September 30, 2012, and

$5,531,892 = 55,318,920 x $0.10/share x 100% at March 31, 2012.

 

The fair value of the derivative obligation was decreased by $4,425,514 at September 30, 2012 as a result of the CYIG stock price change. The decrease was recognized as unrealized gain reflecting a non-cash adjustment for changes in fair value of the Company’s derivative liability.

 

On October 29, 2012, because the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into the Termination Agreement to formally terminate the Purchase Agreement, and return the Patent and the shares to LY Research and the Company, respectively. As a result, the derivative obligation and the unrealized gain were reversed by the carrying amount of $1,106,378 and $4,425,514, respectively.
XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (USD $)
3 Months Ended 9 Months Ended
Dec. 31, 2012
Dec. 30, 2011
Dec. 31, 2012
Dec. 31, 2011
Sales Revenue $ 6,922,363 $ 10,112,489 $ 23,521,007 $ 26,477,760
Cost of Goods Sold 3,450,065 4,712,730 11,367,854 11,894,299
Gross Profit 3,472,298 5,399,759 12,153,153 14,583,461
Selling Expenses 552,318 713,694 2,216,642 2,505,249
G&A Expense 1,184,227 1,570,674 2,387,125 4,028,897
R&D Expenses 723,790 183,693 1,272,490 577,514
Total expense 2,460,335 2,468,061 5,876,257 7,111,660
Income from operation 1,011,963 2,931,698 6,276,896 7,471,801
Interest income (Expense) 23,346 65,818 82,138 209,953
Other income (Expense) 3,872,370 (3,319,135) 8,297,884 (3,319,135)
Profit before tax 4,907,679 (321,619) 14,656,918 4,362,619
Income tax 258,827 1,112,777 1,585,251 2,283,837
Net income 4,648,852 (1,434,396) 13,071,667 2,078,782
Other comprehensive income        
Foreign currency translation adjustment 474,863 (1,724) 305,206 847,925
Comprehensive income $ 5,123,715 $ (1,436,120) $ 13,376,873 $ 2,926,707
Basic and diluted income per common share        
Basic and Diluted $ 0.11 $ 0.00 $ 0.22 $ 0.03
Weighted average number of common shares outstanding        
Basic and Diluted 43,029,245 73,780,610 60,029,581 73,780,610
XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSTRUCTION IN PROGRESS
9 Months Ended
Dec. 31, 2012
Construction In Progress Disclosure [Abstract]  
CONSTRUCTION IN PROGRESS

NOTE 6 – CONSTRUCTION IN PROGRESS

 

Construction in progress represents direct costs of construction or acquisition and design fees incurred for the Company’s new plant and equipment. Capitalization of these costs ceases and the construction in progress is transferred to plant and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is made until construction is completed and put into use.
XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
PLANT, PROPERTY AND EQUIPMENT, NET
9 Months Ended
Dec. 31, 2012
Property, Plant and Equipment [Abstract]  
PLANT, PROPERTY AND EQUIPMENT, NET

NOTE 5 – PLANT, PROPERTY AND EQUIPMENT, NET

 

The components of property and equipment were as follows:

 

  Period Ended 
  December 31,
2012
  March 31,
2012
 
Machinery & Equipment $617,363  $538,461 
Furniture & Fixture  164,767   164,536 
Building  10,123,714   10,109,560 
Subtotal  10,905,844   10,812,557 
Less: Accumulated Depreciation  (1,410,361)  (1,149,219)
Total plant, property and equipment, net $9,495,483  $9,663,338 

 

The depreciation expense for the three months ended December 31, 2012 and 2011 was $84,813 and $27,885, respectively.

 

The depreciation expense for the nine months ended December 31, 2012 and 2011 was $261,143 and $155,283, respectively.

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
PLANT, PROPERTY AND EQUIPMENT, NET (Tables)
9 Months Ended
Dec. 31, 2012
Property, Plant and Equipment [Abstract]  
Components of Property and Equipment

The components of property and equipment were as follows:

 

  Period Ended 
  December 31,
2012
  March 31,
2012
 
Machinery & Equipment $617,363  $538,461 
Furniture & Fixture  164,767   164,536 
Building  10,123,714   10,109,560 
Subtotal  10,905,844   10,812,557 
Less: Accumulated Depreciation  (1,410,361)  (1,149,219)
Total plant, property and equipment, net $9,495,483  $9,663,338 
XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY
9 Months Ended
Dec. 31, 2012
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 13 - STOCKHOLDERS’ EQUITY

 

Stock Issued to Independent Directors

 

The total amount of the compensation in the form of issuing shares of common stock to the independent directors was $50 and $22,222 for the periods ended December 31, 2012 and March 31, 2012, respectively.

 

Stock Cancelled for Return of Patent

 

On February 28, 2011, the Company issued 44,254,952 shares of common stock, as a partial of total considerations to acquire a U.S. patent No. 6,475,531 B1 titled “Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function” from L.Y. Research Corp., a New Jersey Corporation.   The shares of the common stock were valued at the average closing market price on February 28, 2011 in the amount of $32,748,665.

 

On October 29, 2012, because the conditions set in the Purchase Agreement with L.Y. Research Corp. were not fulfilled, the Company and LY Research entered into a termination agreement to formally terminate the Purchase Agreement, and returned the patent and the shares to LY Research and the Company, respectively. Subsequently, the Company cancelled the returned shares of the Company’s common stock. As a result of this cancellation, “Additional paid-in capital” and “Retained earnings” decreased by $32,704,410 and $32,748,664, respectively.

 

Statutory Reserve

 

Subsidiaries incorporated in China are required to make appropriations to reserve funds, based on after-tax net income determined in accordance with generally accepted accounting principles of the People’s Republic of China (“PRC GAAP”).  Effective January 1, 2006, the Company is only required to contribute to one statutory reserve fund at 10% of net income after tax per annum, and any contributions are not to exceed 50% of the respective companies’ registered capital.

 

As of December 31, 2012, the Company appropriated $956,633 to the statutory reserve.

XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
TAX PAYABLE
9 Months Ended
Dec. 31, 2012
Tax Disclosure [Abstract]  
TAX PAYABLE

NOTE 9 - TAX PAYABLE

 

Tax payable as of December 31, 2012 and March 31, 2012 were as follows:

 

  As of 
  December 31,
2012
  March 31,
2012
 
       
Corporate Income Tax $25,502  $774,423 
Value-Added Tax  369,944   225,223 
Other Tax & Fees  29,426   18,897 
         
Total Tax Payable $424,872  $1,018,543 
XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
MAJOR CUSTOMER AND VENDOR
9 Months Ended
Dec. 31, 2012
Risks and Uncertainties [Abstract]  
MAJOR CUSTOMER AND VENDOR

NOTE 7 - MAJOR CUSTOMER AND VENDOR

 

In the three and nine months ended December 31, 2012, the Company mainly sold products to individual retail customers through nine major distributors.

 

For the three months ended December 31, 2012, the purchases from four major vendors was $1,802,900, representing 80% of the Company’s total purchases for the quarter.

 

For the nine months ended December 31, 2012, the purchases from four major vendors was $9,445,424, representing 75% of the Company’s total purchases for the period.

XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
INTANGIBLE ASSETS, NET
9 Months Ended
Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS, NET

NOTE 8 - INTANGIBLE ASSETS, NET

 

The intangible assets of the Company consist of land use right and purchased patents.

 

Net land use right and purchased patents were as follows:

 

    Amortization  As of 
   Period  December 31, 2012  March 31, 2012 
Land use right  50 years  $1,614,510  $1,612,252 
Less: Accumulated amortization      (202,597)  (178,052)
Land use right, net      1,411,913   1,434,200 
Patent 1  16.5 years   7,318,430   7,308,199 
Patent (non-US No. ZL200510045001.9)  13.75 years   9,863,973   9,850,182 
Patent (non-US No. ZL200710013301.8)  14.95 years   1,590,963   1,588,739 
Less: Accumulated amortization      (2,257,508)  (1,317,810))
Patents, net     $16,515,858  $17,429,310 

 

The amortization expense of land use right for the three months ended December 31, 2012 and 2011 was $9,831 and $9,439, respectively.  The amortization expense of patents for the three months ended December 31, 2012 and 2011 was $330,933 and $1,419,727, respectively.

 

The amortization expense of land use right for the nine months ended December 31, 2012 and 2011 was $24,545 and $29,856, respectively.  The amortization expense of patents for the nine months ended December 31, 2012 and 2011 was $939,698 and $3,315,517, respectively.

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
INCOME TAXES
9 Months Ended
Dec. 31, 2012
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 10 - INCOME TAXES

 

Shandong Spring Pharmaceutical Co., Ltd. is subject to the Enterprise income tax (“EIT”) at a statutory rate of 25%.

 

The expense associated with the recognition of a contingent obligation under ASC 480-10-25-8, is not tax deductible in China. Per ASC 740-10-25-3A, “An excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary or a foreign corporate joint venture that is essentially permanent in duration. ” Therefore, the tax difference in the amount of $1,382,973 ($5,531,892 x 25% tax rate) caused by expense recognized on our book but not in the Chinese tax purpose at March 31, 2012 will be a permanent difference.

 

On February 28, 2011, the Company purchased a patent (the “US Patent”) pursuant to the terms of a purchase agreement with L.Y. Research Corp., a New Jersey corporation (“LY Research”), which purchase agreement was amended and restated on August 15, 2011 and amended on October 21, 2011 (the “Purchase Agreement), On October 29, 2012, due to the fact that the conditions set in the Purchase Agreement were not fulfilled, the Company and LY Research entered into a termination agreement to formally terminate the Purchase Agreement, and return the US Patent and the shares to LY Research and the Company, respectively. Prior to termination of the purchase agreement, the Company had conducted an impairment analysis with respect to the US Patent and concluded that an impairment was warranted. The loss from impairment of the US patent is not tax deductible in China. Therefore, the tax difference in the amount of $7,920,122 ($31,680,487 x 25%) caused by loss recognized on our book but not for the Chinese tax purpose at March 31, 2012 was a permanent difference. However, upon the return of the US Patent back to LY Research, the permanent tax differences associated with the recognition of the contingent obligation and the loss from impairment were reversed and there was no permanent tax difference at December 31, 2012.

 

For the three months ended December 31, 2012 and 2011, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $258,827 and $1,112,777, respectively.

 

For the nine months ended December 31, 2012 and 2011, Shandong Spring Pharmaceutical Co., Ltd. recorded income tax provisions of $1,585,251 and $2,283,837, respectively.

XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
MAJOR CUSTOMER AND VENDOR - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended
Dec. 31, 2012
Dec. 31, 2012
Concentration Risk [Line Items]    
Number of major distributors 9 9
Supplier Concentration Risk
   
Concentration Risk [Line Items]    
Number of major vendors 4 4
Purchases from major suppliers 1,802,900 9,445,424
Percentage of purchases from major suppliers 80.00% 75.00%
XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Dec. 31, 2012
Accounting Policies [Abstract]  
Useful Lives of Property and Equipment

Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:

 

Building30-35 years
  
Machinery, equipment and automobiles7-15 years
  
Furniture and fixtures7-10 years

 

Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars

The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:

 

  December 31,
2012
  March 31,
2012
  December 31,
2011
 
Quarter End RMB Exchange Rate (RMB/USD$)  6.2855   6.2943   6.3009 
Quarterly Average RMB Exchange Rate (RMB/USD$)  6.2992   6.3933   6.3403 

 

XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PRINCIPAL ACTIVITIES - Additional Information (Detail)
7 Months Ended
Sep. 30, 2012
Landway Nano Bio-Tech, Inc.
 
Organization and Principal Activities [Line Items]  
Percentage of ownership in subsidiaries 100.00%
Shandong Spring Pharmaceutical Co., Ltd.
 
Organization and Principal Activities [Line Items]  
Percentage of ownership in subsidiaries 100.00%
ZIP 49 0001144204-13-008541-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-008541-xbrl.zip M4$L#!!0````(`!-,3D*'/"3]DG,```HN!``1`!P`8WEI9RTR,#$R,3(S,2YX M;6Q55`D``X7U'%&%]1Q1=7@+``$$)0X```0Y`0``[%U9<^.XM7Y/5?Z#XH<\ MC6P"W#W=3LE;MS/>8KLGTW7O+1=-01(S%*EP<5N3JOSV"Y!:0(DB"1&4*(DS MZ?2()'"^L^#@8#G`I[]]#.W6._)\RW4^'X%CX:B%'-/M6D[_\]&WE^NV=O2W MLS__Z=-?VNW6%^0@SPA0MQ7Z^'WKZH_V;^=/M]/B+>58.,8UM/Y'@"=`/($" M$%N"?BKKIR)H=>[^K_4V;ET:@?'B&>;O?JO=GE9\;OBX4EQ#5!T\!O-WT9-+ MUPR'R`E:=QA8S\+?_K""`:'_JX5^(*_UZP0!IGXL'VNDJI=!Z/E=8_Q3ZQJ] M>:'AC5M`^JD5@U).H7(J*1C4A-+'FV=;I^3_6U@@CG]JCBTL@$$0C$Y/3G[\ M^'$\-H.^YX:C8],=$M8@@"(XFGQM6\[OB:])3<>NU\=?"N()>?V&>9Q^3MYV MK5D!^F/E)'XY^W2IZA]B]"W0=?TD>CO[U+?2/L25@I/?[FZ?S0$:&FW+\0/# M,1-8K`SLB]];OBM!H&:5B+^8%NBBD8=,8C8KR^@GAF=ZKHU.>H89M-''R#8< M(W"]\37^/:W(=$,G\,9)L?G(/.Z[[R>3EY%FV@)HSW5CAIZ'37I5N_(FI8#EO",_2"\2OTLIY!B6Z:>7B5Z1(B!9Q+?,]`+X M1=KGP!EF@]\> MD>9+FL&I'QGX$^JUHF9Q.K&I[,9S,O+<$?(""_ET,XTJ",8C7-JWAB-[]FS@ MH=[G(^(=VE,G4<##FY*6%V\+DP]>+T`_< MX2N6S]\-ITU_[:ZY`EV@5XK8C?)W511%S>_')T)^!]-4B5% M^G2R6)A4>)).`0O#P'VV@@_PN#D-M$EG)>GW\]`=^<%%*)Y`=`$ MIV^G3^8D3Q)B*B0W$;3O#(\H0WB]MAPK0+?6.^K>.-AK]:TW&W5\'P7^^?C. M^)?K7=B&[W<^+/_U$6-P@@<'W:'A&_)>;U'?L*\B843OGP>&TW6=_G*]3: M.!@AM@IJU<;C/CZ(98!;*VQ#;5YZ_I:S#-9HK]=NZ*UHL+?CK]C$?L%_SBTW M0.;@UAKBVKO[W7+G`JFFZ69+M8HV?`#&^/H90DM<`%:Z<6`JMS4\R\O`0WL^_TRQN!'?LHY] M5+%6S\<^]GT-K]+5K=K:AGAW17J=2V3NI<.%B8ZJ(J$QM:9;P^E^\]&3U1\$ M_KZVJ!0F:]JJZF<@L3?:1].8%DIP>%!V,8OR:^EO%Z+\!1GPBO)UTC9`/26P M/#R4UC"<"KKI!:$U/4Y=>IQ],)"FQ]E?NY@M.]72WZ;T.)4M.T%]NFP-ZRL# M&"T_ZFO*8/YOAC2NOU]1RY#UDD799@2K2G=8$-KKC6.Z0_1B?'3"8.!ZTT6D MB_NZN\]TX+@3C=,-3R_NZ^@>-Z;72]1#GH>Z%^YPA$5GD(RWCN>1C0R$Y7]: MP>#&Z5KO5C!X:$HU??1&)/7N`=ZL0(;/?3F'T5V@7\B7!_1X:7E(3-P MO1WI;JL1R"1H6RV6@S+"Q:TA]?+)B_U3I5M#J*;8+&%L?@ECAW3=+$<Y45=_3O$`$FPZ#HD_HLTW.EV+1(W&O:C86&)71@C M*S#LW=!U)FOS&:9,'@]'U?CGT'6>`]?\?:_4N\37X:BT8YKA,+3)>43M@K51?F]W!,X`D%AN6@[I7A.9;3][\YQH@<,^19QL[LD"ZH M_2*L[I/BFW6BC:X3[4;[[AQ*ZUYF]'"4_HRI(+_SZ$UF>/JFXF#O9.I5#[??!:KFFQ-F]66OS%-J3*- MK0GAJP_A]T#_3;R_P7A_#^RE&1Q4'B?6V4HF!]W4:QYT88\XEH'*ND=\TS;3N.,-NN.:64J4!D592I,&=4!I4(R'8U1FA(M'X-4K,EB'J!+Z;DY`*;DS`?;/<:5#3I35+MT,X3A='\8XWO#<2>7&&`9UKO19ES( ML)J91N_I^^B?<6?E]!\'AC$UAS9L_U;!_;*.)HS?AK#:`Z+:0RDR5'?XEG&^V07S6EB M!V$8S9KI%O>O[[1M-(NLC0TT2W*;WPA75TMAF1.LMV6L-QW8F`#N$AP3,^-% M>_Z>+/_W\_'+>(1B#MHW]N$2\QM=W MUU?U)<88>V(V&QJ2-.:[_1#XD.TV71:-P59LL/HN+<@RWR2S&:$U2RMU65K9 M!P-IEE8.QRZ:0>_V![UUM8U'S\45!>-'VW""CM,EX=.(,$O9R'6(@Z4@]!!^ M?VU]D/^:!I%/)&DR^N@.M]%A.-P-LRG`]=Q\5K-?)FZ<1:13". M=9Z'%A:/TU^V2.-C3RTRR7)55DB+K['"'"N\,\P!'EAZ8_K]`3G)#/X;+UD# M^RS6A^^MQ]Q\']YX3RY]^-XZS,WTX8V/Y-^'[ZV3W$(??K!>I(Z7& M;\^72]59OBM!H)[B=^RUO6(QOD8WQ M(L<=6DY:M44%E*CB)(D^F_-12#&<)$M>YADY94!H_^/3R6)90H@\Z^`'7?+PVC;ZQ2KL&;:/XAH3I:=53LD\ M1FWH*MX94*SJN8-*(DY4M4CGVO)-P_Z.#.\:/_$+4Q*3-!:J2:<2`V&@\X]4 M*E0U4SHOGD'V/3V/AV^N7:SNB^\W7^+:$X6G-<9AY!/J6SZ.*)S@WA@65,/% MUYO[3NO[Q4OKYO[EZNF^\W+S<-^Y;7UY>OCV^!-^>'$,7-"Y&GW;Z*ZN:TKD(\8"&5A^3Q;7)Z;Q3]@@P] M#PT;%VH]H9'K!5A3+3)0,YPQS5^BW@4ISN?<(W?J/X0!Z;*(TE,1+/?&+>)> MHF\F'4>KBTP+X_(_'PFX/>BR*LM03`@\@RK!-PMQ#7_0<;KD+S(*?3?L:``: M7!B>-\;?_FK88;HZ9N'AG>$1F(""27JC)$9%D!1-P#;!1)@KTMG%K]E(@2(" M15*$[4*=G/J]"U`G324'JJ[HJK!=`P`%H6J2)&KR-J4*]6GCAYE0(022`J6M M&L#,`>P"U)E;SX2JBD"2!76+4-.]?R52[9C1U1K^$S(1_AR/>N]1,.E-.>@= M`%D7M3F^+')\8!72L<".Z-%#(\/J7GV0&S81/PE!0=,H6TLEPPE'P4G6+:,M MUD@%'2B;P<%%:FQH;YQW_`3'DM@4>31"7=4DC6J%=/WKT2VF)%D!@@SSZ<83 M;1S;E`05(,LBU"C=5U11)'VO5GT^.`J)"%= MTF5)$]EQ87)XK!I&TRHW#B[5QP,;_XOG^NDC>D:;`;I.H\J@Q@54,6N"`M0! M,ZC%*6PLR*L/TP[)\.^+ZW9_6';Z1`6C7]$T192!0#?P?,+5`"V]6S>344F4 MH+![?";WNF1RJ$I0%[>KRD(M`J@Z5%45U@%HQ38'@`[$G>.3P>84&X`=%/7=O>N8#("RIP5%D7AC M2B@Y)+FA*Z8R602:#C>/CG6VA0$7]0&7B2@1J"(]=T'5OQ;9TG:\,#]!;>_C M-^LJTU%K"I%2&`H.85@P4`M7O(2@BJI&SY`N4%B?>L'Y`)F>#,BBOB+[BH,( M1$53=87N^%?0*@VG6```-!R(L*')VO3,8[)$)K,EK6]35/$XSR9FAQF MA%`9^D*R%A5)$158!CW][XR3R$$.7+N+/#_>'L_%9A5=T'7*,);)G'$`42J1 MF,V-;X6!Y?18ANYW.R(OG/W)U%2WPDNA-$86UUT++E*2M5CZQ:WPD)5[Q!`1 M\\0^V^24XPE%75`UJ%<-HDI/J$FR7I$%%&:`U1-J8N5ZWY`G%`2H:EOFI;0G MA(JBZWI%KG!M-FKD"@OS4$M7.-E$F>,*=5W2@5R9$4Q![*PK+,A`C5QA49'S M<85`!=B&MLQ+:5>(;4@`U3?%77:%!7FHH2LLNBXI"WADH%8.HC)7N#2ON!7\ M;)YP87YX.Q+GXPFCN:!M2[_\\'AI^K`6?-3(%7(YG(.;*Z06U#I.MY*)P^7= M(7E$^0%<D1>ED*TC1RJ+F`(,,6!!.%Z]*K@* M`F_0Z;+=&.@X,Z\3!@/7L_Y88UDF-1U0DET+.V6)]IJ&BP0)O^D0LQJ&FM#*VJ) M'*'Q;++1DI("LE!EMA'^37:>@UT&4;'4<+Z"6I48OC8VCB);@>W9L)'_A-Z1 M$Z)5*2G1A>)%DY/Q!U#2Z#F<)`56XLE#!+*)0T52595.XBY)?.$J]>RT?!W" MY)"-)^,Y&Z-$&6+_HA8B?N'ZP4./;`'WGW$86UKED@J@*B;:18(`*VT6C0.@ MZ1*DIPQ+$F?1N"CA*%:1*V(\=PNF0K86%R(>Y30]>F[/*M_`95'759D2.%4Y M"TTF+4NR)DH**$V43;LJA+K&F=$[-2^U`5@5%I?2>0[`L-A;+D`2H:?3^LHJQL=@.[G5(>LF6Y)87"FBX M/Y;7PO:$?&1X)CGTXA*'#K8;90YSLS8-.YG$_ML,:N5@L1B:K*HRD#8"B\7& M5"BJNK`%:>7U4"KVU^O@>AB1\PGGCBX](X3%H"`Y!XN."I9(L--GL1P5`.S* M!:[T64P$\R^(=!H5=_YSNE!-5:"LLM*?[UPN;P&Z"!0Z1DLAL@X&)BO`XQ]- M2+/"CRZ"9.K0KCUW2(A:3H@-:N+Q M7,<_1SW7FVSWB%+R[RS']:Q@3%6>K"5>2KY#P<#MDJ.=_(#$4>6[R+:(QYM` MI]G;&/@ZR8QI["DJL)$96X/&@P)541N9,0VF)$56]&2`LD6AX>HFO>0Y*N:JL'5=-=A>6/Y-E"&*KT:74)H$^B%YOK+X3GQ1DCE\\ MP_&-Z-1$W-5$O^RH:^IT_Q7&?4MF4CR;:U`A%9E7@W)+VQ>+0VP!JZM)1:7LJB%Z'BIJX:Z(:3$S;3``452!O M6$YY<:&H*IHJ,H.:1M[3K=WGAF^99.'7LL-5YTUE6M7*])!D7,]0F.# M\N9R]D/!+*@MH-Z(O$F=<0[<9>CAE_%%NG&9>_0C>I4^?WR!!XSN\!6"]H,9 M%`H0)L>A+YXAD$N>$V"VN4%FFY&3&9F%6F$5S M;/5/+PS'1'8\X_#0BPO.#]V^=KTG%(0>?A7?5E(DC*N,T[8(54&2B,]=!_O9 M]GC.LMRTV6L)DG/6=HS)TDMX6+V2HBB5<;Y-:T[U3[F&7!,FF1UO;,$"N41B M)QAD--U4GHGU:@JYSGTG6,XTW*6;/&_'7UVG_PO^:D:G&OCD>,FQR#LH7W,S(DMB#,[_MJ/R6,RH:SB%5%A6C M*6P(%=,:+NFGZ03)S6);WZ>F;4<5%)'>]+%1Y>>THJ5KQQC`31=+4)?T4\CQ M^7CWQ9FK)0I<,.0LH";'Y[DP;AP3B\U'N/+H[QMG>E'VJDO(F#)HH`0E54_N MV%Y-CR>P///1H*Q(7'!U3-,-<:3SA$R$K>W-+I]Y)&0!6Z97`;Z\C'Y9%S.U MN@9(#P=H]'V?7'0\*]8Q<>_% M1T=`4'&/"9(;JPL2KPQR7I:4)B='\N=L;K5X@6&=2-X<.1SP% MYO#F:VT%8,VZ(0._00^]>0)Z(3!G?[6#G[O6^U_[P<_D/T/,E;=A5$ M`[PS?G:K:%E*E)4EK21GC_=+"B1`$6L0X.(BF?GUIR\S@P$)4*1$2A2M5"6A M2&"FIZ>GI^\=>G<&R!%.:/(7II$`?QB]_T&.-<`/9^?71X9M'!CGE[_TST[^ MW;\^.3\S^FG]Q>7)V>'+1/S7ZA]X`/]"<`T=(PW^*LVW^>K?F$F>/\W)\R<>&;8O6[/-)S0 M-6)OZ>0?O<"YPV+V46CTI[$?&$W3J%M6IZ:A7'TR-$T\.1;=N=]8EQZTVP0^$/$)J-'G^_B\E"?HV:L0E2X M.A]D,AUO!G<<`,9"2@#@5D;"&6ED.(DQ1QQHQW7"64V;_6F/)G"I)SF.&-?M:4F85;1+]C,%H].1]=@$@$,TDW[15L@S^"(P(Z M.MM>,50M`@H&*KL&H#\$<(NM?AMMYPJJPQ5T]?G3I_[E%^/\V+@Z^>7LY/CD ML']V#;?.X?GGL^N3LU^,B_/3D\-=N'XVM7;\X.,'VCLDQ*FV>S2YKY:Y;_?M M]9A4HP1HT26F.X)3`)<,<,=$1HT03O"<"/Y&;!%P-'5B/L@.T'3LH@QFW/GI MF/YF&I=75@!PW'#Q7N`4\+LWU3A\]>U;N'F-7_K]BP)GWQ?*N\BQ!*O/]^.5 M_IC^`#M!YGI$+%4$JEU.!6E'7NRKWE*E0E@_"``(D!T.AN(,I'DB&:#\G),VB"6^"!_<[H%1F>AP,`$NOH%7<;U!$)]C# MC_CAYZL<8N1A($:2\3Y!,0>D(1)*0**<.%^]')]$50YH^Y,I4UDZ=E+#(1L? MG00`)HJ1Q)P)N7,1)(=MX_AJH#G9\&]\Q?6381`E6>P)1H-,&F>O>H]G4C+K6"?K$R1_J9AKAU@DP1 MA2]"$V8LA,J972-+O%$6`'IO!0Y\F-B/:?-)Z&!/#K^E'$CT(,@BX8V/[FS> MI[WA(6@]I24.\8.7VU'WG)D<1S%1SC0#;3?QE(2E*(R.)^)D%$1W9D'Z0N+T ML6.G`<*4,?9OQG"M!3[@SB7BDQ4=610#FHQ]`!7(=X*:"S(EFBSV/&,"0(]A M\M@(4`<#%C3P%K9B;XA-!@W-]IRXU#I1WP:9!H;S`Z2;"=*:2[S8N4-R@'>< M@)G1U!E^14Z9?PM76%$--XV[*/Z*?'.*3M(D80XWPD8<8QCW!OLUU0P]%`QE M(>2.>!/P50+D#,R;+I\D-6B*^*N7,K72=ZZ74D@M0@JZ!=PKG"=N.)PH#I(6 MZ&DUXU-^=Y)0%GM\]_#`&B/FL?$G,1=!Q-=KB(W->+DIOI#T_/.6+)D(FYDR$3-ML7&O$ MAH2$5S,2$5)C[(N3AJH'GQCC2(\+_BL+L_\_(0[5$46C$`Q\9WOIF,< MT_KIO3&(8I=4MR!PI@D(;?+3.E,;Z&%*@$W"VM$117]/'=<5?RLP8@D#H(S, MXA(!:33-CUKJRL?$&`>!-T)0_/"](:!O`_#TPH?,#_`96G#J+HXA7FC*%QK6 M0:-ES#PG3N;>>9?&&X2T;$-T^);^O`50/CG#,=P<*'P716@G2Z-)!'J--X\0 M_M0YL+]'?!UG<>BC/5O*K!J'4Q4Q M>6);HL7"U5]ZR=_O=-J"R*XT7P[!JY0^MN&@W[.+1C\1,=[P#-4!_?RS040V M5)=/[Z=\#$+X&_]MF6ET;D?*;J?2H[AL:GM^;K3H&FAPO$2XA;A1-NG]S&C' MQ7"T-`=L]&'?Y.4A2FILMA[,Z+L;E,9"=;<-G3",4E3=$VS'BZYID"Y]8%2W MOHOV,V!4PX)KNKB#OX+^`@.:\V-/G)EQ$Y,E3?=R$W0@_#$-:?X8XHC1<)A- M9Z0MYOY<@U_!3_@VB\[2G@$2*1R;Q"B."TL><%XR<\TY"YB4PD$G'?O#,:+( MX5Q8>`$-C6CJES(K+X*-BBA;M\1%]L2:VG?+-YZ1<7`2^9,QC+_^95=$E9/0 M^(2]+(VZ95M%`Z)41]&^`CHIA^61.5VYPC!6YC"*IZ7\@CPA_):?5-K0O6_# M(,,:K$PSR);P<*.B?!/,ACAU.INRV`00D=&>]%*I<8(.[$?D9D-GBM!9F2F* M:`\1QS$7+"*,4\2-'.W4U\6IEYX#M0AG.@WDY&CROV_1&%W&3"NW!@`;\L(< MLVP9`^P,/&)_BC4IGI2,T4$22Q-![*$H20P2`5AVZ13^%[<52C4:_?I=>PYJ70!^LEP[$W\H>&!2C$=.S"^DXYGRHNM>R#Y MH.@7\)M_G]8MJP672K-E67:M]Y9>G(N7]&"]8R\>H$M`!E&1<3@+&5<($.HD M#CJ]DVPTPCBE<%@*Q>+T'9C>;C1@^NY;OND+&[/2R4$4K7)TV&TX?W1ND5KL M1JTC#@\-:3=K/7680'^;RJ"^]P8[8_RX8-)Z(:=KXRK7);MI:9]N0O\[B4$I MN\'B14P84Q&T1Q1*KOX)7!YYZ--5ZHQ&1A[D9WS(@L"#3\6(V/Z'0A2Q;35- MZ5+6'--N?BG"E=._.C3:5LLT%K;JLFRK:L:5$WCY*OQ$+N3/W!LC'?O)6-C* MX/@/J:PB^A?I9#H&7;\!K#C&I")ZS/OF)^CVIUN4C-HP_,C_AL*4(9/`%'/8Q$D&:BN>VC`6RO,&//!9[1M*SS<%0N1RK,>'%.$N&4 M,PJ:(!.+S.O#E7L``!I7L.4<>4X5^PB\6YQWB#Z?V*?UENZ]4^!>B4(4K&X: M)?X^>4H+D0E!A(9#0I^SW`BS=_P`Z<#W[D3,"L=Y"#=CB%U^X4R@KBL\BD*6 M6\`7GK8`R!-)-\PP!)+$N6P:\4E'G9G:8]`0?"*0_E)RS7,N'P<6^?$PFV`9 MU:$GXH%0S1_B*::_!$&31T">)Q; MP!KPVQT4(_0`FP";D"F(-488H:7`9U8P/Z'@$/?@`7@/0J6!)"*<*(^85C(" M,)A&A-=P<:)[T5TRC8_TIB8BT2B;2*A!F`-A$H?WW#R4)"%;-,4_`:OGP*I< M(6(%C0TH%'D%0Q!K$[%-N3NR`-M^"T2B-W.*V7Y/R/D6;?)5EI-E4&R;/XH8 M.^%P5IA"ZA/2.A.*'E@XDRH^W*$`T51XH` M)E]=84UI!^V';S21ZNJX?U60L,ZB&JRO9^JZD#X,@B\VFM(Z#>UM:6-449NZ M4$!Y*U+/A(57!%*.1,"7.GVCC-QN*??`26!HC]B@.&6"81(O'#NWJ`UYX8*( M6!X+'=.HG`>9H--?@*<3LA)F!!LD8PDP1UT0@P$Q%2N>B9!+!G#@I7<("RTV MK`B/1!5[23QJS?A=A4RJ^!L1.9V@%8X#BIP;4.S@UL2KM@S)))_Z9(6:H%2' M`0O!C"-QD%<2]A)<,P66XF[%NNBW."8(\?"SNF2$UZU@KG9]5S%B0A['[%B M5B'ASHT\O@CI5-``LKZ,X:@Z$C6C'P"+P0PU#@D+*2],'4,'JZ<4[[7/5\H> MR*55Z)0=>X.8LCO1S,07Y>D74+@2C_:0;*1D$/2^><,LS7TT<\ND3%/,.B!I MQ]3-C_BVFE*\7::.YNOTJ((@CLA):TB?,2DVA8&E("C8,BQ=^J$5$H4`@#D\ M@$E`@<;"]?.Z+XH-U=(^<%R73^J>*S)%`T#LB>"Q1,8T1J"XN[GN0O&;)G%; M$D@967U"%O9JTRT8O_<+&==XWH(Y;;U`O"KEDI,88N&KU)R<]%TV^`]E-T0P MO315WA;W#-FJ8\3"<&%W?I+3@BR*,CZMF6P2>"Z`Y0"HI#H,\(41,GDX9/CE M%&M#%`\IW2D[>ON8L+"5(3XAN M69$/F8U2>WYLM'MFK]DD//]8K[?,>KV!@B'ER=]_>19-N7O#I]0%0U=>[F?8 M!(Z)"YN(?8Q1W1?2OYDP!+E6>H;1/4NDU6<4J\"UE(BD:%C)C.':Z MG!&11(C"VX^=>L/L]"SF87:W8;9[C=U@3,^.S1"]9FLATS;KG;K9E.AL=3IF MRV[N!CHWSN?[+L7@)*PI)'MO6E]8+Q$*O)),'6#.G*>*#AEX1'A<2OGP'J%$ MEYGD^@QG`4\H*]FMKMEI23[3ZI@=.#T/XEN[<9R>&9V=5L_LMMN,SD;/,INM M^H,8UVY@<^/,Z9/C!S)X$RTTP??"I2H-W),RC(P\=F?-5T&AXE`2E\?]JP]H MWLXQA[[\@V8+M&KYS-'$0[!O#-%F[]I)OAK'43STM+?>Y&,>G5P?:[^\S7^A M`8RS2/NUEO]JH9M,^TF+*)BSB%^-_:F*W_U5+OC8$[+I89$6C+=%2ZE0DQ.* M+IB6XVW@8]F^8M@!X!)U1EDOH&;TA0-3G>EDRWVT#$0>.QF2\LG\>);?^CE<5P%G_`YCA;1"=H$Q:WA=2RN"PZ&B*<.IG>/G81]JK'G M#,=LHYE_J&C!U@;4HMCXREM$@4>M]C!^-HVSB8B5ERF!JE8GWGLE!+$W)_\, M,^+9I?0&0W#>(AH-ZA!8<"<<713<]7O.&+#0X-"`-7.2!(I(KA]D*HU?D)=T M)U(>%]X1X0(V"[4#F)C4,4$/)(I3@OH7RFB$&=UE5(J#WZ+&C4:D=1&7VI`L MR/01P80Q$'9128D/\#1"EZ-/(4-B)70RN603!;AAN%+B#;$$#1HW,5>,_"K2 M.9MP_#M*KH73_@8>(/4-USA5%5CI1Q,AO'-B-Q_%-.XH4I7'4P'^^I"F5OD* MH[]@3D[-(@28<\QFFM=X4R.+>EIH/=7J^>^^;% M0RX/08O'M9&L.K=_^R13D8.:9//09W,YB%!MVS+;G5X1W3H^G5N0E&AGD`X5 M8:FB2 M]YWSZN,8O2;`[S0_=(VBPF+D?ABF6R6/R+K%IA;_5*S%(HO6841O/K%P1/OA M**"`+Z7+8F(!A;N8A@<#19@#1%%3E-/BA;=^'(6JPJ``EI-E9%8PUU?E,"PI MAFBUL#DKC\:>%13U*B15.^?Q4&&4F*I%YN0\4H\@BXD"*11K-L7%<7!^))Q0 MHN83`N%[:KZS*(:O90E8'/)?&&`YT^ANE)DBM$K!B!!Y@2/BR6/O M)N.&LE1)*_4/D"PX9"K.508S!YEOBR0G,9!X4RX^,8@C1R1/Q:IZ)-\['%3H M?'.$0#_!4"N^>T&R#V]>O*^O@O^1RO&[%,KSZ-$3)9/OJ"'SKW_9J#%#\/YE MZE7.Q'*%)9$I262>J"K4:*+=$_OK+=0;I32]`\P$,EQOD)IE(?:)09WGOY$# M6D;-*%T*JX-*=[\?\X"RBN&2J+2]":?IE\LW16.3C$<%-ASBK!3)5[J?>6"" MB&1V1<5'$1?&6:LXMJAE#!CW/(ICU?5;P3A(^BFGR1*6(\/[\E+<1)I448GK?@AYX/+3!U6_6`TL8UM%+-#G MVE7-P!*0LAAD6#7:YZN/?.$OP+@(3YY(+@-I83H8H,S;4YJ24$CAU.T=Z`G2 MTQ.N(Q"/C&[#TO,3)!$=2B+ZY&!EJ,34)$$:#4Y!>7 MJ4F\B$X%BDFA\A7Y#/.H$48X*5.)^,PR;H)6N_<%"X5&%LILELP-/O83+"F* MX>"Y>%.HEBL,(SY\P_+](G0+)I`BN//&#A'H`B(@H28_P2`)XFG)2W2IR7ZB77:RZ[PN@]HA_5>SS`FJIN"Z7&N$[C]G1CPVSW6R; MC;;P^C3,1M,V[5;[Q46U;NMVR$N(%LZ?8"J.&TTE9YH>X6#6($3E5Q26-SVO5&Z`%E161:( M^V?F4`VA([A[\2Z1+9,-[)ELO(&OWN&]\78]-,FB?C^5\OW'4@(O;[MSB/I^ MJCJAF*5=JW=;KL;QM+#O/=VS+:/1:ZQQ?'=W&4UK8\MX M\069%XV[E][0*[87F\91&*&3?5VGTMZX*DY"X[3G4O.GW@G&4#6"-5FX`M>WWQC7F)F)`?.AZF$R=>@>G5"!IH2X\%W!1]9[8 M>!>1PQKU>UF[2`(BG,U^8GR>4ABAGW`])#<;>GE.-U>:PT"_;Z)OEH@"Y/!= MO<`4%L$217`4K%S,:;%V]6!F)#[6#1R1QV0%@HJH##I0(UXJ3KTV;RN$R MG?!-'-UR^TP_2 MR(\33M!'@V-B_#<#2DI%:JHS3*.8,*F:.&&1%C*'WE>G!=%Y'^IP!%X?AXXZ M7)"3PX/$C+C@XIRAAT8ZA[LWB0VD/0;8<5$,_/Q>EEAJK[)!*NGT``WD.1DF M!;K])8I,!1:#^<$>I:5]CTE_11NR5*W_SU+\7:.M[0=]GV M1V;`XJ%5ACL<'NW0W"R2C>C3V`\,-I\VY@KVR&(G7'N)QW0YK(\9`UMR=2&:!=<.[V,9ZC0IC?OAO.[%L!_-@ILW$G],JW!L.3Z<^3<_7U#'$?=( MM-.$`8B0V&64,F_\J)I^/G.K<7Q##D<6A9$S\8/9SPOOT]_O?P#L_^FA<:-P M#Y]AK_)&X4!=7!Y=]$\^RC;E\[W)<:ZGOH0?O=SB+?X2EW`]%AUS?5<*2UP" MBKZ1KI9% M9/_ON\><-CRM\M2KYHR;.97;VOC\I#6-@YP63\Y^/SJ[/K_\LI>A"WGC3"%3 M):++L];?DIM@'OCA0:$)9J%H4,TXB[2^DBP5JF:4CF@S69JXC6.MDWA6*SVE M>`IYV?F.*JKF$B:3:13F3MR\8R?[X!+AI-O9QGZ]'6J;\MVZR=JED%R0+S6' MYPA)>`?<#:_;MI*S*(?HU1^W#3?G#N'W*;UR@F]WFL)@?JE?F)7+7M]!<*^3 MX<,M18;KQBC;K;:MFFUUG"X M5@VUPM)>"%)LL]?IFLUN=XM(*76%YO;@998AW8)T(>J87F"ISW[H'LE"GSMC MY\V-1ZVBF?:T?W9M&A>7YQ='E]=?C/[91^/HGY]/+CX=X?=G1]?/;E;:0'AS MT;8BJ\[.U61=T9MQW"_'B/') M&6(Z73SC:P[_-=1U_&+4^[;=P72E[\JDT6J`M->NCH+?'9/&/=IL%H<^%83/ M*?#8_X;?[(Q*V&Z:G7;GY:NVL(Y6H[W[=H]2GHJ/?PGVRUG:L M'_+-VV69-M;EMYMK'/+'(&#?D&?US%9[#8O4`Y"W#?,O!>FE3K`S;,,R>U;+ M[#;7H,-=Y8"6V;7K9JNU,6;^W'EA].*IER0_8Q&$;"):47Z4G5)DN8Y]/^]O M;+,)N]M82R*J1,!Z67,O&&=VLV?6[HVX7H754OJ';/;;>UW M'9*E^%N_<56]C1="0W;G:9GU;G47L-SMLXX[1X7]'\IN<@#Z27@A(AT>Y0`J MJ_ZZ_>CB=L%!='A^=G5]^?GP^N3\S#@Y0T_1+Y='5_/Q_$]&@EIUWFV@0M]% MS#>2$2MZJU8N%9]W+1KJ[V".CM;)F)NQ8M3B6Q9F&U8M15;RDNVQH](6A=3)6[1'QBKB6&,U M"$3)-]4/L9C(A;'XHF&!EB?'A04Q78D.;99PV6E9KM^EV.S"R?=%/#:FV@1S M"\GK_'/WZ2G5"H;9,UFD7SLV\K-(%ECYC.K.77@)C>V<-X0%G'?0J=LQ#HQ/ M_=_.+XW#SU?7YY^.+LF3^_O1VR%'F/*(U?TQS2[V4@<)4/5!@NFH@SE/YOR':J`G7/`_BE]\U=Z']C$2/PRQ4T4VR:]7-GF69.5/%I,&N]=.RXI0I:SGY'`*^_W)] MA7U$_,@>:)XJ34?OR?X9F,$(!+X=G'K5PC54E.4QQWM[")*DL,VN)1GB))2 MM19/"Y=4)=(V$")40/)#!UF,%;*XH,D#AGBY`5+8GJMIMNQU`@#V8]5UL[Y6 M;L3.!8:MX^EVEE[V&_#:K@C=1@[N$\"YXFA[Y>>N6W6SU5LCYN,U,J#373/! M:M-Q`5N)F-'_Y7!V@H+V1*L#V0C3^3NW_S8A0S1IFV;/7OO@R:V MC<5&TZQ;CXG/7#-Z8F,1FA=DES(60\V>5>QGM+9KK76%_1T-UNR8#;L+5/+R M<\IA)5;7M'L;*YWPU"4'!,&_":/PX/.5<1;5C'^?PMD%[A4>OLRVGHF=UVP^RM4\1D=U?2LDR[N[%ZZ4^;L%1U%CIP%NQ&`\Y"=R?/ M0K/6VY>S8(,V9YF]=3+^=G;71[)5U81LI&7;;;-DMD"^WG9.Q MG]CKF,UZ#SC*$]ID]BRC19=S5$;&8FC7(W)<0'MJV)RBT3.;C=Y\@D:^EB8XB-6OC?HZW2:H*T_ MK.;A8PH_;]006`''[TZ0>0=]%[62LK/PT&UZI+.FT>Z9O3VH@E6'HU=?AW1V MV^541UQF&U/NS5*>/PAZ>;<0Y)H7;"%:^=0O'W=+SI#UQ:T'^4>JIL'J`-W.8^+D M'XVUUVW`,!H+^':K^?B0[$WU1%EBS"Y6-WK9%Y1H.SS\=H?'[Z-F* M6&W5FZ.:-U]-8ZSN<3%VXHDS]#+BM\9A5#.-T]2M82FE)!O\AQJP1^1".4*K M!+R58)D'4MQ38)MO>!G=>MUZ?W1RK?ZRW[\UG!0[LJ=.FE$G7=+YHY%1;_U4 MY2#;QI*?S6LFW5%.DD18O`K4NSL_'1,R8V\8W82^K-3E$/7#AF"L930`6-BC M!9JCLPR+<\GZ'*(]-[K+1C!$"/!BA:,I>M>`3"*XD=EA"E,.G,2G M%YV06A$G*=4$@^D='`"8"=<&\UT?:W]AT3/U_5`9?_X3^?`2ME#*J"J80\W! M`21/5A2;>D":H1C:S;A>3,W02`P[B\<>CFTJZ%Q_-((OL9&S'^IK`X!_M,U& MMXYAQ<:;'UMFJV&#]%LWOB%)TLL(V5MCZ&18CV,P4ULHMNM/^!8W+(N!5T9? MC4&6TD:(B1#[6'$-1YIFL%#<_'3!K^0'@3'PL*^Z6F`.]-Z?C/,0U-)!G"%I MU+N$$[M8>RNOB.((/Z[Q!G_7Z/?SE<%A4@5^`R\FF1,JC@7\:L*$FO>H=VYB MS^,:=G@63VM?:L8E;!KM$9HF@0$ZQAFLX#?S81JA`Z1NB]_G$7(A MI^O+Z0"2<^W%GBP)Y6:>Q,_(0>Z.)T^4!'2)(0'G]Q1-+P[,CE$D^U$6C("8 M/;>X?PB[AAV#S-FP#BK$Y]"N`(OA"HAJ4/@)SO&$#KY\PJN`0+1P]X!S,)"* M'%1]PP3N-8\JMNF0R%\%I'/.?.,B]C%<("J`*!CDXGX6%SUV7,(@,&/:7L.' M[_UXPD`YP0QY)I&IZ M:<\)D&%D<7SNNR_69:,=LU?'=@UU8*/`U]I=RVQV.\Q'=?9)T-W#.U6MR]68 M)YZA7!/F48VC4)QRQ*)Y/@0F$;5ZFMWB\K%F2+W&2G_L1/46)R0%",4-J)[D+/I;K%.!W0C%'1@OMC2C>3"X#7C!.XHEP6_DQY^^!_TKM(O]&H M>",HI$XJCZ8CZG_"1Y0#;,ML-9N:\`5JCI\D&19VEG=R-*0BUW2IPFL)GOEI M[!VX'DM=\*QW2[4?2<`9^7&25@*!(P!)6)@KVN[*B?'FC#VQ;>50E&&)T3/P MD%T%?B(D\_/KPP\?4(F%#__\L/<7[`>/Q#?>JER"P=+'B$)%)[#IY3(V(E_; MKI)]I[+H7IPZ5'?<6]AX/G^!8,8S&I%W41,EJ0)Y0>(:8LEQ(4PE47"+(C(P MD"N@=+ZE>I*!Z.`.8+U`@6AT2`,F%QP5%^L(6!<)C.JZ:T>J8I%<@1@.B"XA MWGL^Q5!,;O.B>8X5M2/W@Y>,HRQP)0+ILITKD"PN]!Q7#4M31.%A4#OM6K=[B-R6X&NVM2CU\KC0*\I,\$MISUZI(2U_Z M0%ZX$U:MY8<+^\3_YY^>@DRV"A+'89PJ3(.XVFFWS%ZO;ORM!-O?>,OV_6C] MJ\"\-9R@/A_JTM0<_G1K+QG%7)[_WKT]^/\HU:&J*\OGL\JA_>O+OHX_&+_V3LWNU MZKTYX!M1M85/)3\?[]4!*7MX=7_(IG1X_%*IZQM3T8=KJ.CSJCBW3,I[0I4H MY/<+^-*E*+1<@:+$`]8:;T\Y$4KQAP_OA=T/E/^VV8';5>KA*X$%PE7 M=GACLA<:Z9W11P\"U.]*'DX6+#S'\B?=PO,>QU2K**#23Q?1=M:_^MC_)\/! M[5?X)T4RP$:9^K,4#1S*:Q$B,1I7>#0`,LSVD_=+P:5_1+JS#F"5^GN?_8,4 M8JFLI+S7[]DLQ(KH_00I!B$M>A#LOU.[5#P2J*[@?*,L)@%`*+C3!P7CD,4>E3MB@_"/"#O=0E&G,9Y9WD)F/`"'V"6 MBO(CK`MJ199:^DJ9P%0J@*G[P,P'&J(9!F5$>A6P$48*=T".R,S@"(]&<"AJ MAFZ]DD#Z16.@N`N4E0>^%8@!!L102Y5>O""KX7UX)<+H3VZ@*C,;R1V7GK*!WV"<,>%PWO$3.Q*+>5:=O%# M`#D376,.>8Q08?9%JU^ M,XO"Y:XK4+H*1T_-BXQ82O)R5SJ0MI^DP%Y6^Y MA2JY=!0.Y.6FT6!9L%/.0?!A@.`KL!5A.!T5E/,\EDGQ?C$V,W^=O/G-G(G# MLP!90(P+CA$'1;.MEWE_-)#L:JZIF7P-)D!V/S=N"ACSTGD1EEK!CGWO5EXV MZ'&B4,LR45&%519$QEHAPJL@=`RUL"1QR]&BG#F$L!&XU:+BP[VZI<0X9>WX M&-=`(\H6/!%A1E(EUEJ)4H[9E&^%()(OX!NGUN8IV>>%!JU;IL6Y(U!FF-C` MN?/EAPP_?/1*8LNJ*9HM[9DZNOX24\3&8"VB9=F4V]@5>9UTZ\RB+5TDNO0< MUP=.JM"(<6S'R$\HB583<`J25+%F4)'_`*L7"F#B@4`M?#VQF,C5)P*6D3B! ME_!.)7A`![Y[``?KP$F^`L4K)3#A)L:D;J?(^6^!1=`8:+.4,Z$NJM2_V+M! MGW.L!YA]KEW5\&J3#^,1/I(O`/>9P/&EN-2KH\.W"(ZPN6*X]@%\.!BB,\N+ M!869'%BCH@O3,0;9Y8O1P)>&](J1:'G3##C),)B)./&<59XYPD/<%T%S@M:U ME7ST`)$@C/2S%`@!W_UG/GDR`T1,&+\SX\(/OX)<2W+TZ>DAV5U2@!E?8GXH M96Q8DB9D"P8?BZ=)P)$VX&1>;RJ&E>MJA+;CFFMLN95$BT,HHX'[=BDMO23+ M9E7>N5)Z17+QDZI5*,O$`A\NK/_>Q4I)%22@BFAE<24%0&U)JE,9!YF,6C@WF]8[0F[!'E'$5Z+Y29&,:1)ZE?Y<7"TK[PM.(N$"FD0`,]JH MPE0:10Z_G/Q2<,P*X*RZ\09H,!])&%+K;_=>IUGQIEM3B"J)#EGG1MSN0I_W MFKS64*?AB)A@]1$O[GQ2*_'&.Y* MM9$O%>:`)MOX*H0LPCFS$Z"7,#UDF'L#TA5(JU3FL1LZY\5'MUY M_Y>]()Y*W.A>9ZSBUS/M1HN565?YNW1+1*E_S=[[`ZR"YYU*9[A$*>ZI'Z)C ME:]\W+)IX`S9:.B058&-F&SI'(,B!5=3%@;^5R^8L1$.51_F_:`5?=+4)1AP MWLV\9'/1Q)0DPK,SQUTTCJ+/MZ"9E.O?]DQZBA7 MV[4#I+$#DGKR4*D'-K+>:HP.ANU;;;/1Z1I_TY72;WR+LX@!?_'^IZ6R`5#` M[JPGSV5<7(]M+:RG2,QKT>\.AG,],6V[WA#Y#O.^'[$L%5:&;9;3"=\T'`&B M))YY\5%:L+-M'L]G)SWGXTV/BF?2XJ"L\JN,H M0.\)N]G.0`W<3(;0$T0^-8P#X^KZ_/`?OYZ??CRZO-).NW'TS\^KY`X]BY2[ M*46-MH]=IF23/H'+:^K1#69\]('%II%H$O7DNN2V"U^C$YKRW:S7ZTI_FP)8D;L\ MZ5@EH_(E[LL<:1ZJ"`=$UJ7*619)9=^)W?_^`$3AQ[HWK(X#28RI$Y-3"HF> M#L%<^IH6"^*PI5T$>V"/N[;9[)!0;7RP#9$:I#D4KIR19WR`44/*9OT89S>T M>==PYZ43>=5>Q&2R$O:ODW`$HE?XIT._G80DY^%1.YE,LM`SCK.0K-2Z(3J/ M4%Q:H^(PKU%1VBF!,TFJTSOH;B;)T%4QB2)+!>\X!++HHRK9JY(R`8VZV6EV MS7:[M5.G=\?%QXJR)+M5=D-:7#8@5UYE@\3[;T9.DKF8%<48V5PH)EXOW[4@ MN/)+E,M%0SL.[X*J"\].?>`?\YDH!;J1BA/G*[#3Z32.@.OFEU;,J`,V$&*0ES*I.Z,4_8G.-VP<)ZLI:*X! MK,\UQ/1/\@$0F[GQ0N#R%)HTQ.@[9/]#\D8BR\?"#4-_&N1G[<*+X,_"4<.H M1'0#XR.\#+U(TL7EH?%+OW]1"$LNNZ&.*(`35*:2:Y>4S%RHIE5Z?_0"CIU/J M"\8GA`+QG:&XN6".@1,X7,D,@\@#GT5].@&%#2TEZ64$JA/RY\0['QT!ZB=T MD':`=#]S/T!/PO0=T"LS1A5W4T&QN#FH^E&%%>29GZ]RB)'/22$K`9A"YT;I MBR26*GRRK)0DV60J)%2J6TCBG!",1'`@&P:X;!"EH]"K09Z>K!1%5]WG@MW( M7(6J]W@F5]07KCJ%9!>Z`ZT/_U\%&IEL,@&,*/^:8/59&:>=%\5EDR;HE\,T MHVJYJ&$BT6,(#1?J8P,.A\0HE('*"WONC^!^P37E5U6.5.':RR^H9LBPYC$Q<].XB^*O!M4@B[`4.G-" M#!]/QNBTCB(WP4Q\GMX7DE/12H[ED&*^I!)*/!=F,S[E=RR)<)S.Y(F!-8:=9P>(N3BB0];&P4@K3HK#>]LEFPAF[<'UB,E\ M[+R30]%MG@]B8LP\+XE3X&#NBJJ:Y>="/SL7XJ:X`+$SA5-W)"^+'3Q+%Z6W MVIX?K/)%$Y&+.AQ.RB3`Y<0$(2*145ZO3W9V:@CARJ('*@J8_432CL8N8AB/ MK6F4G(#CT14R4*(5CXM9:3@4FT#HE.(#RH'"XA\62U"9*C[).BG[ED&"J1D? M/7A?IIX4:[=EB9PO`24)3^,!!J9BM/,XH>;K$L*D[$0,ED0+=@.C6BCR',<8 M2.^R8T3VO$'E$W/?4$$6/M4$79PPK932!EZ*PA$)_C0..T8P9K!4[%A5I-#% MD%]`C,,Z1/#XB5)0N1S&_-\\RB[((SEDLG+'LXLB+_7.J>JJ1C__;!"]#=4] MU/MISF/]QG];9F^=VX_[6K"I4[EL:GM^;C03&VB_O$2XA>11-NG]?&G7W8;&GC@SXR8FPYP>X4'082P/T5`A1`LFPE),TQDIE2Z,&D13646" MA4U\FZ5H/2TM=A.C."X69Q"1),1`YPQJ4B"7.;%8E7>"QL@_178D^@^D^,J+ M8!LEBMDM<:<]<6N*[Y9O/"/CX,#1G6886ZJKQ!'$<$5;1?-CWE(,XT.F6OE' MY5W[NTWS,&DJ030<>Q-_:&!ETNG8@?&==#Q3 MCG'=G74NE2&,B/"[:ME4Y7KHZMK5KI>MDE^UDO M\Q9J.V@7%D#JC=Z>7Q-[JK(2A:LM7L2$,<4-DWX1"BB8P*V2!V%=I51L.HQ$]<%$"PZ(M!*@\BTJ5E11@1RRBJ\$WBW..T2/4>S3>DOWWBFP MM40A"E8WC1*_P@%[[Z$O.%]5X,%Y_-%/8%@G.!^=PHUTBN#KC&6GF,9)(6`B MB-`62?AV=L24\V1U:8!P?.].A-)P^(GP:F(`MLK]52GI>,\NX`N/9P#TG%)P M-D9OFH7"V\6JYGR$N(^444Q_'_KQ,)LD*4?!<8&2T$6FHE7$@1-`3J*YQ.2$ M[`+"X(!TC\Y;+&RMJI\VVES]M'6`-42T)&3>'JI:HI11I%0K5O5$F2JT0+G$M`KM84M@*W>P/X#W%0-71-O+7>2/ MJL_GDT9C+L!1:91YZDQXG66*:$#AULX[HN95CYEV]!#(F;0?.%@0T)_F/X[AWO"E(:YLC:5J^0.JNC['I2B86%5X1\RK1R=2!%=6Q\!6/-**%PF,>H M"1Y*[''LW**JY84+8F9Y[#:G!W'Z88*A!0(\G9"50"0X(UEB@%_JPAP,B#E? M\:S06'K@I7<("RTVK`CD1/U]2>1LCET8"T2)3X@];MB)&BKN5JR+CXMC<@L0=>\(WU[!$N[Z MKN+-A#R.&"D,Q8R^K.%U2=V`?>J]K)(&@-A`(`]%8543::]&]G\#LZ$X/D;U M35FQ]S+ASHT\OAOI5-``4TJ1QPM654BI&?T`6$QV,Y;)S%3O7!U#O7+]0O=Y MU7W'U]/&,66L-,JRD[MTSJMH-9$B0`F;IMDTH.RBF+366* MC0O4.JGYYTPE8BZ4FQ,#2]E0L&5L.R&\W0J)0B;`C"3`)*!`8^'Z>2V]\RON M;+S7AS/_YFOR[V\>GG/+:,DH530.9>Q,(GJCE3Z;ML\!]* MRL!J`-(H>EO<,^2QCA$+2XC=4>FMW&Y)JR*,AP3X#X!*JL4`7Q@E7$T1O\3D M^8663F%)J"YK;/EW\W>RC#OD18K0/=`(5*"N6/W>.P`6W<>P>*0G1/>%,Y.E MI?4"'.V>V6LV94&>EEFO-ZHZ"*Y3@>=_W]W+D(JV7F;O_=#]F#L0CIAY[D[4 M3:%@A>;IV'-&5K5L$:'+M]Z<0VFN8J`*>9"!N&201!U8Y@O5C'NF(5F5*<(M M1H_)X&,B6\DGYH*6%>-3%S^%?U#9MV%N7ZF`()=SZ">6A`(A;U'U`-(MLD3( MU,,`A%N0ZAG2:>"(F)2Y0,P8)6(1AJPYLTE$X8,^_E['K]T#?I>`;#(DZQ`.]@S*L!B(SG3UG_@OK)3*"5Y*IPP510"Y$ MKY"?2+=/*9?>(Y3H9S5;]06QM!=9U#R\JU'\=^U.4;K!T+,P0B%=VD'M]TOJ7C06H MWP4;JS2A3\HP,O+8AS9?-0;)3.'RN'_U`0WH.>8PXN"@V0)573YS-/$0[!NN M+IN`(I]\-8ZQ*:GVUIM\S*.3ZV/ME[?Y+S2`<19IO];R7RWTS6D_:7$/5UV>^ M9*/SKLK+7,'X`X67ZF!_1_>-:/2:%,MJZUH96D6P/X,WF0;1S!.MUPXX*+?P M%KMYY=5C=.QN963V8C<'V0R.JB3[%#?-=2090&8[>5DHD\O@^(GR]\4>^B@" MCSU^:?DD7GQ+O=ID&%F-^R_R0SB2['LKBNS'AORSX"W$$/2SYCS].$W;NQYPS';`N:?ZAH/]<&U(+R^&Y<1(%H%YEW M*Z:71`XDI[ISEZ,R@J@HK[72@==YQ)&H-'OAQ=3S>P=YPUE>9?,-AA"]U1KS MZ>Z.HXM";,&>LPZL#C@T8,V<+H+2ENL'F:IL(`A0^CXIGPVOFW`!FX5R"DQN MZB")&IGR?"Q4']4_/VGY@S1WX?U3D[;T9N*[&B:%]!3(XLR96C'S:L(:64E,)D` M6.#,D-U),3CG+:<">-^\>,@5,VCQN#99H[M0M7J/*)Z\Z5P]UV?#/4AC;=LR MVYU>$=TZ/O-VJ4B'BK!4\:EE;JP5;0#W\%#E>+_TDZ_8..9S*)K"(PV?A$<8 M-@"?/N#6>\DNBF<$.2>BZK#O.8NM2F(0$1^J/3,<:/3A`,_3?.4U"F.+D0/. MU:,OC#40FVYJ`5O%$C6R'B!&)><3"V>YS\T@AKEJC-D4%)]C&AX,%&%&%(5Y M48:/%][Z<12JXHT"6$X=DAG27-Z6X\94R>[+PV*.(HT]*^C]54BJ#B#`@X5A M;?,]-1`:/>0M)OJCV+'9%!?'&0F1<(F),EFB7+:<[RR*X6M9@1>'_!<&2<>A M<92A.Y%AYZ%EY=6EV#-ENT:X!4/1D7DX4ZVWJW$AMU!L&EDM$PR)X_J6O'E: M4':>1XZN3YD>0ZL4S`B1%S@B)C[V;C)N04#%QU+_`,F"8[SB7+$P=KP%+V8X'F#=EN-Y`=)M;R,B@._KMT8[775]W17+Y;B045>!9?$8>"W5YK M-;2!%]*?@E_OH*QW/'^_I3F\>\ZKKBD$>:B*.%EPFEP$ZTOB-[+NQ,L5#\O=E+P!5![Q+\J]GD!M50"F6N] M\&W)[.C'AMENMLU&6_BM&F:C:9MVJ[V)8-^7C]U",=?"^1-,Q7&CJ>3L\@0S M[Q4!`?RI+.'%+!FG"EP`^6'#"W3) MT0>!`U(@S&%02X;WAD[(0VK%6#X[8!GP%?[MAWHI)/K))9$O-M[A]WABGVOI M^X%9Q?U>T?I$!&L_[=)+BP@/8-68=Q^ZR.FB^&?C?X;#T6@X?&^LP(E*+BDL M,_S>*%V`K&TMZ_/],W.HB-,1W+UXEQS)F^@2KYLW\-4[O#?>KH[9E-'J- M-8[O[BZC::V]C$JJSXO::L;@A]IV=0/QF7>GM?6,HS!"O[IF3=Y!N_"E-_2* M?>:F!<#7L`WOC7_D)#1^RX*9,'Q0O*6(F\1BO8`65U8`1*6=?B_85=EVUFCE MME/;?F]<8UXG9@.$KH?IZ:EW0.6:C(5Z_EP?1Q5Y8KM?1.YU-`W(:E$2$.$: M]Q/C\Y1"(WW1"=S-AEZ>)<_%`#%X\9OHF"8B&SEV62_IA67'1(TA!2N7SUJL M.CZ8&8F/I1U'Y*891WWW$T5.V&C&=!? M@`DGN,E\-E6RHWJAM!<6.KNACES"JIZC:8JU%E,-O)$?)USR`&V5B?'?#"@I M%6F]1_J<`1>'X?#.EQ,E0.:Q(RXX.*:^R02KI]`!MZSD9)@6ZE85<::O."93"SR*N M1'_]//?ER;=Y,S2,'>#/!XRQV$O&5),"T\5'LL+]V+DETN07_''$9:MI#!H; M#AA@8*B.B+;5E(JHNL93O26J#RA[4<)AG\QC287ZBHSPD9^@=9\KY@X\X"BT M']P3_@H[1),J:[=$9:%BX2)OZ+ML-"3[8?'(*HL?#HX&;.X9RM;W:>P'W.#> M;LP-*BO)<&$K'M/E,$1F"VP"SODWSL\9ZX7(&UPYO(\%Q-.D-$:),^(70Y1* M7:GK7GPJ=JZR9\MGRGP_]4?>-5[6C[DR7[NCO79'>_D=)UZ[H[UV1WLN?.U7 M=S01P[CVU:,NK3E=\:/J1[Z35]6K?_/5O[F'[J)71]RK?W/WT/KJWWSU;[[Z M-U\4EE_]FZ_^S5?_YHMU#'Z__LT5Z/_IVG<*I7I%U;A0/PV+<&2!=SXZ";$- M0Q3/^/5T)]5I!:1T57$(NRPW+0IYH^'UP`\/1#BV3+S4JEO7C+,H[\8@G&UR M:*R[.7'M7'\-N[9J MK!&^G35O6I_#3__*Y;.;&`2TG=$$VEVSL8ZJO*,:3=-NFHV>M0659MM,B!V> M!7%^5Y#:Z?3@B&T,J<^V#MNL]^#?^AK6S1VQ^)3=IJ0N12E%P"D5J7)E%0,\ MB'U7C+46&Z\8HVZVVK9IM=8P$54-M<+27@A2;+/7Z9K-;G>+2+DG3'U58XEN M8*D,='C&./1%^\*T/*)N15/#JU5A\^KI$RI**]H+C/7-!*\V@=<8C>?=V_E*?B8_<&TE>^N8V8C>T%:O!V6::- M[1+MYAJ'_#$(V#?D63U0EM>PRCP`>=LP@5+^7^H$.\,V++-GMR9=?NQ$8"E.'LZV^\\2/5::ZI]S3E3/0DGFX2I^[-98=PRL6O+ MRB3`TSUJKV@(PXVR0>!5T4&UMK#FD!H%],QFKV4VNX\)M%UO^7N%O':[838: MZUB='[+\>RS/]UN1RX/ZCJD$`A6ZR"L$<)F+G8SOP[94`;5$23S>!CJT,CD; M/CDIV:Q?@^">P5R]4X]7BG)E`_4G$2#CSPI1Z0:;NLJG.RU<4I5(VX!! MN8#DAPZR:%DNKQ.PW^9T[&S7-%OV.N:B_5AUW:RO%4VRPBSM++?@,Z M_HK0;>3@/@&<#]3J7K15I&[5S59O#0OAJQVITUTS)&W35J2MV%-0YL?NQ!3V[1MLV?OO8EMVUAL-,VZ]1AOWIJVMHWY\R[( M+F4L.B:>5>P7$0&U\K)I+\^UUS$;=A>HY.5'X<-*K*YI]S:6;/+421J"X-^$ M47CP^ANLM["YP]"H=?;E-/3,;KMA]M9)^]K= ME;0LT^YNK";&TX:W59V%#IP%N]&`L]#=R;/0K/7VY2S8H,U99F^=^-#=74FW M:W8:+_%F>+72O%II-FJE,>NMCMFR'N-]_^[L-"`C=\SN6D;N:ISM6L"/=M\F MKQ::O;(M;"-\QVZ;+;L%TN4B!_GK7U[Q=S_^.F:SW@..\H0VF>69MRM'-*F" MX=?.-R^Y<&;TZV.#GAZ;>>M\`_00*&NT?][%/-S6/@4VB8$WEP)9$BSQD$)= M?221K8'[FF^[O_FV+P^S.U(3_8&'8O.VA+(8J\?-L@-`/%,:=%4AD,,HGD;8 MB\,X"8?1Q#/@?J[$2QX3\XAB*\M";392/46+_JDL+],"E?IAT4"/6/G>H*_3 M:8)0_+!$],=4I-FHOET!Q^].D'D'?1=+VI:=A8=NTR-MHHUVS^SM06IB'8Y> M?1W2V6W+;A4U?Y8P^5E#)%K"F/5RJ=^^;A;LCFN+VX]R`Q9-4VSWC2[ MG<>$HSX::Z_;@-YJ"_AVZU%=?!Z(MPJ3\3TVW[SY,?>N=FZ\\]'Y7>C%R=B? MGH17V2#Q7=^A5@ME]N'#+`&H_VA8!U?>E$S$?YQZ-TYP1$W-^]_\Y`\,)+YS M9F=.&'WPH]0;CD&]_$1VHQ^,+/1YP&D6>S]0I^J)$R2H6?_=KEF6;)!Y/WA/ ML92K,:PE"F^NIMCK^&+LQ!-GZ&7$$@^CT]3=SK+NS7O.VX2N8L3_HW*<#[/K MV=2CI:HB5?"[*$Z5\.K^N,1N0O30)S_T)]E$K/KO%YTO*R1IY\`^U]ID3:7% M]3C?"NMIM%[&@E1-._WW?=FMU2AQ;N=LZV4LKIH4YS:K\4(6M"(ISF_7(PY: MM0_TGN5)AF\??')B7*'UQQ)_ZH?9)^<_47P8.$E":^"XB_/0$ZNKNBR^#%.T MK.9K;7]I?\I7NPKXFUQNO7MP[`UPN38`T_MB6Y_JS8\[`<\#T'\<97$%_D]G MOP+V_P'_"K'CU)]@MVBU$?NS]IU8#)RC\V'ZT,5<8U>Q_(PTO]CV)[O^!;\RQ[Y>\*1M8RPO?$52C8/A+U`@3M9*6+A:\B'7,79L/OQ!) M@R(7#7EH0,FE!J@GH%=_$QJV:((` MOYQ%X9#_*(6JG_QQ/M+$#QVNSUK[?J]886!+;&]-L!NP2=BV`W MVKU>L_EXL/LNV1X3D)6/ODV],%FRTY8$S5X*FMWJ=.QZ#MKB%`\`H"@S+P>@ MT;.:K4T#4$WK91CH=EK65C&P'(!.J]=MMU<%X&KL3Z?PTZ_`"@/X/Q#+=>R$ MR32*4\J<.(RP!^JCZ:+9:6D$N]*D&P)S'>IIM^OM>N^9`%V'RNIVMUNW=@*C M]U!CN]6T&X\!]%]DL/59B-VVK79'(X0U@=@*_*48WS[\6DH5N=T/H\DT]L;`2$"OS5W6@T;;NEL[G-@_FL6%A1$FBV&^W&DV%A M[CT0.,9H?T(Q3AO#7K8RY0JPEXB,36#%M4:KJ5'PBE-O&-K2>Z,<6LO:`6A+ MSDXIM/5>L_'\T*Z@/#"TW5;K0="6-:VO>%YPQN7Z3ND54DX.3:LA-)ZUY]\P MY,=?CM8AC4:OL2N0KZYC"J+NU1\#N20PU7OOTKG[)/L3;T+=[-2['>W8E<[S M2$!6TU%L^Z&08&?=D_`BCH9>L@F<-.TFJ&PED!0F>BPH*V&EW>XV=!Z^!BBR MH>POV$]V`UBQZSV[7F^5P%*8Z;&PK";!=WK=3MD.58)2ZJ_Z)8XV0C"M1K?9 MMG-PJB?;!$BK$8[=*0AAJX%4YH/=%)+L=K/5T(3CRKDV`-!J'*?=[+0[:P(D M';EHVSH!.3:Z]1"3F\.295N]5ENC[:4S;@BTU?`%#S0Z=O,!H%6Z>C>'MJY= M;[6TW5P^Y::`6Q%Q/:O5U:VCJP.G*4]ZYQOX''@D+H2N7N:]Q1L3[_>U;:M:5L-G:UO8[WZ0(^V:-8[W:YV0>MCKS7G.N9)N]6J=QL; MF'0=4V.WV;4W,>_"=,/_I)&ON##,23=6VL M\QK%R=GQ#W_O"77BGJD60/H=GJD"8>%@_`&_8,AB3,N[]).O6NS/53:=!CX: MN3KR4O+X'S4>K:S.Z7K MT1U3]ZV']G#>'4]RQ-&W89"A?(;:T)T?!*L)`8\,(+G'$0DZON1@JP&],VM4 M@25+CU:W9=G=^HM<81ZLL53W;H"LW7MI>U@65K-<.41CQS/NXX;"N9:?QI[5 M:S=>YAI7/(WM1J_S,E>XZFFTN\V&]<)6^(#3V&S9ZZ_R_EBS1%/J=.5M%UA0 MIVOI84/K+V+G4"!J&*ZR^`8LW[9V=?5/0O5UJ][J=?8*!:L3`-R^G9;5W=3J M]>]19RX.L(KE9:M;W6LV=,/:4F"?<5EKG-^FW>O4.T^TICF#U79/)8CX[1>P MKM7WJM&P6RW[J?9JT\'QR^6_AOT"EK7.5ED4"O$,U+?ENZ[9:K9>P+I6WZI> MH]?N=1^TI.$PSA`6#(VCI/[#C:47=#K-9KT8G%<^UP8`6LVLWFI9]37AN2>Y MX.FS,#8&W#9R+92Z1]&7>I&(33@%N]V>3*-9&/^A,Z]&.+UFO;UL9HF>H]'( M&Z8JUE2D^%QZ`,+0#]B!TT^//=>+G>`J=5+TG\P*#S\RAHULNGKHS`9`>H85 M_J'>Z&?I.(IE!N[AV1ZNO:1,R/>T_'EQ9IT2*:OY.%X@4JK=Q4^]POR'P@AG M4>AZ;@83`0]Q M?^O@AF-NPWF8_[W%_6BU&G:W5]=C%*J@^/O#8=T8MD$2!;VSN65PUXGQ6-C_ MU2!:@TI.)E/'CS$*"`>L*%&U&6KH]/#E^H.(>1[,W&6@?C@?G0+_)ZUIB:Y5 M+225R+5VNVLUNU*<7#)50=Y.H^'7DR0!K>%C1I<1[%$D\L=D;,/Y:`F,)153 M[DEF0\IM]G3C_%I0$*O8\A*>M,C*UM%5#&7JNZZ/E(O5V`#&\`:`!\$?206^ M2'R\1.\Q8#\_IN9%!E1IYB*C5EVG0M!A-)E$H4(N:D*,4OG7:AA9*9>SU90! M1/?.RE?C)B'<)>I^`#9>+"[^0-&4@KROAE[HP)EE;4#\4>:5+\59'1#6[MCV M]T%!]V"MS--?BC423WKM[CJ4IA20_V8`+/T2#CU@M_1H?Q)E%3:II;#;R?WZB&X(-/CJ>\, M0)Q.JVK.;L)IKI6!6YX#T&[U=!UP'L`\.AF3!ST7HW[E,L]''[U!>AZ+Q8?G M6#3Y.B)!C5G+@UB%#N)!&[D__R,#D!\"R),LXTDOB:JBH"\8E94,Z<4N8TL' M=^,X`#W>9^6`-2M0)FYBC]/SEA)_7@X12[9]$<`L&T[->>E-E>:FR28KG#AM MTGM$(&'BDDA:.N4C`*LV&FT$*A73Y/@Q%9\[":=9FIR/1E[LN?_,@#L\`&&5 MEQNEW5BUIAY.MV3F1T&XU-RVY.[5G<#W`3ID`-X^OH@Y<303D,ZU1SX7*%K9)R\J7S;0JRU5R;%87NMPK9:BZ8!T&6 M,[:G!.X^*+_3A&L08!^I>?CD]"U[_UW=;C)O?C6.\Y"-[\6EN+$/OC- M"0$G5OO>2UI>.,MG4T")#@F7'HCTP`@*UY0C9^D*!8= M.E,?>VAM!OZ6A']C@+'I]O\[.#".HR@-8>N-*X_$*./@`/$0^.'7GT?BMU/X MP_A&7Z6SJ?>W'V`9R,G<'\2W<83]E<9I.OWYW;N[N[O:MT$')/V!CX)]NL]-L-__WW?S+[1^T+#S*?@7^;>!5V9BS#VY\N?K5!-_E0VX`#Y=>ZOBA MYQXY<8C5ASZ'SG0:1]/8=U:[3^`8=;NZ.[H`X:.*>:P>(F:M4\H#Z/-^QF4= M_):%0B_8+L-9__Q:S97/K]4^P(36!Y_?9<+!F7='ORQ-C5)87"XL6RN*RVK. M!YR)%8'!&UL550)``.%]1Q1A?4<475X"P`!!"4.```$.0$``.U=W7/B M.!)_WZK]'WSLZQ)",CLWD]KL%OE@*E7)A")D;M^V%+L!W1B)DVP^YJ^_EC$) M!EN6`['EW-4\!#QJJ;M_+;5:W1:__[F8^,X,A*2G< M.`@9TR>-\9!,#UKM>;S^='B2?A'7(Q:)\?'IZUUP\:JY=E" MTD3K^>FZ;;OUU]WM@SN&"6E2)@/"W!0A(``J@^V&7,A24$K_')54\7_I$R@BTAJ-& M>.S?),18NL%(\'!ZY/))2S5H&?;64CR[Q'=#/U+.+7*8X!T6`3!/C;MZJCH_ MS-"1Q7`W,9JO,.(BJ:IXL`B((9%/$1JA;(X(F;:4"EO@!W+])%)J\[@=@_)+ M_/COCI00R,M0".1L/8!/GL"/AOT[O5VK9"XOB1QWF*?^7/\GI#/B(Q>R$UP2 M(98XL[\1/P0-]V;TVZAW1%)`(MSU&/AQ!_+DE(A;M&0XF42]-2G"OZ8?"C[1 M*7@]+G^-'`X7'@A<_'#M"R4RR:>*`>(WG#G0T3C`_RH=PH[K\A"9[8,+R/B3 M#U\A,+`['9G]@.FECG$ZL0FGGH`IH=[U8@I,0CY`Z>WM1R9#SAB24YL@N6$S MY(V+)=J.!HE$,_L!2$H5Z_V#37I?B9'K%)&OBC6=N?HD<3!S"^4N-GP*(ECV M?,("=&S*J4W5'DEOZ5HR:]'0"VOF"TK=='&,+$3H*CYN&'(_$B#E%\&E;D[H MJ*R%1BNJF4LHUR%@Q#>BN)M8B84&=+UP_5`%N5\X]^;4][6.PH#<6JS,A#?S M)V6"=DO)$_4QW`.#<"NE<;G<#L@"9(\LU98UG]VTUA4:4+:JMXTI54S[_.1] M,`91R("R*&J!2J:X]CG)#2[-IK,E"&2I7J-UB^;#12@I0P_=<7$/%1^A<1:@ M!T"&E3.GR/%*OT&74!&=BWSES,V=-_OV;#>Z>^O-O@EX!8+.D.49;,AO!'4> MI=U0YLIMW[;U(>#N]S'WD2^I@I]@J4$GI7'9L2D,`77I19SDG3"GM:[0@+)5 MG7(.MBNF?2O^)9],.#."8J=I+7#8%="^M;;C>73%0X]0[X9=DBD-B"[4S**H M!229XMJWM/8A(.C9O6LB&'ISV9E.!9\*2H*7'&4*/%JR6F"D%]R^4X!M?A\9 M>1U46X2U!&M;^!BNW^R!J^.ZX40I%;PH*,55>BI@#+A3GL$-<_D$;KE49U#W MPP%9Z!.9A7JJ!:"%U1,C_-$>A#=VSQWF%=JBYI+:$4%HQ=+$_\;;P+K)F-;2 M<+/5VBH*^N/GGU[^':;*:35M7E'0%!.^<>U2/$K)J=@H%=,3?$AU$?UFJ[*3 MQ0_$!]F'&;`0]-G+[9:5INI3%+LS7;8EL[&\Z))+-$Z5_Y$/.+.UX6&RI>WJ MWY$L?ZEJEJ__^VET<,A&<4&-[C1\MVW)YU#@^R^CZV9JLF&%KBY3O3N3=4LV M^TYRO@!#67STV!UO0AF5@8B.,?/AR*.L`SZYTMMWZM,'":@/57AZA5[`YU'1 M2CY<>KHZ@)4CN7W'0,^2O<1>)NOP1FL;8-EE?F<6;;I-RZ.4`F*E&*:ALR^W M^F@M1Q>%7>4/0V0ZYIXS>0%#+N+X/ZJPN*.,"XRS;E@``J2J?DOVL@K#[B`8 MLQ5UQ&<^@KYSQ-?MYU=,&Y/_; MAF"F8?LV,!OR1Z>4ZQ.67%O8(O@_^FE:M&\7A&9HM/])MJL0W52&=_5?H@G8 MN+S'8L7KS@4&4OK3P"R*>@"=(JF%>\&4A(]!+DQ'52$Z!L)L8[4%J'W31I>6 MZ^)J04=L5>?I+@>",$FB=R!PH8B^Q2!X_PY7*X,!MF\T8+W,XJVT;D^62KV" MW/7Y7-XPCPIP@U./Z`)9^2JY=_D8>>X#.*4EPL'R6@XWV.L#IH M![.\8O("G92=!7CMSJO"#$QQ2`[B`\K%Y0IP)7(IB5>9SH2+@/Z(OFH+I+.I M:HZ95B&'?2U_=QE53S;K/2_5]2W^2H^]4,B0L&#`!V,8@)A0MF)R)"!:Q5+P MVJ^_FB*YIQ)M?,__D0D@/OT!WA="F5I-[ME+F;]N/M+*O0[,CU=S0', M48I916?5..[>PU,(SA3R=X=JFHIBZBZ.[0OT=X=Y44X_NI M%O@FRWVC(Y9GC9B]AKUWU^_5*HQ5&QO,9YL,)D,OJWS&GH!?Q92:.G_LJ\6Y'@[!#>Z'UPMW3-@(^B2`>Y:N%XW]%^JF,OLO M)JS)D>3!9D!FBG"/].`5E:[/92A`'?5PICA0+XQMG!:8Y0CS.WJ+1&'^J'6Y M][4*'OMD?H?F+2CQ]2%86OM*XZHT-6=>5IL4T\9W29I0O:9&P& M07TPV1+4QENUGWGMJG=^QN!%[_.9@)(DJ`\H6X(:Y]M2'-/!7=(Z*DP&A/OX MIM0>RW-2J<.7?G%\1JB==V-P#F'94_6.N&/*0"R+R*`AJG3*FH&R/8EU*K#1 MY75#P6B`:%,/!AJB9,1Q. MM::GU:E'-P?9(Z.8MX1YCQ+Z:D!DKQ<*=ZR*=WHHX&LVR?E=ONTN.7_\TB/! M,GZ[8<_BU.U1HH7-A,TBU!7'LN8P)$I.355CY3X98_(`;NE,)0R28FPL8X;5 MX:_HK':([Z,X\VN:WNK(8T`6SY4^1=?M#=JW7:`W!BIY-ASB)TY*_PU%5:VS M\8:OT0\H9M!4.ALURD_9865);>,B&UV7IW9V"Y?*#?/.ARJ/LBZ`Y6J@E!=L MHBJVG)K0C(:V*SI+OKT.V9]_YAF__!=02P,$%`````@`$TQ.0LQVV?I>)0`` MFGT"`!4`'`!C>6EG+3(P,3(Q,C,Q7V1E9BYX;6Q55`D``X7U'%&%]1Q1=7@+ M``$$)0X```0Y`0``[%WM<^(XTO_^5#W_0Y[9KY?)P.SLR]3-<^4`R?J6``=D M=N>^4(HMP+?&XF0["?O7GV0#P6"]V):1N')=76TFD>3^=>NEN]7=^NO?7E?^ MU3/$H8>"+^]:[S^\NX*!@UPO6'QY]SB]N_[IW=_^_W__YZ__=WW]^^VX?]5% M3KR"073U0-K,/>A>O7C1\JKWY_57#[Y`?/4U'>N*#/7^T_N?KLB/TV6,0Q=L M_G)U!Y]P#/#FJO7]7Z[:'UH?KS[\\+G]P^?O?[BR'JZNK^F7?"_XXPF$\(I0 M%H1?WBVC:/WYYN;EY>7]ZQ/VWR.\N&E_^/#Q9M?P7=KR\VOH95J_?-RU;=W\ M_M"?.$NX`M=>$$8@<-YZT6'R^K5^_OGGF^2OI&GH?0Z3_GWD@"CAE9"N*V8+ M^J_K7;-K^JOK5OOZ8^O]:^CNZ2)MW&C_F<,!/MVD?WQ'V06P@Y$/QW!^M?WQ M<6R?=O."Z,;U5C?;-C?`]\F7*`V?H\T:?GD7>JNU#W>_6V(X9T+1G&-!I<^W".8C]2"%MIV,KHA2M@!?40V@Z="4ZDR&N5W#U!+%* M(C/C5J%P28C!3OP$K_?`%=*9-WH5:@,464J7S';`A*8=0:+!G8VW(".TVJUV MNEE\M]N.=_\%@=L+(B_:V,$/W>0:N;!*+46!7I MG40@@G3PX?S."\@^[`%_A$*/CMWQ01@F9XHLQ9*CG87F$<"DR1)&G@-\M0"R M0ZM#8Y.#?@5+T+KMJ(Z2R9)`7"+?)K`\+EG8]>0CMP/0R=J`3MIV-4W3.\T/%1&&,X'-];`_N?UM0>#JQ! M=S2V!QU[9/6MSM3^:D_MWL1RW60R`K_,AE+Y0\J0/H9P'OM](N-P.!]A1`Z' M9`[0R;"F?"Z.23RD,NHGCP\/UOC;\&YBWP_L.[MC#:96IS-\'$SMP?UHV+<[ MZF15Y6/*$/=>G24(%G!,ED%HN6@=07>*IA@$H4]^9:U0'$3A'4:K\<.M'43H M,?!(DV39A%WD^P"'Q:$K^:HR'HS&O9%E=[>\5R5>J5&58:#;*PK(8@CIJ?%, M?D#8@R5$PQJH%DK5;!#"$=7-E#Y9HZ/Q<-0;3[^1_;7WCT=[]-`;3`>]J:II M4_@3RM`]6'\?CCN/D^GPH35&JRB8=41KU-SH/!O7W;[UF326\Z43?)I$=6AF4*7D=@`YY\ M::TRMZ]"WG;(1)Q:ORL[SH4CJM,FI[_TQGW;NK7[-MDC%&F.$H,J0]#MC>VO M1$G]VE,-0WID=3KC=-CY]9=AGWQY0C=K95!D!TZ0N'#N!9OG1'N69L[NPXA-[17"Q*K_\HXTCD-""E': MDZE(^B8>M\\."B(RUWI^8D^3A007J3ZW^SN9UM#]\B[",:Q9&GVX`'XZ8ZU7 MCS5ACEK-VG5(A.-]S4KHA-^G(CDEF"F4,\SV33?CF,^;[-LFLX]U<)9U0Y!E M:P[/&'/]C=A+X>JL>WC14AMWLS=%E=F[IUH3FW=;X90,*SA*:)/9][6P-^_: MJ.J6?43VCK^M,S/8(C2XE(X['RP8',ZTF7VZ&!8?T[WC<5O3)!Y!["&BG+E= M8GP*9G.F[>R'B^$YB_X=[S]JXOT=4=6!_PT"?$=^(U)+CUK/?KPX_I\BV$G@ M>ZT22.>%O`P.VL]^NE`I9#'LY/#IS'*88D`#F":;U1/R&;S/M)G]?#'\/J9[ MQ^,?M&B%8[CPP@B#(!J`%=?`/&HZ:WVX&):SZ-^Q_DAIT8?M:R M".X\'^(.(66!,'\)9%K.6O68_O4M@!/RWZPH/;L/6JU0,(F0\T<27!,.XX@& MUM*SB;\5<3K.6I=CU,JAV4N)8>S>9!WDZEWFDB%RI6;,'(1/"S/54\YSF[<6FWN0**69[T_(9G=*=SV74T@9G$-M[T^KSI M;*8W+O7&I=ZXU,^QC5MA"*/0>J*&G!-QMO%L0RW.]C(;^@G9JIWM55F_-26D M)7#47HM+GLU0P=2,@E>L0`1ENXO#7%Z:;%\U]27@(I[R"K[4)I_,/)!$!TF(?`7`:^;GDN$HKJ8 M"($Y1T4'!01,[-#/VP&A>X%A&-YC%/*<8YQ>>FX8B@I(`,"DX^0^^+Y>7?-1;KKN98H*C%9)*8=/<(S1\_U0SGK\O!R0?_Q MTO?`D^GX5^( MZ6*Y'6`RQO8_H$_>F\;N-&OI-/Q9S!:*)@>%,1*:@E<8;G,#Q09/3NM92Z?) M+^!ROF@8*(R125+MXQ091RZ,'K.63F]`*=EPD)AC_Q2230Z8MDY/02FQY(,P M1Q6XC4.BY82AY9"C830)%;&BNZ`AQ,O^0`%CE!\%4>> MM76Z'HH=60J@FK-&NQ![SX389WC`!"F)"WK.VCI]%<4D*@'%G#5\0*+<=CIK MZ_1!E%8'*=GF.!Q*6<`<8Z6MTS&AP*3B0S-G?QN1L2!9Q2E*T35X3NM96Z]W M@LMFYHU='@IC%/>#$%MA7,)1TUE;IRNBE#3R()BS/MXJ?8R`Y]I!!ZR]"/#< MWHP>L[9.IT,IR7"0F'/=(B==MUM;I MBR@E*A$<ZPW*<>!73DI#,(K)]%-*+ ML>%\"E[Y`5E%1II]U.GD*+=M%D>H.FU8I1Y?2'^??=3IIR@EKGP0JI.,Z[MI MK'##./MHB@]"P<45"Z!`53$D'RU;\;Q)3I.EN$E.:Y+3FN2T)CGMO%QMDM/J M\#Z2,W"(D^7H)IZ@$<1)BKFT0Y(UP,4DLTG#,<=!EB4Y+0E@Q=$28>]/KCW/ M[Z@U[:V\R')@F.,JRR/5#L.XL)C23EK3W:J*:`_!',_8@2.\Q$XHT5MKOEL1 M@?G-<6P5+ M*LETTYL^5TE`1R@$M?;.Z;?:OA+7>*4:KU3CE6J\4HU7RDRN-EXI1=LX\&$X MAL\PB"$_6_RHY<7XF4[I-L>AU$$A43EH6FTX03Y?1<^TO!B7T2G=YOB(DC3T M$49SCS?O#UI=C!6D=E1'1*O_(W&*I(9;?8[PC8-,,X)M-GNQN@(+R%3QWCR\[2AHU^@"C)7)I6<$PHASC;9QGI$)OL:9B\^>L3!$].7'V24D0 M;?>U6Z)?\TUI1H_+*?K$`;`7C'Z_!CE4I!2A3#N]A9V*".&$[#WK]3LX9))@ MTE?TR.\Q!"'LPO2_$BGDU0?76PVJD)ZK!.M^9NCWO_``W9'SP5L$:9D89S/% M(`A!4C.3'`W)O_RTAHC[KS@]"R22S^KYH-[:58IF1?$I5XUAQMSVY*"3F$F< M7GK+914,0>&!V.\4^GU_NQS97?C?+0@]A[K"/#^.H"MQ4$B.H+>H5A'A%0"T M%Z1^YZ"`ZO("U%LAJX@P2HGSL"I6!2$Z&V^1B*;5W@J&_F;V&]G(EY3.9V*@ M+>`@IFB/*#@)4N,LNNJ#ZBV/);,.U6#<+TW]'N-<+,-Y0OX!]?(KMMR`>LIQ M*9)F_MHNSPC^DC]G#&A";#8_.V#6-VA"19M0T294M`D5;4)%#>5J$RJJ>!M/ MCT1Z%**`WDLP=A"I?O6$D2K=4V1QF!-6>D0@A#3@DO9M.J'C&&5&[[*[*4UAIBY.!@['A>&,3(ZR"X4 M2N:DK=;8XH+RR"/>G%.'44)5*!)N/ZW1Q07%(P)B3N8#KX2J4%[BSEH#C0L* M30J-.1D4$@4WQ0M.=@R]`C'G=]48W5UR/+$#FY&H4 M*>>04_W`]+L?+NGF:!]5B_E>3,!R/NWFZ!8)?6D!EFZ,R3Q)`W+2Z3.`+\F? M^/XBF0$N)T)8'H\Y:@:#YO3YJO(RS/:_G+A?:3@J]`I&W$('!`[TTS"SX3PE MYNTED3N$R$H#,2?`L M&4M_*3G1)V3SDSKI_YJ@Z>(QP!<3:%D??D&*XSG#>SH@7-[YZ"6TB1V#H1,U M(3Q-"$\3PF/(=7L3PM.$\#0A/+5IL_3P&V'T[)'C\W;S2'8K.]@7E;#(9^7K_(6'.QB:L:5@F:.+[2P9!EV(O>>DN"'O^!?TU!K%<]X%+^:$0?>KVXQ9 MZ%(_'3%=1'MZ?@>]L3WG%2^;`^;DN.%[TR7 MZ:XW<*DF>>;#-$?GRJ48Q]!-ZON-P*:,8(_[ZXUPJD^R>3C-4:^8)&??7T\N M2O<<.?A;&:E+#JTW7JK>"5&`!>;H;/(.*25N=+VQ6(I=M`4PF[,Y,.A.:[0J MNC_A#&9^K%Q@2)&1R1IN1#P):L)=&7J\9OK?B@^@- M&"LIK'S)%P-MC*:^(_L.84*P`Z&;5&(F/[LQA0^M,(3J[,$P0*.R3$V#"@4LAO1_]`= MZ1GX@NKW18;16Z"Q4&7-@JC,4;[S:1_WUU%U4)\@<.`;EP\;K=1H?"_Q=J+4=S!%>I;>H8LM(U!QQY9?:LSM;_:4[LW>:L9=K`GR.=)<'UN0N MUI>[6%0464$V&8U-1F.3T2AY$/1!X+Z`S0`$Z-9#$726Q!!AEL$3==&2<9@W M+7.V=C[9-2J32_)A%"PFZ\0D7`*B=3@PCCR'&"BH'[&+#A;IKB6=4)+S\A!J MM'B)+>Y0HW`!A_/A2P!QN/36=C")GT+/]0`CQE>VJY9$/44ZCQP\<[3\QQ#. M8[]/,T6&\UVX0R9&Y-S!#*R0"Y[6+]]91_T19PG=V(=O_#TA3UB91'((#35+ MI%C.B#>;J;DVX('C"1ZF_",4>F=IQA. MZ4^A4&+L3EK+NU02&!>3.1'G8QI)+5`J]VWJ*;-R9M7Q$(UAY5A^V$YO^15)EA\3;(XFQ#R?=G54JEP$2((S MY]IL\OCP8(V_#>\F]OW`OK,[UF!J=3K#Q\'4'MR/AGV[4UN`W+;`#+W]1;[G MR`3$<;JH"(`['9X;\,9H?NX`-SY3CF:J@'`3KJ`KMV$)%]UB.H MT@3HV\T#^!?"'1^$H<`J*#"*[G`XCB`9QELA;,8<\QRRWX@>@)7825EP)%V7 M:B7E55CH#,R-X+7?^^F=`6<(,DQ?&AL&;'LUKYG6YPM*+*2C5Y$(O%?IXZM+-(_="@A]; M+0.C'Z4X?`8#9I?!\LV).@BOY3)V,HWU7$3DSL><[9=)>FX39)DLIMVHT^4R8, M)_MYH=_QI*'>RN_\.9YW>N?1;\QB*!:=5T_)]1J/C`SIYI1K+1$>5H_'ID0L M'KLF\A&]9LWQ@MPV9%,OSO;_FF@\G6ZSXYF`N5E">V7#=Y\8G6%F>I/"<-]910+QG4E$N]028:\)-GE7JOCA?2 MDI[;E[^<\G8\;C\]!=++BT\(QIP"]Y;[#''DA02@6$BGC?44/2\OF7P$!E6K M7WKK-2'N%Q"X/JU$&KA3#(BEBW"4Q!IW4,A]%T1N`#U5TBOLA]*H5!2L5R/* MWR"]&8>N168<6,!!3)DRG'<]/R:_31Z!#H=Q%!)5B*;FP&@X)V<];P-6_S6-U>#+[>#UL&`WHW[2GHAR^/91:+F$#J+'HQT`:*V2 MMXCITV;CAUMB2:%':E>YB?C(U:.B*U!P'/4%AY(2P)'G<<\"Z7`WWM&A78T[HTLN[M- MIJXIA7J$X1IX[M:I(\Z?9K57H9@>CWO3Z-3O[<%`$PIPP.=:>B M@%`5#N=V\$Q^0,G;'U57VFZLS=NGA#H:KX\*/2UG?*ZNQFI_;GU-P)>\K8!# M>J.WU:RW\7C?Z&Z-[M;H;N?0-?:K<`Q>'D`$L0=\7B!%;GM]3K]B>[X(A#F9 M='L*?T/X#SL88>3`4$HNF0[ZE,"*@CE&84Z8YIY$&K@;+J%[CY`K)9E,!WU/ MOU64S#$*G4@:A[78RV*YG$] M(XRZ,N)H[+S&SFOLO',<'[FOZ-QCQ#4JV)VT5MFLWGYF/JDG(3(3*''N1B5(D.'Y' M,U]:DY"<$)9!Z7EOV0Y=N,;0\9)P*?*S#Q..!ZZU0CC:OG#/1,81LJI/F/F. MF\1T4,@`CGKCZ3=KT.W] MX]$>/?0&TT%O6C%LLO$V-=ZFQMO4>)L:;U/C;6J\3EK;]`=CHU0F#HH<`AW;*?FFH$`Q MIU<]ZDXM^XH<&G/NSDYQD2\**ZES>M5T?R9=XUC`>-DC^Q"/N0NKNK`,*9&L M7FKF;8N3>+WV/5IMZHAL85%E04^MUY^"ION:L-9Q-;<4T-QB`B M9F"$O:>8#,%,)!-TTWJ16<1*D0138^&.W<>_D@]+,'S;3.O58&D&OQ%?YY.= M,7:6((1)0;?D1<#=^F*7KF!WT7I%5YC1?"#FQ$^<`!L1W9/\`BP@KY`0KUM- M#R+6("E9-.:$Z`]@=/@VJ16XNXGFIN]HGML)R'D#5,8=*--=Z\TIAT#YNU/1 M(!HCK5,/H448WNSO1CTQ^D`JR6?KZ+[/EEJMZ3-,>(X^ M]];)1W1A.MC#S<9ND6+"(POKXGG1'L2+E^T[R^:=(D][P'\:IE,Q?5A(='_*R`>R(@/!4*VNU?)(7->Q!/8+KN MCBJT>";!2Z.?2&;2D^MDG_<@50'-W&N*#P]#.'R:]9\^#`>CH#^=!K,I%GFE M)PH]4>B)PIL^G/=$H2<*/5'HB4(,8Y$G"CU1Z(E"3Q1ZHA#'P;);HA#RP/^F M:449)#P3X>G16"'\.$>I\)(Z(U:>TF#/K`6&YW:*6?CV'.[*XXVF@R[CV6JWFS]SQ=]V_U"O&+ M.K;`5+]5S3[Q..CU\VR=,/F`K<[@9@/2YMBMM1_/-O':1"VW M*9RQW=Y=[S\N/?7^ MY_G]DVB*.?XG*%6I:ND7L\JIP6AZ0;!OM=,#8?0U+%KH*$G3<5S]5OA/G@E&$6KA+S4$/,>L M-=K5\&4;4E:^\<$A$:-U?OU28>2B;GND"&,;&F#9D>;Q<^/EB&\FR]@8:8B/ M+@N,.+3VF:<:`)[W%(^8WMO&@,2\7E7YMA_/BXGCV<=@,AKV M!\/1T@QM$!^7A2O9#V'BKBD0576(Q@29T1C( MD%L2KP!3*U(WBH>;>LC0;(GAI`I`W(ZEOVH[78+9.QZ_^Z]@+EJX2PEYLJV[=@+A&: MCZ1EY%SA-NZF*Y#1M+#HTWCI5;F7*L<0*:JQDFH-;0.'O^K MCMGO$[Z\TS^'NZ+O\S^DM(A:D%R`:54.()55]^S:!II#$=1]\O*2Q,'=O32V_U)$A*FBIQ39 M8&X7M1WR=$CP7,-]"4[AGLND\QZ8?-/")2+K-=Q\AR3P0S`9?NO/AM\"QTSP M8TC9MW"3[V]CXZV3%N6G&PI9]R4L]T4Z!EHST![!MHST)Z!1L!` M-]O%>$+:$]*X'(1DL^`)Z?\1(:VI5NT3OE<)8=^_M*W6,_/QZ,,G?'-(-%/S M,8TCNK>K^?@,!QY:L31+>ZW_22I7#*_Q3'M>D8K*KNQ%,Z/:U#:2:;-^M>.[ M"?DSK[J7_$7K@+-TL&]P7K9D<<5?&8RFRH%BN\5(N4.5NDV59]X#N^VJH7=TJ/!$ M>"G'Z"?RJ_POZ^GL6,"\!W:?E>-Y[`QB&]>Y2#K7A&R/,^;)P*T>%)69YG=@ M=U8U[%Y:6)K[6[H,:3@@'<;;/$O'RR5A9/$E3S)EKU)EF]^!Q?YT"3AC89R&45'RA'#S:52-U08+057V^1U8+'][RT$=P(.7_G"P*"0LXM:& M*XYBWZ%GR8!4/5[J'VW&^1U81'_3Q9X)M(-/_@0?\T[N&*PBJI^2.-(^EZ+) M.;\#"_-O/O(98*OVO^WWJVH!6BU.'\3WU2K3S^]N\$1"B^A8\_!4PM>8D7!# M_R6+#[Q&+F_I5"T:-#GG=S=X4%$#V]&'DJ.*#@4;T]GX_M/'\>@AF$R#+U^; MZS7::5IEO"*?0HHI?J30F=0 M+'+>Y:7I8#>C65$S52(-\^KF@X#:$,-6(EN(.*H--%3-E8$%I@G9E%#3-=W. M$DWLJ&5)T`(2=ZX5-Z7ZU>/;"!JM"?K&TD%4&C>&;(MU7IP]4$8BGB]5QU') MG`P1^6:RFPVI[78+Y%GJV M:\V8674ET?'\-"4V/.VH(]E$CQ5HPB8OEG:G.2)0/4&_4 M:+[4@<*C.+HP4#L<"M.C41K)JEOL)1D6-'VJ)><@F9':]1*^4.KJ9/XYI'R8 MOP^W-%.\YFR4#U:S).TA8E=ID:#QU81D'`E9!"&+:;R2;]75&6"E3S6](X<` M=9N!W342@*(GJT6!!$/;@B=7EQU`B9MDU79=N9?FWL@M$N`Z)NL:OM6+)$!D M2\(6*MCHU8USN:^%18#(X=RT'E% MP-H01,ENH,G"+.>)=Q.2$O9*'O-X40D69/.C.A>,Q,EF>M3C<*AH^AR^%9/5^U"?S4FL?@%%%V3BT56EG+3(P,3(Q,C,Q7VQA8BYX;6Q5 M5`D``X7U'%&%]1Q1=7@+``$$)0X```0Y`0``[7W_<^.XD>_OK^K]#WC[KBZ[ M5?;,>">[R6XNN9)M>59WLN38FLEM4J^V:!&RF:5)A:0\5O[Z!X"D1!(D"/!+ M-SQWE? M//J91N13VA=A7;WY[LWO"?MQ];B+8M?9GY`K>A_MG&A/SGY[0KY]=_:>O/O^ MQV^___&WWY/)-3D]Y4_RO>#7>R>FA&D6Q'_\ZC%)MC^^??OY\^1_R:, M'MY^^^[=^[=YPZ_2EC^^Q%ZI]>?W>=NSM_]U/;];/](GY]0+XL0)UDC[&0GX=K)Q'OJE4OTMB"_W::-SOE?SH]^_;T_=F;E]C] MBK^#*/3I+=T0\?@?D_V6_O&KV'O:^EQM\;?'B&[J=?"CZ"V7?QO0!R>A+N__ M]Z?L$6G__S?[\U>$-_IX.SOT(GK8Q6]W\>F#XVS33GSGGOIY5U^]_1,90;L? M./JS[XO:S?EC916KK_*'4E^I$-,10L,;&GFA.PVZJ5J1!M7Y+G&BI(?6!7D@ MO5=AXOB=-"Y(`NFZH-W>[4$.ZITR/TV[O=.CY("Z)K*>QB_R^`;Y.,)_GK/G MES2C+PD-7.[^TK]R284O3WT@'P/$T!2N2YWY?#`(HS+.]=Y[8%C.OCW[-O.X M_"^_Y`-G_J\3,/HG7K*?!9LP>A*#RN0^3B)GG>0="@CB,;^8]_'V3_E+*.D< MT3C<16MJ]`+2[Z&LE'/?02D^Z+(>>'!!@]./=U_]Z1!0%.1)V@$I]$#^EO?Q M__XMU6$F!"E\J1A;BW8=?/$HW?S)_D+4P)U'9C3C1.M>5_=B",VOQ=AVR M(':;G):XN8G"IZ[^(E6 MAZSL3[^(YWHT7CGWQY&EX"#E-@`.L$ZQJKWDGY._B1;`[LL*#5N.@LH4]Q`T64(D",:5&[T>&6O"N7($($@5'6(]!@ MW-@8H!BI0X(B0348,#9?5ZS;%GZ*)L!\S-1J_.;YYWA<0]'.@$==](/F2-'P MZCA1L+JQ.#!ASW'YLZY\YZ&!!.4V0"RH*E;](@^?$]X`G@?(^FDPH9^&4%RH M-<`B&>JL;^P1X;`>?.DD;4-#N2WP&%%5M-'=I0W9Q-@EO"G>N&&-Q@9CR5`Z M0X\OM69<-]#4V?#8'+ORXK7C_TR=Z(K]I6V"5&T-S#-9V48;2)L2WI:(QGA< MLTIK`[X-J3N_W3?2A]$1F0'SK*D@6SI-R2ZG:%')G25:S=FMD3X[M M"&^(M,UDC;JZ>TY#*0RZ`=5@N](^5+WACDNK"S:\18X_"USZ\I]TK^15M2TH ML61%&[[YK"$1+0EKBL4MBS36IM=P.L,RK,&,98K5V_!8'+O815%I)J=>,VQL M#L0TA;I5,\B:EB;8>*N'MBJNP;N15(>B7YN%%QG88M[C#G17GD^C"_:TAS!2 M#W/EEJ"#7%7)!NRVD/;(.K"CFJU-BN/:74&.W+4&#X]A<%= M$JY_O7MTV->VW"7\H`Z?$ZI#2)4@;#RIAM`4]@@I(L1(*D<*@FBA9F\P)Q!H M],-0$#S`(:H&9VKBU7;"F%)]X\3W`D=^=$SPG?K)X3!9E?C9GW^Y2YB3X0NB MR\V5%SC!VG/\FS#V6DY#&(D#.`%#.%5K.XB1Y88#U#: M)P*/YHK#`HK&&'R:*U+3"Q8PQSH58*/"I@SKKS(*U20K;J1;U83A*#>)8YK$ M&A%MI2$@U205I?1=T0`]&-74$XM-'=6#9$Z],5994VN)T(S)%GBUB5-M#\X? M6>$&&N5+[W;0J5WM7%]'M/\1EUZ]U86G6X,EU[.NWHSAR'?AQ(^3P.7_3/^Q M\YX=GVD33Y(+)XKV7O#PR?%WJ@F8GCP@.74!26;$!`@_X"]^*(B224)R82*D M<>C;&]B:_T`/HEB\MA['5JJ=!(8E)DY"[NF#%P3.QIA4L0BJ6 MH)OA0?IL(P=8]>$FW@\PH%JOPQW3XY:N*=/IWJ<+FF0#C2JN4HE!AE=J]:4H M*VM.CNT)$\C#+J18JR.&Z-`>+>P:7'/0"$S#]*5`K-WNX;A[$]&MX[G3ERT- M8MI.VOKV@&QM4KAJ*%D[DC7$I:>ITDYF(EBD'$I?2"HJ+;G*0949PY%O%CRS MQX;1GCD`!>=*S0"I5E&O^N4?/N;#'PZO=#7$XA&:?DFAKFE7[42%4Y(W\B@J MN^NH4B5U#4^05A5U5Q/15A%;5P^M6(5K-,IU:0T.ASU#:(JV6*BU2(@0C(9L M@I[L;]B+3-@\E\]QMWQ[33T^*L5`0U.E^G+PE#8GHKU8O#A(X`VIIB!XLQ.R MS;%P%#07.2'!"#"T8UC;@6BY&4,8J=?9&H.!C=3;:2X'[*T_X'L&','0_>WY= M(0LC<=!9NA8<>>Z9BY$L\N>+V`=)DHMB3>S[@DH#;M0(Q&X0FDL$(T*`73_0 M)[V\KJ#->.CUAM:%!O@5AL:E!=PEA<98&7\-P5`U^$4#]6H!N.G//>?>\T4M M?#83$.?-'D/?9>,*GQ4D>XVI9TL^OA&`7&G?+D8.HS@20343]5O-'8ZN*^>% MQC?.GB>IM6]MU[4&)&B]LM+,BK64COH"!8U2TTLPO.'RR31QK)_DGA$YHD`/U"L])5TQ`M2,?3!5' M]A(#J0M)OQ9[KE)0;M%R_;$FHU#R%J.-''&O6%UQ@V.]8-B M<-9=TLA[=A+OF1:463"@K11LDP3D8SL(Z6:,@T1I9#S*X`R.O8",25E-1S.( M_B@U/PWY4&6R'AE0!E.]411I^%2/FQ:,EXV#CDT#9! M[*U1MN;(:=HJ*VR-6"'%5.$X+?:\=2+RS!N3?_GNW;LW[][QJA0DYA63_T!^ M^UWZ4TR<7?(81MX_F2!/"?#B>,=_3,@=LUKZ=,]DWK\[(?R;%PVNF6$_DO=G MZ9\03PYCO),R>/E]G"&?3&YB8HY!4E-.GB]4 MP,9?^7Z8%,_8?3K[[W7IW[T]^]_MW)]^?O6OOHDR\$\):;^F:S^Y\M'ACT-?] M7>%U<_PMK[_[NSN^>_:7]]^?5>4K[<_4[QKV/$B]PY`/@=1Z"\"<:=<5=<8= M_\;QW%EPX6P]-O=3.+@F"GBR9:?88T\)Z&N@J9* M,4"NMJA?-9V\.+3]&#C=B%L11*2N!*&=O&41.^BK#X-F$K80N+_FF!2N9T`;B6O-'[20Y^YI MY_-GBU07%K!O(_I(@YC-,6;!.GRB\S#FYQ^7FY7SHHJ;#7N"+?=I"+*F!F7> M`TE3F4I]D+03PGL1AZJ7&YYNB%88=$"TH4"[+J'U1">(Y4-1\`$7&>U"RYJZ MHQTXB;FW:+2GB+N7J+>':,\.7.,^>%S:?Z/CJ*VU:V^;T@9UVK54/S_473]W MV`?KX7VH=M5U+7VGZ<)E@[*X>[+Z>['6G597.+E648M.I]<8C,:I=`O2EG31 M2&E"`I,][A(4DDU'SINXK\D>K&R,&R=:1N(".5?LAMS02-R:K)V@T=@!6LZ& M`E);&@<3)`D5;412YUBTL`C+ M.Z07J$\..\O:7D$21/,&-1#:O$`J0HXR-C#?"$=&$RDSP`[FCP(%C_E-)%$S MOH$AN$R?B2P/0Y9G0L@,/ZBNR>ZTO3W,UM"_3`5O'``]&#T0!&PFETF@P^(2 M`U!2)#N$\3K2.(F4!I%A*;?2PNB]%RI;XO9102"E")J&Z_IL0>&_0:"NDL+A MNT8\6.*Y)?%Y)P2V1>:C@D#BMFY`WLX$1"ZWAN)-$I@<;HP`Z_B+&8$;:VY3 M[#V*\JA<58?<:DM'Y.CR>)+"A*A%,4RVEM77H6Q!PA+>:F$HVW\X(HBN#!X6 M!BJ7:TC12FB9$9`7L?"<(Q'//^E5@FV2`+UNI4EI^1(,D09X:(I>0,!.U;4O M4QE!>=@;2)36+E\ZHC)UP*P\QZ?Q+7VFP8ZJKV&LMH3,QY.4E)+Q>`N2-<&[ M7=%04;1\P7YJ@N:"U=NGE`A6:YR0$6R<+#?\MJ#X+O35L\MR2]`XM:JD'`_% M(I]=M"&\$58TJJ5I.*JFVB%G?UUAX\I:4Y5#R3H[A6.4N#SP)@HWGFI0*K8" M9%)9N>KW+3XEZ<=85HFHH58Z8W?](+E28X15GL@6"!B\49_U^3!]V=(@5FU) M5AI"AFY5%:5((VU`LA9(<9NAEFBG*'LK"AJ[U9JG%+K5V2;@.$,#&CG^)'`G M[I,7>'P>QFNNM).J31)R/&H%(7G85$)DA)=E<)G8`!M-%O*WI7!!#(+JG<:$%\0I26SIJAEH_2UCQ5 MUD;#K[>3)E.O-1+HE"\^P%XQ0!=AP%BV8T1;YA%#?$XW8925HQ)7GEY[01AY MR;Z`H-Q+6LWAFB:/(?ODF37ADU)5T`JI!7AJ&M3+;0@`1=4[+DF."I"C!B15 M(1_?T]N8Z4ZY1N<*#\9O)\VI,UQDP7-M!\ M#!=DY(G-="7;*'SV8LX)?*?1:-7U!&\R:3@RLJF1U@)AN1T@\:H*5@V!5^8= MUP@5=L!N4]!!?BRO+U?A4Y0J`EKK+7*S-UG]G#2/XT4GB<6%LJ/)`SLAT((1500:'E@E!5LN0J%\38D" MV0N.Z,CT"RUT!C%2P*;^":$&UV7U,2HL7HX6B;WX.5%W8[=V)OS9-- M/7^74%=C;JG;`R"=]4%)-V[D-\L=:BD2(9QF[[T'P=.S;S.6\K_\\AR>[FE4>8I4GTHQ M^@_0*0"W!X%>M;>\/Y)U2-(>:P(%N9(<6NPP[IMPLC<1I&\BW)1&7-0R=%\N M<#=<[_B47ZP`V&'\DZ/QGYA9/X2/'LX1YNY[,"\(%ZO5:KO<"`4+^NF'5N/)7J2$O(`X*[;(5)-N M"]18>]*3![VF6`^0?'-Q7CJ3^Q+YUD[T-:?^P,(RL-\`(-.^JQD>&VC1'Q.6 MR??YZE,,P7&D>O`5]3#@*=*3%T^5&ZF6PW`4#0":;2TSK:,$LS(F@^T7-'&` M:6_*_8'U1^&WB@R-O%8P`7`%N:S$9?CD>-*$V>R%_2YMB M;1U9I[;NLO#0BH,N"JNL6UH*5I@V9!W+B-_B7;X!\)KR:81J>%5(@5:X5"DO MUV?DK4GU[LR_I0)8XZH1!.G>SQ32!+?49*L%R74GV\P'Y0*<5K.7V^)<==-H M'Q?%^VUP#=M`W70-W9(+7]26VV0!.WVJY: M#M".VP!4C>38GG"!TUE`,A%D"^\!9,N!>`%9IR*8IJ]E3U4:Z!@39.W1A(5. MU,TWUR?;;11N(X_?9MK*"PUAT"JD&E#D8IBI$#DDJA3%D%G2"1&?M.Z8M>P) MKXL9/2/7\]0U+[FHIZ9M`0X?Z_7N:>=S#9H2TMN'$NT^((<5`V"29S[*$L4! M&.3A9BB`%S/4\<;4`*6QQ]#Z\,:ACX'39R2J%4<!`.H?HTSQYJU1MT,4_WNEO\.V[%(DQZ:_;E+F(: MI*?<4\46]+/X2+U'K-4!Z&:Q)B1YOL07_%))DHKFU2TR;\2DT\^1RO%TAL8_ M$`R14_2=(B.M%=,UL+1[5!VAO-W>$NS@D&%MSL[T9T>3]9P.6 MH7N/3X[/;S'M[#PJ\OB^0P)DX#J$K*V>HQ68N>.PS%D`(+3`C=0S3M.+U-*M MQ^FI"_XZ_;36PG*3/D\\6CSH*HS8[&D7L8]NV&0I:#PO9=H-U`DI(.T)Y3#0`.C921+QV(2"[2\)E^4XF0?;I>[[_&%-W%APN6YNL$^_92WB.93OE M.W0&6VO<'&I=<6IAA7DWY'Q/>$=D%I#C%8;'OM`=QR"P"\03M[S4(?T1L?HY M$D+@@N0=F5I3M;P;32%34_/JE/$JO*7\%7D^+95;7X7#.:Y1'@>:"#O*ZY+3 M3@^/(:N0'!Y$*M(%)R&9M^0L,CA_)\>K M-1U\E_NEO"_8].CQ?)J<53V:0X,;!"[IEGWCGI,5+YX\A5'B_;-VU:'PFE52 M@"Y9K7S5T(NM17F18GLAP8,J_]M)T&<)^GARJ;A\ M=;.+^"9BL@I7CW1%HR/+'^ M2*%#0(&7V\IVQK\B,O*M`0<8LFLRIQBUZM`$^37#N ML*D1/QM$@[AM]M$@`'VNH$[EVL,%1+0DQ:9(^UNZ:HL]4CE/S8G%36VC@3`Y M)S$>#/`$_D;;K\WB;S)\T.NG2S?3%58TLI/E&LO!!IW`7E*M#ZWF1N7*S92E MI=A#&03D==A>&"\>V6\\SSTH+O[%,4UB,9_W/>?>\W$73M$``M^6;4C"F@NT MS1B(Z6%FP3.;G(2\$)&14RG*H?J1,@`MUU$0L8=*;3C23_=8P?Y@"N-RN<;< MV^DKVSHF8R?K=;@+DOB6KBF;6]S[U(BX->*H_*V%HT7C7)(<1>VALQ:L`X)H M!`1]^3T4`ES"-[.EG?>-5$&F?[2C[LIYH?&-L^_"?TD>VP'4`-+U`%R4"%F2 M"=L2_.OA2E7?CJ1Z'_>%I_P`GJNO\NA.JXGC6EZK@>`6N*WY<98W"=+"18?) M4>&S+AY-MVL;G)W^:S#R@P51,:=.BW@=5TH*GUOF);N_D!P[?>$+=QGP4`#/ MN&W1).]UH1W(#X.BM<)Q&WHY;9]NYN)L/(BA<.P&G5AY\*+&?HT/7-A_"J$! MI93!^O4N%G=2?U.;RSK\Z!,FCF\[2CM/7#1Y(6,^HOL;ODX7#W7P2]49OO]1 M0S7R0X>N;#K3,`AL`7DCCD5Q@C">YD@M.(5@W1=K@7?2(+"FEVIG+YRW8I/P M[###9/V/G1=1IBQSHLG^AGV7"0OD^!4XVX8DXPZ=`'HG(VC2+2Z9,$\:SL1) M+D]$!R+>/W2!Q=1>(/,K`GAJ[/:`B0Z/R6RR!HD)TK&8@#Y*DU0AQT\;)UB"3+#LG5T/$WO;/-,R7/>JF5%8M[H"AM'/ZU'_: M!'\W[F9#U\ER,WU9BY316^;9EP'7E@5?_!\>@#T[/O>5"H]CU`WD3;IF\*1Z M^4*#5+K/6 M^9V\@+J4LX#%SYY`%VGAEA0+FZ"D/_'P`-`5:05#%@`%O;>V`S^E*VW-R0EX ME'.WW?KB&+GCYW479P&;`S^EA\PU*IIJ]@!YV%,;E'3ZLR!YK*M)"L+H&U@# M@7.]>.V'\8X?K^3G+?,=+4;%0U]H6UB8&$$/DYJQ3SI=:D2]7N75V8S.\4I7 M0UR%D<([:(G!%5)O4[\V\N`BE1M;^((PE@/H`X7?ATW<%`JOHY+>M!;SQ4YP MDK\:')H5W6%L"[!TNQ;7*_7:=8@.F27.F$3CA.ND"%U*S4"SMTOJR9G8Z;`JO;()R.JYD?Z`G*<(GFAWF:*%)N27L.8>*DC7'%GB] MT_R@%AYA-!5->!/$Y M>O5,M7!7;(9SD>I9W0I.\;[4,_0K49M5S*X;X_E",8V>O37>N#Z4ODC7E9XU M#>\U)MIC;!>]9>5EJ0WH_7+C9*F\&;!.#&M7;U:_]WILE4`;!CBC(0<2B M>T''P8)7SEB3(*7Q3X\=<(/?,GIP@JRH^T48Q*'ON7G!]QMF"?EWNMQD0[;C M'ZX>TSG4-4S_@,/M4"^D:LK%?D](J6>QC5OLFV<5'7HGQ^XMN'C/BM<3&K\> MR)%Z4$I5A_@A^028NNPP)T>7F^S,*M-;X3)J&D.F(M>I*DW.1"-.TV,SI/.9 M.NHN;S],%K._3E:SY8),%I?DYG:VN)C=3.9D$_,?:\WK[9J%("^I4ZG>4!1/;!IFK2T80D>$`'H3 M6:L12?>)M5D0'`/.G=B+EYOBB,D&T#OO(?`VWIJ?+Y1T7=&7Y)RI]*N"([VZ M!6113_A5(Q7=B7O4BU$:#]L*79):4^;=$M$O4G[8P*_B[N/U]>3V9[*\(G>S M#XO9U>QBLEBQ0>IB^7&QFBT^D)OE?':!.-Y:`QC260W!]ZH[&X#L/5;GQ!%- MSYUF%;GR,E07NRABVJ1'%"\/"7UMNW$=>X-:R^L,MO9@J^>2:;&065J=+^LL M.Z=,CMTAA@Q?-GBM1<.AT6MV=&#JFS=X"XS].%Y:=^Q%<#`WI8JQ>G5GIZ-2 MC:O=R(H63@V-_G9Z,YE=YF$$>+#TVN",X$I5>/C5HL?3`L2E\3KR[IF1\B1C M?G63$^Q_$Y-M9L/':J'KS'33^V9>BV=M#`4'\$F0&8S932!:8:&.%&AFHTKY MQDM/[`CC0$#`IANVFI*<>MAF1ZA,T%G=48KA M_FP1>3OIB\S3UF4-#2L'K+365/--8^1JEX6LKJ8!1)X"I#(G=448+1C.(#&! MU@_3-3JI2G!7-B..>4K1Z=W6'P8>'6B))?%6X,RY5KY"+D9 MT49T":UK]OH=V.(45"..%F]PE^%[P5LN[E:W'R]$HMULP4?6#[?3.YP%^%O$U$OGIJX!;N)TZ\6_\J7\C^P51(GC!9J7V*CE`*=&;0"J M5B;:BRE02<*"98;QD4#.";0,JSH)T+$JP"J<'&F0I-G+7#6SQ00M<A^]GR?^:89"X&"!^_>IP;)A]WZ`70.I@"K9IC+B_'HV(-5 M688V885D8R?CK=*RB^6"5G9K4$EOP[M=&K8.G`:8FNIF"D-$'Z8[@EJL)HL/ ML_/YE$SN[J:K.]1%_#$Q`!>ATV5+36TZ3:KT6(I;.2_Z2_'UC:&6V)I4E3() MG1<[!D%+M=9:7>JH-OX2N-*@2RM%*FL>BE&M*]D-K5$XI4S/K9@G[G*TOMJ3 M_R(WDY\G;$3`9S^6HN:$U[<$2XBN7A-6D@RAWJMAMG2S%$8=6,U$X[PFK!U# M,0P*E/*L)OG2;9:$R@6]Z:-"#)<-Z@ECK2%9,%,T@[&X6%Y/"1NK\,Z:#Z@R M,ETU)H"MQ@Y8U8T?0)I[SKWGB]JJ1F.8AC!D/38=*%*Y(''8K"!EU\`&B0FT M\IFVV4EES71MS@8.Z8Q].M)6L$CEC]4FASX@=@2U^FEZ2^:SR?EL/ENA'2<: M17D[R-XZ5NJ3`X[NES3RGAU^O?M,Y"2E!1,#]R?J/I3JE!N-I7UZ!70/_RM&IFM?Q&0#!^`$E7F]^>#U1Y!)S+HU:W=/D$U8:1&$OA-%!:'V(H%,X#WE)FW5AL\1LJ-?O`YT[>KZ\*%LR/*O&ZUX(5\N+__QI.6>CUMUO MQ%%BO"6"L7'@^P2#(=:42^"UI"O57O?I?PVJ1K=U`%\?NAU28R7H:K'G??X/ MOGOH"8Y?/%0H^8MDCG>SZ+L"I1CLF2B5^G5' M5(_W]5C#=$,4-Y$7K+VM3P4]UD5AQ,-/(R$`/O;42H::XTYM3(!C\\>8+C?3 M./&>G(2J[BZJ-`1DK*1BU398`SXP'YK@4%)+36:[=#0U-9G76U%(@M7;9Y52 MM<8)."0Z\>,D M,W6++DAK6:!+=Y!+!MW@2H/2H1NRC$C>$5_9YUT1T5HW+YH3T=X.LG4& M<>H($,R&4:HS6::R5IVF3K;BY+9RDAD+7MDF'9*6BC=I,!1R'2&F#"W?];QD MLQ\_%`NHV3V]K8N3.M*@:PDZ8.39:RHE%B`+(L*8Z*` M75O0YHN\NJ!+%CCZ3USV#29>[`4/%V%LLI30)@E(^W805&6"Z1'Z3%0PWA["=P9W[7A^CNTQQX;J``"@@)[',V*2=!C/A$:0AVZ>>,"1 MWI!"?2>AKN'(K]L#Z%$<75#RJ9RC),E$;0L)NJ,3!T+)N1,+4,=>\([JC(T$ M]LB.$97DTSLF/(+S$%,G"IBSBF]H=/?H1%3?,[1)`GJ$=A!5"\LE"!,A0L8> M#V".9D$3XJ4+ZE_[81Q_0[8,5BQ@??W5].;NJV^PG``(&$@_H$F8*O_UV-)C M^Z#V1L19,&7_\I_.=VS.0F.-D;]/;U!;#IW!ZEZ-.0M(WAG)>\/W$&-AWQ6[ M0MG+>'6@M'8[1C=3K\9,\3=)^KFBTO9)+S\$%T5=.5XD=GJ6FRLO<(*UY_B% MPF>M6RMZ\H`1E2Z@JJ%R.9+NVBTWY"!:JG"(N<,R`*ZP`1=6A`4("3+.,J)4 M-=HRX1.@EP@CZCT$%[LHH@%S5Y'#)H3BJG?NXL2OOAA/#-9GNO<)Z4UZ`)?, M-NV+Y)V18F]BB"SVAQ^SC?D.UOD[2([B:&X("1^H3^I+8,E/]60OG.]:T,^% MBE)1&(0\OBYX4WV79=P5H*?J`%->O_A<*O96ZL2ZVF\#`+ZE_!IVXAPQ;TO] M8'DD!&B0SJ@K(ZL^J",=>RQ5-1[E_1C3SQNZFVE4^Q3K./XKQV>UE+5D`9[4F>Q)T63Q5N; MZNQ[2LM271U/#Z=9"14+=7ZU7*6N.)2#U(?3.@$LE-JVPA-VAS9]63^RWRFY MY?7HR,0-MSQ#(0D/WU.O(!]_C'P>,N[1`A>AK[O1#@K M^5\N>BT_.HI=X[E+0Z]3;0ZFI5,>DU94:=P&9-ZD/ M2\JWR43YFOVQ.ELFC>Y4!P#(LV_"0$S`PR-$A,U.2"R@V9.&G)+R)\T(94$1 MN%[EW^PJ_-9Y$HKO$SIA*C/(CDDF."`K:K]UK_IF0_APY?&X4Q1IJ!:*ZA!) MZ/>&$E28@%7%%VD_65D6N=Z;?<%&'^`\EW$NTG9B-JWQ'AY3#WK#5'X4V*$)\:<;8Y43`G;8_%GQH]"`FJ)1ZETU8A$8Y*U M1O<"G?3/M4=9=K%&6:U5DNZF@;<4TL[!TNI'*P%[N(/C4LKR]L-D,?OK9#5; M+B:+RYO;V>)B=C.93RY6LT^SU6QZ-W%=4=R.)T!MPNA)?"^*NTT'?@"4LQGR ME4@7]AX7F)?1@Q-X_TQ/D(E1+KU@R/&+ES4?'T`*3QCS9M5V;P;U@@J=BSN< M#]V38_\(+TC'AP*]HE/-EW2*\)JTO/?K?T]@@\;@GKHTQ@SMIGL,247'R.;I M![=X](IB$&P:<'3%H883?3A5`]8;(?XFQ#'&@=>*3,>!OU9L6EX7"1R8JS3T M("5':.8^3-<*8[I^\Q`^OW6IERX3LA^JJX/L3[_,Z8/CBZ-)^\F+5WIG.I"1!)*FI)&2K9=YDV0&`'LGX:M.BG(10?ZLRO2(8:V^L1&_/%\<_. M?N$$X;D7)G3].`O6U_3IGD8UMM\J`A4#J]66O%W:FO#F)&O/9F-K\K=4!"/6 M[8?@=,4$3C@&:=$1)N+K_P6<*+\!L-!.@P"E<*[=^GNP\8[7'`N#A[MMQ`\\ M/#IL+KRFN\1;._Y%.$]<-3-UQ:%8J@]'KI>72I)4E)1ER45(F#0F?4>$]N:$ M@T/B-=97!L9W0XJ5N&_&KU%7K.9>0&<)?:J;R1EW8<_*51%6QZ4"W@41?=BY MA&4YQ&'6LBP'.="BUK@H+5K=DKR-X0I7U=7T.:!)(W[NU7F@R\WR<\`(^>AM M9\'=[C[V7,_AR<9-+E%'%.P0IA8,*>/U(,73U0YRO"1841+CB&5?/.&&A`<\ M7D#B,?%HG:I\58CT#E)"&AW+G)+:O$/)'A@18(&%MN0BL/!(; M,.*&M,#&AH"\E]2L6HZ>0.D77UC M/5%KFM1_X553K?VVX:SRVED_>@&-2C/Z5A-520':JUIY^=[`K'5U%H5JRQTQ MG!!Z`,#A.+LD?`KO/1^WCH^&.54)T&Y+@!7V=U'@);N(,EVNO!?^4]Q*!H40 M9(U\E>I2K;B\L;"=O#EJXH_^5R`506][_W#V<\OK#[8L#1S;0%YV7U!,*E(M MBB9BSN/1M-.]D;ZC?J!WS5=-3[I1OF)WP*QH=:/%5M#,:'24V;>+.G]%U="$ M(1UU!&>)>CB1[1`P&O<"[VGWU!Y_E]I!1MP5!:7X-/T<.Z;6TQ(U4*[[IJ70 MN.9KAIP:ON@98ZD=Z/3O1?TUIY]C&Z.>EEB>NZ-ZL)/*&D.4IY&R%5JP#3!7 MG`$P$+9A$V"NR*16)QO,L=+]!\'4L/<^)JB^Z__CP+)B\5\BE/;:?Y5-%GB' MXW4?7=Q#0=H&_U`"T_4R(LO\@Q)3IK:?9P5NBUF!A^59ZYS#")BL\`PRF;1= M@\2D0;+)[SY>7T]N?UY>W M`I^!/LRK4>3LWNV>GIQHSQ,A[[R'P-MX:^YWBA0HY/(?EC4&H*FF6[_\_[,DR2?_4O#"&W?D#/WI!U/YQ;[S&4%>[US)RE ML@AC4W.HX:59W:IUU@T#>"45[=1;Q^W:J;F6`QQ%=3!7U,+,DE-1TQ(PN:+Y MOH/S_;7S]S"Z\)TX;MD^-^D%,OW"")R4CR&D3YLN-3G?$]$%$7V@;M6/BO,> M!*?F_!D?*6C:C3DYI3P<8V9:X7N.FBV[/!!#2#-K/:D9+.\(^3, MB"\)<'^O!`W9$O>DXJ^!BU*0MT\E''%UU3)H3G^J;096X4923UJW%RT(:X)9 MR4];SS.DHBU#O$>X8BSU1EDNO%)KD;V9L/HUZ MQN3K(.1_((OP#?GKG#WCN[-W[W[[W;MW9V]^^`:3)CU?,C!-)(NMH4G57/O3 MA+71&C**#8&I4E*QZ7ODC2R@BX:N-83Y'2/,V?OWC#"_QR5,_U<-31K9?NMH M(QEOSR+I'V,J[@]M/K/3V!2R*+JL9ETM[N-UJ,T'[>@UJ:EYOMKW'FROVA>@,-X5VL*--2<$&#\C;X(\U.II^_?'-W1LQ MSGQ_\MO??7?RW?LS!90\);VE"L7U_IBQ5N^?WA7B]X8?U:(ZXMHU]GP7VBM/U/K-/_ M9/_/+N:8>T]>0EONS&B1`HO=VI270HT]X1*$BQSNM,F$4&,Z8R!O?G[3#`4I MV@/Y-N"B0"UFE`-"'5H,FOXS;[O10B6"EP8T5QR'J,WNF*/>3V$Y@&Z)059! MZ)@A-"0&Q%0AB<4MZ4)5"MNP;:]UITS&?Q3GL\N[=G:MOFN!#-Y M"J,DOW/EAD9>.'S\T'LO7>^(S$:4Z/6.7X=3^W78L4_>?CK&@"T]@HI/CK^C M$]>E[LIYN673]*900FX(%4#4J5@U`M&&B$:$M2*\&4*HH*WJJ2-439BJT1BJ MZ@0%UBBK-?P/905@`WTCLTK#>Q.M`,OV.SZ-^>F[E[474Z;%C;/G"@J%-?U$,[D;=0);O-X,GK1IQ\?1\K.A`V%76!T&JXM\/YX(F MY--D1;:I%%J=_E%1@%;B[T`KJ1J_.:?@_,;$9=]IXL5L9C)]V=(@5H7^-8T! M?4"MJE(D?&Q$LE8X3#;6=AW&(\PZ-!D[C+:0S&PVW"K_&JT6<'1^]+9;]OR? MV!C#.G]@G%]%3A!OV;1-Q$L7_'6JQF6]#B!'9%U(\@Y.*DAR23'PEF7)Q2AD MT!N"NP*[=KP#G,<<&RJK`:"`#L9&+)*&81,*P;F&OU">>D+="?M.G0>ZV/%M MAN7FTO-W[*]WCPZSC^4NB1.F-M-:X2-,>P)T%N8@JQ:9]T"R+DC:!U^ZRWHA M:3>DT`^.`^D/-D.RBQDJ+V#$>]KN,L<8;HB;X:5.%/!R_&3+WD/,1;#\C#V( M(=U11^96_5(WV@+.$-;KW=/.=Y@RR^211A?LNXGH(XNCO&=A'%^% M$0,2I).:]5ZX5C\MG>#^?1R6&S8!4DTQ1G@:Y!QEE)=5LRV6/X6( MQY#2N.&6Z;D* M\\?3R1/?=XZOV!N\O3Z?!4GXD6](N7<);W\9^KX3Q?J%T09]&GR%M(%?EJ(^ M4_XDL7O!RZ&)9Y%5>/"_E&2/(_QYY)9X$2_Q^IQO'2.\0K-Z:O_S$H-EM<%@P/F_G2Y7W)D MFL0?QR7-VQ+%M60M<$US1G:H`P-L+B$.WQQ)KU$]<[8_KQS(O8(,@U< M,4DJ0_N:_>GMQ[O+?QG^X+9N`GMG9&FUD.LP2!YC8WB@">UF;)-RVHVH-M+T MK+"^FFZS3NR($IJA-C#6^2[YTB9]4.@S?R'OS^"L>YH'% MV'M&"&RY-@1=:H>D/8E4>:-!]HMN;J)DM55U\.4]L6K(A8O:+R)86IY\S;(>XPV*:QCE.S36>]\F?#*@U7!DW! MO7(IM&;B#4?]UO7^QO9(+D"UIBI_U[@K^=:JWL$IV*-\%^\PF/98;D*]WMY" MTD$F=3PG,0QXP>7E9A8\LQ_"R*,&>7UM'Z MTR*^$`R?V13L-2(TG&4A0$282&GZEH:YDYYCZ>$$\T[WQV!-GVS57,5`*EO M#YC.U*1PL\&PAN30$B=/25=IKNK3:*IJIAX-HBQD(I'2AJMI0RH#1J#=7\+H MUUEP$X5K&FOQKBR`0;RJRLW,XRW9E))D;9&YUZ8W__S4"TZW4?@0C:&N*?_Z M*HS"P5J#;B1AG34CL)#7QXT?J?LA#%TM%I8%,%A85;F9A7E+(IHBD[!-[8.R M#Z,H:TK!?NJB$+#6EAL)6&?(@V\&,'YO:93L>?G)?^R\+9\<=-L54/:$NSW0 M`E)[GR#O)RT4F_=DXY9!=\3596=XS-VW$5XSZAY;"XBPD;<;=+R7QKZ#ANN" MBWRNG?6C%]"HI,V'*%3.011"@!&04G6YA&36N&)LHCU.*-11_W]UGK9_."+` MBHS&T1XR4&HW_6JPU&KW@"<4=U'@)==!#@FT&+QT+;+%V.*Z>[SR?U\KD5?=G3]LH M?*;<<;3R52T'R-DV`%7S.;07O"U*8'*W*PHLP@ZE+R1+M4R]RE0=.X=C:QZ> MW["7FYA$Q2V"@'QMA2#GM68S,2$!$B)KDL`8RMWN/@D3QQ_>Q_!>P=2%)*V> MQ5=9JV7N*'6A+^DVHFM/K&VPGWTJ3D0%;O%:PD;M%00?[!$X%:#[OA95V>=B MW^30N7`DY\&L!()9H'\0^* MNLQ#.(=A#M?/)XO5S>WR9GJ[^GFRN)S^^>/LYGJZ6"VFJ[XG[3MWC7#LOL=K M4)W!%RZL81&;UZ^W_$S^.&_EE(B.3TC>-6%]DT/G)X1U_QJ.[/\W>SNF)_I? MU^O!./#?U_JS'+06*RZ\E_+&\O/MZMEM?36\;?3]/%Y?*V9S36I5/X M.*P;=,5P<>W\/8S(Q2Y.PB<:B0CL$PU<]C>[0Z_A7P3OD.0]BD$S[=/Z.&OP M5W&J>!FO(+"R_7T@1%(]/&9##-7=7<)%3Q?\'07LV5R+6R_^M>D8<8L`8$35 MJ'+5/$L-"6^),Q-167HW)E":.2,WS_8H]<_+BJ;8'55*8 M)"TIKV$UYWO"!=@8P41L(:PIB#$1=&7N@!A0*2RSH97'$A4PQUGVQ,OPR?%4 MBQ8J*=01MZB\M@VE$K9PV2X,GH&Q(`ZT$E$:!WGJBSHL4.PV'%OP*O2N71+ MV7^"Y-*+D\B[W[$N&@M"M8E!K?*WJU^UC%0B+8AYD"%%(80U^LXPP@UY$KL1 M[I@`=-;6+8>@M1[>!X.N-8&M9&LRN[16K4?K`=Q-NE_6ZE[R9M#NY*A>L_O( MVB!ZBU8M#]1Z'DE7$\>`KZV1#]!1MT%1<(I7V%1+Z3*5^I3G9Z_]T8FIN)Y< M;(7G4XWF"OT*$;`B_4JUI9,I>6O"FV<[_@UO9V^Y;G\K=1&7$&YHQ/_@/%#5G;A*,&&`H*L^%R:Y570H"$NLQ00Y;6A0:9*8,D(RYH,G<"]V-,;[V'1WX.)7)G.G@_A'5$1$\BY?#0%TD[LR7+<"#4IS;@ M-DLJ_)*0&^8/6@0=(570V)\U)`B:.C/`[,'&A,Z]9^K.F'D$ M#]Z]3R=Q3)/&2QH[=`*YZ6D"3=HSS(3Y@E`J3H0\.79`TAYP4PV'`1GF($^A M06K&%C1DI[1";TA&P&(KP=G%K[D2Y'62IDXJ"TBPA_1PY!T)32]0B M('7?M%3SH^9K!JQYU\P.:>NVQD:UQ"$KX>G!J:LTK1K=YM@Y#KUP-7OZ,7'I MEM`#1P9:8<^`7E*Q/7UN];HQJ]RUJ#0T?5G[.UX^C%2-J=*,5D>W6)8=_!J?P67DW!+GO?!,(V45>/ MV+!;U-$=`M;&+8PL/*>X/`0I0L@60<@ZMFT0I(BB6'96'#*HN'"EI4[JX?&$5E3I0(*1&B+_VD;;1:"E8WS(!HJ-K!S+XNQ48E M%!^1M=0F)K*>^@SMIR@L527^R'2MD@?T`IIHQQ=XU^$3%;I<[**H]4:9!AG8 M*V(:%:]9I^=M2=J8I`:2-4>:4!MH?Q%&VS!R$EK0'_'6F4'U!KY+16WJ-9>C M*.T<,'_:\2F_9V[ZLO;B0J#=SM4V21]=P4*-C**X[ M)8FP#W%>E3YM_7!/,Q\="LFM(_Z0A.2>LE\\E__X$+*7&0C]?.+LDL1-=ATEP.(85?1,;='M"2&C0!ZE,9"C$[9;G+WP)@`W3%;X$ MR*:)"19@QDA!,/193:D'9@ZK5^[]X4G*702I'5P^O:2@G-9!RGZS4/XS+3=!4FT M3PF;_5+E:O;G7RX6=<'Q\4.(^+>HBK173!98<:Q2K9]FBPE*("=];X=8K?JE M#;,Z,F]+\JIMB[!*,E=D_I2GR7/4O"_K5#9<-[%#:=,%E$&TQEA)D?C7M)I2 M)1]@MY4@]/[US?I)<49=&CG_'OC)^Z<.^U%@1&@[1 M.V`4.E<$)4,=Y,1FTA$%S$A(?($=C MX-0,9?&10@:]`[*_&A\/1WV$R6]9S448N-3=,33W/IVF1P=UYL,:O6!,D;7` M*>9M%:]5ZH!,1SH6:C:/[@218W,]9K819>3AM3]84$[6SHZ7&+[?YX=&T8K2 MXZ!#F8/K\Z]Q6JY-/CCWQO$R./ZN\"8*(4#GH51=2H8X?$AX M:[(,R/%/.)[!2/_,/GC9M'#MB4)`/%>.)(^41,RL'@*1W,QZ.,.D,_GR$&51%*GEZ;&?N M.??,R2=[RT])#`;[E(BNR*$OE*J&9NN/.A8:(IZNL$]G[>.O5FFM?PYV2+5ASZTVL5`^ MN]I`0<#"%>R+H/S[N%O3P(F\L"6!N[X]9)&*!H6EW/^\'T]H3*DJ6*$PHSAKQU,WWXQR#>TK6W\:C;FJ'=+`-ZIV:SXHTF4FB, MG*/=1?T3&/VU+\(<"P'L'99=%JD?J?9YW#ZHTU#)<8JIZ)5ND).1\/UK[,XWK&!?2>..5/F MRMR[1X=]VS?LVWYT8KK-`KD+->X'*K3I`+!J?VD7/"&B ML"%S[(5DW9!2/PB!T'!0PTTQ[7$]*BZ=&.EU(M,*GVRQ3[!@JZO'*<5@'=U- M#T>9#D('[\RW'U*?G/_6Y!G;!:%26=+D.>,J9!@6:QI-!G(I*&%3-" MI1CDN62U^E6C^O,NY(#E0Z287TYO9U]FJQFGZ9#I5D;]PB?:]T!M"+]M'AR]95D70_\`@Z]%5)P M;<^]'O85G-:_A%>0A6WK>T#(Q^[J"QN2LCLZPAYN_=0+T/NV!`Z0ZZH8F-&%VMD0X:EH M3X:<9**U&7)5^QQOB)^W)8A`15A]+#]=U$X9I2]XHIGZ\T+S>7]#Y91MGZ<[",7!JM M0I$#E.X>-?G!;IU!.<6N4*LFF/5#>$"?NT%WM/NB63]9?>4>OD[8(QT^3MP`O=M&!&:O@2^+D!/YW?SU:_GIHYFQ*S`DSYH0'YG@Y2\O6?+L M?5QD#S<_?=EZ:>91FKZYW$P>(BK.4#9Z04P3$\UP)D9Q@$''9_0=,Q!PR'T62VG[(ME7],#"W32Z&85GM-C^-/HLMH% MP5;!-2!(ZW8'&3[_R0Y;K4)RSB].&R_PUEC7[@?&MLG0*X*CMV[<&\_=`8_: MUN!6@G4]0'G55Y/^/5S3<6GGN.QS67\GI+H]E"-2*-RXIAB3PN+<)?@EC)WU MYG=ZY6J["'[CKU M/)YBVB'\Z11SR(J$_&)G^9ZEW6=3OD#X9B=3OL`78'@FQ;XW@'`:I:/G:SB, MTLWM058H?J3NSN=!)]?T?'_A.W'CB14=*=`JQ2KEY3SFM+68H(IUCO,]$1(X MAU-ZH@AS%/=CH]`N63PN#MC"Q:VTD$L7MW$"\O+:#8TBZEZ$3_QJN=3%1!%[ M_R)N_(N7/,X"UWOVW)WCB]GF.9]B9F6(XO/]RDLXDF.CEEL#1GH@Z*6Y([TR M^<+=]$&D^"12>!3ASR+'?M(5#B(>EQ?&BKGO$D_DWJS0%O,*!+!7F`(/(8!K MW^5K'738^WW']#?RW<`C.ALX)RUIP16_I6DV7/SH;5?A-$A8Q-AZ981I3X!N MU1QDO<67O9SPD,5>^%9#V@_RS1-#X2TS_+.$-QD?KZ;KLP`%#\TD;1$`'.L;598S6].&)&^) M:BAZ;[SJN96O&\Y,Q")#MN0P5QQ"5[<'-)(FA:6$)+$4=%BJPSM/WDWQ$$1Q MS1!M!-4AB:FT\2HO50:.?LV)R)<]SDB+$UC5:KMY9_@7GJBAUJ=19O>[0+WF+O:M(C4(@56 M/JY-^;I+QH4`R20(%R%'&8RZ]8GFC6P]<'3TM%I>+ MZNE0N(=CN79>>&6<6YIZY5(^?/[HNUVT]7=Q08-5>$L?O#CA9P\OG*V7.)+M MY9B'>P"4NQKRE4B%B-*^2=YYP2K359?<=+,'E$UX%9+C0TCV%`1?"/&&ZET0 MGZY$QU>P'ND5Z#C5+_XE:'GG5TX6,-<_N)\MC1)#.UFX:>_Y+O8"&L=B&A>+ M%-WC!7VE6<0D.9Q]7[`7OHLBJKR9JF_/@)/C_B^A2IV\1U+HLGC38WE^-DE( MH5K%L6.<.?7P;^,@OD:[JP<4%.1<>B`"5Z?7P["WSXERL5ZQ^AQ.F*-D+:DZ M7Z.I.=CI\49UI7.\HJ4HT^[P89(WQDS4,-4\_I%\'83\+\Q3O2%_G;.'?7?V M[MUOOWOW[NS-#]\(5%*+W[$69^_?LQ:__P;IS/4XWQ#<`6LU(5WB6U.`H92!BC):%&^^;QXFP;(]V.@,P!U-:9VU)@O5UHIY MQK47L-!'AZ^E^$>#K'TJRC"3<1[HM1/]2A-Q>76INF>3!VD3`ZLOTZJ^5#LD ME2"I2'I?=[7@+T;!F49IA["M4VQ=A0/04T9\)_8C^S?^Y9I,,^^/]02P,$%`````@`$TQ.0I=6U1!>+0`` MMB8#`!4`'`!C>6EG+3(P,3(Q,C,Q7W!R92YX;6Q55`D``X7U'%&%]1Q1=7@+ M``$$)0X```0Y`0``[7UK<^,VEO;WK=K_X+?WZW8Z=L]DTJG-;LFRW-%&EC22 MW#/9+RJ:A"1,*%+#BVW-KW\!4A=*PI4$=2A$-97IMAL`\9R#R\&Y_M?_O"_] MFU<4Q3@,?OYP^]WW'VY0X(8>#N8_?WB>/'[\\__]M__;^/'_]^/^K= M/(1NND1!<+*XZ?SKXS>,WE!T\RT?ZX8,]=V?O_OQAOQULDBC MV'/6_WGSB%ZBU(G6-[=_^L^;N^]O/]]\_\-/=S_\]*_ON_27ROPNC^:>[[[___&G;\$/>\J?W&!^T M?ON\;7O[Z>]/O;&[0$OG(P[BQ`G.VV4?ZJX^W=Q\_WW[W'GL?*`VBT$+GRZ;2SWRTB-/OY@[O&<]+_]N[V+N_]'UO^;/]T`J\3)#A9=X-9&"VSN7^X MH>,_C[H'(-9N,H_"=/6=&RX_T0:?E,;Z5&V^X\1)$!U\,'O$`6$,=OQA&&,Z M=MMWXCA;9*HS5ASM+',>.A%ILD`)=AW?+(##H# MV3!",3V_Z-<(G\=X'I!]Y#I!TG+=,"5G6C`?ACYV,1D'O2?W?NC^7AUII:_7 M1A,RG96#O<[[BJQQ%._6?1K10Z45QRB)'W#L^F%,^&20'&4_7!LENL$K^2., MUK7`%8Y>(W=#LJ^2]="GZXM#TLU?A:;9C;Y`Q)HM2E&ZP;D#G- MR8ZK9PVK?ZI.M"[Y,S\[1SC^O2Z@\J_4N#.)L#G'+SZJ\3Q2^4AM""?.>RV@ M../6R"DJ(=6%1CAZ;9BR:ZF'G1?L$\$;U;/Z5#Y2&\('%.%7LK6IA$O/L^R7 MY/S^!7ES(HVTR/GV6A_T2E^OC2;CA`Q_\"2@;6LA@/JG&BD9;W\!*R'O9M%( M&DT<=+]U)]W.N.5YF3+1\*'T/>=2'D7&OZJ,1H,1YUAJ_NPH;TI]BJ-:@P# M58^'0?:`F6WO9@U14#Y0+3,U3P9/'5&Y-/?.OV'P<@0+IW!C2'JHZ3G!!ZY M049XOJ!RVS"-R-$34UM=4FJQR8<$88D1X5! MC2%XZ(RZWXB0^JUC&H;RR.9DQLF@_>LO@Q[Y\I@>UL:@J`ZLA83E^^)'4?[M M`,W)$>91SY<%<1PFBFXT7P[&RCM]^N^;<\QPB"(<>IV@ MW%2/>I]USD2RC9(*LR[T/].\)V'B^*5F7.AYIKEF=W:)F>[ZG8NF*(I1.9KN M>QJ<:W(Z3VU"[BE(3JE505W:(],XF"!Z)^*31YW*\M_2`4QXPF7.BZ%[\"V? MN@N&D>R4I[^9JGRD]1(GD4/=AO(!?0HZ^\Q4>XSI]_F1KC3G#7DRTL?(_6X> MOG[R$/Y$8="_9'@^?G^[\6+\#_*K:?9EJI#.Q;&3&9^TF=[F,RJRKQ4=SLZ) MW.U0Y*\GO#MTM-RT^+3*'.8^N@OL[]@^(Z_^\I3;SBGD0[D)(P]%/W\@C=.8 MS#).80_>C5M,[$,HSR79*V=/)`M$VG\-#N'1P(%K0 MFR;3SV!499",LV+WOICQ?(@5,, M6QY\!N5!OC+4N5!H/_URL7PX1+'EQ)_.S(E)Y-`PNO%Z^1+Z'.H?M)G>?G]! M)#^9^I;.?P81RD=HCNGK+$CZSE+XVCQJ.KV%>766HSH/P9;X/X`0OYVYBOO= MP$/OOZ*UD/I';:>W<$_/LN1G0-C2_R]GIO\F>F9__XAE'E[SZ2W<4U6?"R(4 M6T;\"+(1'K&/HC:9RCR,Q-O@H.7T%N[16G83G`#84OX+S!$4+I=AD'E69\&= M\2!-:*0WO:/$YY&@X_3VDAZZ:GCV3S,VGSX=*\^/\9M0J"L&:I=:-S,G?LD( MGL8?YXZSRAY.58P_VSRKRAZ"?`X-HVNX(J M\X[:`QDA^'P1\>]T[A:PD69[:04>_8,ZFK\Z/J+1LDG;B:(U$>F_.7XJ$NJ4 M^@-9/:3L8W-;%9(%W-]$=\8CY"("E-Q`?91L""7:RX)N0/:5DKR6(#%VP0+R M^#`OCIRYS/9`UIJ27.5!X!LN+X>=NXAELE`%7"PV@S+\E.3>\=3YIL[+X=H! M"52E)"C34=FS]'CN?,NH+N.*KM;G/CTY`?/B[2?J!F62TI5Z91ALN!S9";>^ M1F$LTB((>D%9NG29*X%@QTUYF/2!+-O.N^NGU%+Q-0R]-^RS_"9TND,9UG2Y MK8K%GJM6>L="V=[*Z1Z*EK5+ODX+&@NK3))PB,U6#@X+^'F<*53.4TZ/Z1VLFJD47P58++MHY7QE MD0%6`U6*I6P8YEZT<-+S?1H363*.6RX1,C;>;&&6G).`I"]Z[&V*'K221P=' MF:6J'P:NE/451Y[>P:JT]*YH`V!M.!OV>9(+Y%-:+9*>TSM8'9C>:E``8X,V MK`!.[0J8WL'JMDJ+W73BYA19<*=]*>V(X"EZ!ZOP,O!D%H.SX4P>;B>:094Y MWS!:3^^@M5Y"%G'M]2P<%CRN"M$24D^JHZ;3.U@55RE.LD#8L"_W*>N&#O:Z M0=M9X<01F8\X/:9WL,JL4EP58+%!-!JAQ"$/`J_C1`%Y!,2MU2H*5Q&F&S2$YII?7&FGZ&CHLK MP6HV#'ZFA\MY.FA6\"Z:?FZ/;,F!XYD&L35O>H/#OPS+7UUCP:RSX-1;\ M&@M>#X$[UUCPLYX_O6LL^$7&@A]J@LD-/8@RM%ZF31RB*,LYHZP2YPUP0;'C MRH`LT)8?8LW3"[729!%&^%]"Y8RX(W"4>7EN,X#8H$QG@>S&<:K-XKP3<'1Y M5?;N0-B@2B_8?THU9P>T''HE=BZAV"#OELSG:5*-^AH]4K4%ZR-.96Z!P;(>;A'RB\_&@X04I^TXF;H->[RL*4.3XK4L<9#6! M:*"DWY,CL4''-R)\(#2D>6\?R!WOAUFB-SF?A?TN2=\G!6*#UF^P MRN*:=\>4Z)UQTO:2]'O,R=O@V;H#MG?%5N'AOC5T\LE27#RBU.&T*AY^];7+.82W6,E-DT58;%3TS8@=)Y38HM/^C+.`3IZIM_C.2A9!_;M+NIXVM-@< MQ??D$236M'!Z7%(23@&$'5,O665&[E`EJ?&@'72B31T&GDQ\Q[9+UIVIA&'F M%/-+_Y%(*GZ_D@="Y10RM*?[E6(YD5IKL3NBBL0D$O MZ/2EFOYK(AB[$^J24\5OLU)L?:7OG1B[5#V+_31!GL+EIC@"=))3'<9K0-HM M@DO66$OPEF<^=,92'4:66@K%+*4@"\!=XWG&UMN[#5/I;Z9_(]?6@B)\)<_O M.>JGRQ<4'^>N#_@3WP\\U+C_HPH!8=SJI6ZG=I?OD<#':XZ!^!X^XH8?NF MN.OS.,5Y*'*@-.B^J>)9'-$\=H>)%9X0E5N%;L;<7L">_5QF<3:O$(@=:MYM MI*Z4JR=M@7W^-7G)FKX-H1J<[.%2=@K[`8<&:+)6!L6&U"^B[.%27LL[`X<, M:#)<"8\-(2(*^:+E&UUU#.B``MU=KX/+CB@244)Y[4.`U1TZ"J'B.<"#9$-T M2=4P]J9$)NC'L1>"$BK?X+"O*8U<0(S$.8VSH]V>:*&$LS?U7EIE'C]D/E$" MM16KE3-H7FR!@)/,Z1M[.#6#EWGVL8Q+YGW M&$9$:DPC\D]#0A)F(=XRPS30D_^4P66!&7L]E12_=#E=G";QN7)X)_))S,W%F]_PCCZOVNPA+[G?_,_TYGDN:[W3BR[)E<.E6:P\M_=HVXD7CW[X M%G?)4HV0FP!ZB.[FHN<8>M+MZ@^J[P_*(J),G7QU`VV4NO_J!OH'=@,M:<%J MB-;\CYN(F8CY].@=1N$K)I?X_?HY1EXWV"42:Y%'PFM>^59^*>H/UA3_T)Y2 MK@Q]0"JXD\-CC"/B`R51<[&T55:QE&"?Y7]J-@O0EZ`3O!UL5J]L(2TZ&)H>X% MA^ZBR6.81G'J$#$MG"S0!$5+'.2@YA'*KF^N+:CD>,"NL^=9)E4I9(<`_!Q$ MR/%I\<&OY&U%23L('E"$7[.-`C$L_JX-/`!H_^XT1E!2)MPE;4ZODI#@+M]GO>I:-'%QMB`DX1TX2Y M`?D:%MY'PG[0KL::;%1="T<(&V0),,G_ENN&*=EN9+,A#ISP?:P\X+]_)+=Y&/: MT;+P;V56C.+0T/[1]2XF#2+8(..J*SR-V(>@7:\-&Q`T4-M0O)"#.*_[8,BH M*!BL@7[=NE9%"3H;=/OD(MZ\(5ON/U,<(4(#LB62]=!W`EI`A+J\K3C:7?U! MH#W#2S*:O6KT8%=^%7W)%TN`YC0&&W:Y/(81`>LBY&5U9)BX;'M1L=.R*)((EH3-, M`X,2^'4T-'&9>_O"G1)LS"UR6$;1FIR+69"M]EHXZ@^5'=W<(F``,F:.`<\I M<:8U<#GNL,J`C$4C0T>>I:N5GU''\;?1*MU@%D;+G$T*,4-J(TSO&I=7@KL* M-""9*R9N-+$$D7<=?)`3@[R59-53)-VF=\")(S2XPO()DZ.SP`EZ6ZJ6(A5: M0?;-IGKO2PE'\'+:=W,&K`RBP\00&K`^:X!EV MJ7DW]W*D$B0ALTN.O`F9P#VAU^_GWLRG4U$)!^5V`MAVE:C-QUAE6."M+&0/ M9W]6A&OI3B;D6)''6N>=1KSLW03S)&Q);GE_P+'KAS$YW4IL8HZXI_==V<.L MW&A:6]D(#M&VK#(OZ7[FC/(G2+.5O-R`TF9-/UR)]RKXDM:TJ]C1DH?>/+D69YF`- MC/;N'I?\F>N>1CC^O0&7&IT&%>*?R=0B6C--,9Y&V`_@,E.B+1^.2G?@RTM& M<<[%I8C,TBW7)5\)YOC%1P84)696ZMGL`.UQ@%YQ\E)+W28 MD?4&WH^Z].>[U2@`M71[3ISW.H3'@V%EDB*SL0FQD`-.91K0:UQ(&)9TQYV] MI0MWYTG5@`N%,1>U3%&\7B"7A8">6B"@MXX:?;F7@1"/I9LI,R`4LETT8$_Q MIZ3B/"+M#+##5(A:P/L%>?,#E[@& M;,L23M72GS.YM3!9^E.K.(LM_W%U=&SI*/GT9S6^?]KN'1*!KA< MYTTY,`OB!@]\T]5Y+^H&7)6O#,NL(K#04.@.H!5 MF'D"P.(L/.H;5J4_N6I M,UMU".!:A&68KP'-6'H=P,4@,,@?_YP3H)QS!7LLX$J"999'&8RPZ7<,N;PA MVA>Z-&")=:"":ZDI108CCHBH!E)(AR,+<+YL=+7C!;:[R.Z,CN`E[&KY3LR,>R M9>^7)B4HR9(%MCPOJ]$BYYFT#WAU/0VF*8'9JV0N>%>.""\('>D#]H'<7'Z8 MB;2;>%2I8*?0&[PR7JD[7`G6;@%,-:YLB4]H:O;E6&\ M`J0=TR]9E3=>X-6*VMT#[QJPT`7=*NS!)01[9;"9>LT"O6?ATA MGQ:)T#P&%$>`+F-7SB:C#&VW&"Y9`=AQHH`0B*:.SZH#JR\"24_HLG-EF*\` M:<=T&$4?1W!GAK9U@P[YD_[M/B77&XH5=GB%T:!KQ6D+^^5A[A;!)6OQ'AT< M9>^=0C*X@J>>]"&@U!^Z!ER94T`9V&X97+)2[S&,$)X'>?HALLXCA]Q^69`Y MW1O9CWZ>ZT_]:B@])G1UN%++I0K8W1*Z9#5?'[T5"!>%`?FKBPJ;17WEZ`X% M726NS((I@W&W3HSK"R_8"W-"*TC_H7PPN1GZ.';JYQC-4K^'9RBCE4)N/LV! M+LC/LC3`)J82/[IT"H[;2GQ6['Y!/I6:L&KSK00/J^8GO8,Y+FW(J#AV%\A+ M??(@V,UKDZY3NMUTAP`/NBZ1:5$#FZ6Q)#K)[6"VX1\F]V(EE\6F;,,Z\BS^ M`;:A0BH@F-WW1TE9M;\)"'=P@C(/I^.9EK@SE4>S(Z55.>"6;FIV,A?=?=ST M1%>TH-PZXZC2`X[?XX(27O$17/12WI-@,/K:ZG?_KS7I#OJM_L-PU.VWN\-6 MK]6>=+]U)]W.N.5Y.(=6*&%7>557GH%L)QC[@(G=4RQZE-4YPN0$63G^/L-$ MMKYX6!2[0^XKD^1F[45U$IC:F*<5V;2EE!BYW\W#UT\>PKF`0OYR+)>07TU[ M:.[XF5%WW7K'K!A41BL@S9(^)4.0NNH'[A)8O*.*=8((N0+&U+(HQSAWQ MQ)NH=Q\OR)3#8#Y>9:6#%PXY8%V4)MAU_';82SPQIQ2[`\7)*G)-'40C:R/+ MCU7VP[@K=(8"B7JM=)"5`-I+50Q31U.W.G-:L?`O(R`N\Z@;C]"7& M'G8BS$Q)H=H5*&*U#'-8EE`E@)8\Q+;6W5>4^1KD&M*BE+`UX?6612V.ARY/K8N][%5L]'Q?CTAW^:L M>HW>P*F0RN\&/8S&A$4#IUL=)FCR9>Y>U.@-G"Y)D9>Z9N@BO`;=00BI%WT(%,)^6IH!=P1J-*#!;#LB$S MY6,:!3BA=LK`>\3O]&^QE-O\3L!IBRHQ6XC*6!I+'R;9A1/,98+9K@UP=J'J MXE<1B3'&@5ZN&2+IOBRT@DX4=,`"`9?VL[5""'K"`5ZF2_E]66P'G1_HF!&< MN_!XRE8(.^]J["JV@\[KH\BNXRE;_MH46:O4.T.G[JE1]7"`T8:,S`I!;&76 MPKXW=!(?159JKH-#?)98ML;/3T^MT6^#QW'W:[_[V&VW^I-6NSUX[D^Z_:_# M0:_;/H.;8859J%O##'S$A+LA(R!9Y%[(:=X,FY89DK+,RWS85HB[`K_\^_63 M\X\P:OM.'$L>GAJC0#HD"GC)42AHX;)]0>P!]YVEW#"@.1)PJ11-5FNO%PYD MX#7#\S=RR$V>#`*^PH+5#-CH5X+XC//^%%,3W3?S64[>0IJ9A[148M1)^JPIJ#-909Y=(!*EAE@R#` M@#R%1WB^2/@6+UY38#N7&5ZQ<<'6RCY33AO(A6"'A\H6U7,0KY"+9QAY4AT?MP]TR00^KSB\ M%0%III)N.V6IFNZD(71)`S&Q67<>"X$%WBMZ3GU`=0G*'98'TS:F/[@T%SY8 M)<,A#P1\VD_7"AM621\^6$W#,2/8[#J972(6,4'8,6+W/$1K=32>7=QG%7KS9,2;E)8DW_IAX&;_R!ZTFD,,[V# M4<54V*:Z\&!-E(8$5U%-6)$H*^HWO6N4[D:%]U(\=KQ3"I5@Y3P^;3R]@U'= M5&`L&P2L'=30H;XIZ;JMY[JMQ+4*HYPQ65%/T7&N-,#T#C"]5\F#7!E8M)25Y_$@X,7JZ)Z_F\)F^H;W,>!,_A+[O1-53XYN= MCGJ8C\FOF8CW.5J$Q>D)`W]D_9H1`628VBS-@0(A&J0^MS';G3(;#KEW37%W M22GN](\OJ75!I2]0]$K)):T#RP;EIHA">VGJ5B"P*HX`%!.CQ4^.`4(98!-M MAFJSWSSI1`8*[8$@,YN7XWAIG)==+78O[`U'G6&K^[")\*X]*X#*Y]3?!3JC MF2FJC58.]C:*47&0/ZMM,^1[3:JQ=@P'W%5FKY^//-)?Y73KY'0#$1B-KO7# MFW(3A:JC;2=])_':0PK%:D>';/HVO($.X;6EGAS,]I#2KH@_[#<-#X(E2:^H MN2`,R-CQON0\-E`-5OH%=6E5,H`)`74[[+I0'EN"@P;Y*0=Q)'S]N20B6#'%[E(,=M# MBKPR'K%E)1X,"^+D=M#^%D:_=X-A%+HH5F+I00=(V;A$O$#> MUS#TE+AZT`&R?&5%KA[CL,'9?`>NCT2/TV(SH%Q,)CB8S]YR*25UO>4]K"TL:MLKG%EY M[VL4"M]M_$Y-K2&J("P*05GP.F>5W9,QFMNGJ=5$%?@LPF3#CMX62Z7AT]WE M*@I?LPQ;4EX+^S6UN*@"OV6X;'C-<^DC8[JX8U.KC"IP70JL-F7`&=E>B&M[ M0&36+LY81/[NHXQ7@==:AE&"_Y7]GDL3P0(Q]0G@!-%5EI)!$E2/=?^2+[J` M/#Z23=OFG#9B7:*H&W09U5J.F@TNI<=^JJI/(,_>07F7%675]7E575Y55U>59=VJBZ+ MPKB`Y<5F%ZR>/()AB6OU4^M_!Z/V\W@R>.J,R/W^K=-_&(SJEB8UOJHN1Y88 M%$"";(>!2U@99?,8X?AWF;S([M`,Z;`Y7#DT_\J\_W19;Z3 MM7&_GI!O2FHR"'H!2WFJ:UT-B3%A#C0?ZBE-R!>EI6T$O8"%/0G/5"^A(IP& MW405=%CI:N5CFH3O"*JT$(2D)[!-6L(ZCC)*"LD"SX,3<"HO=7XG8%MTY;.[ M"*21I96WJ5B[Y%FWHF^[("$R=Q+AEY0,P0V]DG0#-B:+V7#(.D4X3GO?\W`[\+M`V4FTN2;#8 MX'AS0I,ABN@OG#D29;D3=8.J$UR&S:IX:JM,?V9U91\EQ6+NK<#;KG$O+QYN M4$DI_9:Z:E)Y*%"3MJ"(N[I16S9(,Q27.@R1FK$5(#?HX6BS"E./)U>UYA]= MK2E8)??K3&!J^TX<2]2<&J,TQKBMOS_*H;5#-2K`O$?<=Y9R=:GF2,`J5$U> M:R\8#N1FUGXL"@RQ.%\CHRFP5#>4O!=11,?6I=(?6BM;\=#G`:8-B_!S5YV]AM3W* M[-1=#8<0FRC>'N/-@FH[[ZZ?TDAKFB?M#?L^[[Y6ZSV]A=$J562O)D(;'/$% ME"K$SA9C9,M=!IS!IK>P6JW:S@$1X.IW1!,BB8\!]U&B-E:'I;(Z M5"':DMNPVY^T^E^[][U.:SSN3,9GB"U6_:2ZO55WQ*O9]3QFUQ)\N5I?K];7 MJ_7U:GV]6E^OUM>K]?5J?;U:7YMD?86T2%RXK98'RG*%E#%[!*PA^&SF"&C; ML*%$B07M&8WH.40K6`KBCLVU,Q\PD,U^*31+4HQ,G/>AL\XT&>9T1OM!U;5" MIWU,E&4DHTJJA>];-$,+PZ0#2^`XF/A5B5(_CPX)?M607*Z&1'18B$0@1BO( MJHFB!J@WB:\MUHY3>Z>0V0QE">15I;A_("HFGW.&((H+)6_"^'#L^HMGG M.^\NC@O7GYRKDIZ0E1)5>2N'T$CWX$&R0%&&<2L\<@[+DX:0A0YE3.'.V(9' M7A&2?&LQ6D,6.%3=3NQIVV/];P^>.I/6WSOCVJW^^\NFJK5?<203K[W"MX1O MON-VS7CY:5"*=7`Q0%U?A?7SCT7VZ]O0NK?A>.$$7AC,QZL(!_/APB&;TD5I M@EW'%QN\Y#V!WI`L^C'.%:7Y6_`.V6WD5IHLPHA_`(D[0+XHY6>1=.YV."6< MPI-Z'_"Z`!NG^8Q29>P.1@.E`3=,@R1:YXS=_'#,T\VOI^T^ZX3=_2.PQ5E$ M]Z-#M3CE9H:O[$X1J3*4U1;RH2@_`473MN&=WYG-D)O@U_US8N0D:(3<,'"Q MGU=(:"6/B`!U_#'A#LW7N#YH+#@E#8P.9!86\IU]EIH!:Y-H=(B]'U)51DI( M1'9:YWV%@EBT=C1&@0IH+K%(-%'98(%Y0!%^=>C&Z(5Q/`CV/PNXS^\$%;Q< M@MEB$#9<'QK+N;M<.3C*"O008B"EIY+^J%!QS/4>!2R4L.DK>,+@;J*#62\, MYID_%=[DM[H-10I?4[<5:0QFPER4F7I[V'DA)W6")38C M9N-F&([TR,8U>C/`-4AE=$F1;(`2"Y>3[!-1#Y7MRZ'F@+7&9FQAL5I[O7`@ M-S-@+8_K>0S32"5YWKX=<)!J"?(S3GL&J,8HJ>KU$P"TS2D>S.Q9\[5&S?(6 M@+&5<6@F\180&,2JQ\.N?R&OQE_)?_)#16V`O(P,6B&^-, MD?,WIN>$K;2X`?4,@90)HHIO`\6'2 MD_D*<#N`&H`4ST0Y`ANR3X^3T/V]&\/R5=@2U_V@S5`F.#8;\SC]3 M\F;+4`4N(B=4!K.UI-Z'(@H9+&E#VH9&!NN[&.Z"'A[W'1Z"Q@A6X:? M+`"UV>+/;+9]Z(RZWUJ3[K?.V6RWJI]4-^#JCFC"BOOHX.B;XZ=YMB>RT3'] M%!D_I;>SV*BKTK<9-MX2E&5=?XJ`;3?TV6?W567LU0Q\-0-?S=`OTZ6450?MH"M['C."S:Z3*3?QFI*<'#V9:Y-J?U`+:KGC41N? M#<&Q0'Y0@.98+0[S7H*:8)MX$M3I)P.8^K@">]71-=+Q:1B%+D+>(Z''UA%D M,'M`+\D@VKB'!`,Z[4F8+=T<%=<.4&:PZ6USE3M2QI=&#.M#Q5D,G?<5SAWU M\K.)G$;S"&5*$2[/17VFMX#)K*JR5@;,!N\HX9W41V_9/Y6^P7<#3.\`\U75 M?74?H#0FW9E5_8W0:B=@%.XJ\6DN[#2]`_3[J;JUITJ-OTKKGJ*Y5]+,.V9?L/3;J4"PMT$CE![+AT3B-$D&-W M?STI"-ZB[M,[P+@#@^*W#..6Q7]I$HO)]%Q*\SDA0'X(3<)[M#^EN,R5=IS> M`48?5!:N5=!M&?KC!1_5A;R)>^_M?ABXTD(TDI[3N^8JU%0.;`5X6_Y_:9;$ MM7\K[-\1#^SDP<+VT[O+U'I)0>VU(1>\<9^#"#D^_A?ROCHX.$YZ*A*S)#VG M=Y>I#=.`MUL`-=12.'-PRG@R:/_ZRZ#WT!F-.W]]/D-L2B;K+$*?4##.%4T5 M0U,T!]2*3#'E:[2M6I[-]7Z=N?'RXE<4>C4CRHF;B*1X_OU!">40/M&$L>->CX( M%`BCN%!XDEA-E+!B89Z`H_08(3\C4[S`JTDH\0HO.1)PM$Q]JX*]"O6ITTQ7 M3`(`K:B\$20/.$(NZ1>+'0#Y/8"#;4JPA/%2$,*SP`O^_,&6,`__2G>,'CP[ M2K'!Q5G"%F[3Y+7V@N%`;N9U4#K.$K:H6PGRL[2\IZ`L./!WT23YFXX*2&%` M91[5\"=6/Z`PJ$J'N@R0'8%01^"DAS6S?5,"H'B<8C.8!\6*A]U>%S-T,#GE MVLX*)X*2QDK]H,.IN!QC,UB*Q12G?9@H$)00^,CK.%&`@SG_'2;N`!V0IPMD_6S[;C9S3Q`+)6P/%?M42;CG(K$^RFFOS"[JOLMZ2K-'@XIXDG.7 M]]0K!;&)<4[;Q,8LO33OI!;U@8INTF6E$I!&!C*UR#O1F:,G)_H=)<,(NX>^ MW5R_*W$WJ."D4GQ3P&)#ZF;.,9-Y+)DZE@6#004U&3Z5)0BMCVZJ+4P9*-:I MEDN;!?B5"YI0T7H\(S:-7])@&WCZJ M@"<3B'M!!4&5$@GD4!H9\_3DO-.L*"/TSY0(GMY!(,@6T3B-5GX:%X!-PA&: MXSBA05T;)36/Q<8^`!4W56HU&$4-&TE5C^Z_M5I%X2K"3L*,N5+I!A5Q5?:< MEV&!C:_BQ4321`M^[F-&WJG9+94A?@PC`BB-R&]SOP+>`:`^`E0,5:D=K@>K MQM@I9@3&)SKA%R(XD!_^/U!+`P04````"``33$Y"3']1BS80``"ZI0``$0`< M`&-Y:6'-D550)``.%]1Q1A?4<475X"P`!!"4.```$.0$` M`.U=W7/;-A)_OYG^#SR_7&\FLF([R36>.!U:'PZOLJ23:#?I2PY9]QCRDC@7QR='+\^ M,K#O!"[QIQ='-W:W\=/1SQ]_^-N'OS<:GR]'/:,=.-$<^Z%Q#303@EWC@80S MH_-GXY;@!TR-VUB6`:*.WQ[_9,!'>Q91YJ*G5T87W]$(T2?CY,TKX_3UR9GQ M^MWYZ;OS-^\,\]IH-'A/S)GA.3)"1*'XRYD/K!G3>QA,4>>'%T1\1\L0XCPS0U&?GSA.9 MJ@@3U&N$#V?'`9T"R>N3YN?KWEB,,Q7K$?_K&O7C'?52^K,F;[Y##*?DO-4- MEPQ9XK?-N'%)ZE7(_=P#P5FAI(*8^"Q$OK,:1&'0B8HG[]^_;XK6E-3'4Q1B MMU3X^R8-/-Q,R%*NB#6F""V67!/$[@1'TB"FN_'ZI+&<\',GB/R0/JW/#,/. M\32X;R:-,K:(4EBW97Q)JX31Q43.`PT2CN5R(&](F'W$3B!I`A2EQEGR;F1(& M;GF0[P9CR#"B&48&2$?FGD)J="( M87?@?Q2?`3#&1\$)N&U)N!(2&<=*H!J]@SPG\LH[:*[-][8`C$$%<1H,)EWB M@]4CR!L&3(RSY2'&DD.!0Z!(*P?A%&9^*0`^MP;]=J<_[K3YI_&@9[5-&[Y< MFCVSW^H8XT^=CGV`HCB]0P0F.ISAD,"HZN"RSB@'Z6P+D(P?UR3_\\6"9H$_ M.,<%2)*?Y1/^1FW"QS;\<]WIV\:@:PR&G9%I6]#^8J=Z/(,E-PL\%YSHSA\1 M6'#3=P>P!&DKF(.^,^PS\'(69V ML#P;EM/&^BB,*!Y,!@M,Q2A8C$%F&.%S!@@"^#T979MWX3ELLP M^VUC.++Z+6MH]@RS95NWEFUU7IA%*Y_F2\0(&TR&&47!1HW)U(>SW$%^:#KB MDD?\Z3#PB$-`#GX,+[W`^;H)PIUDR\'^*0_V^.;ZVAQ]$?;/NNI;7:MEPAXT M6ZW!3=^V^E?&$+9HZX#X$A6`8X&(VWE-W"^R_V^A8@G;+.G:LB2`W92V$APH[)?P7[BWKW]11R0W%<< MC3KC@U%<3;@#_\9^XXBPK]N!MEF&'*^S/%[7YK\'(Z-U`S>TZ\Y(;#FP MFNW!Z`!8>A*%R)^2.P]O[7^HB)##]:9XIMEF_\JZ['4, MMX"GA$N.R-L\(K;YV1B:7TR`Y`!#NMYYT&@[,"IYY9"\*VZ2%A@SCLSA:I7. MJ[CQ]`BZ(QZ,&F]CQE1$R!$JQD'L3W#8]"SSTNJ]N%!@^0RW,27WT#V/NW*W M3/P(SO4G[$Z)/S7!3;O?%KV=9,MA+40\VIV1=6O:UFUGA:UP*6[ZHX[9LW[K MM(TKT^H?\(XQ&8$Z[!;CJ@N1(%F(:AX#]\\0.TQ^>,SZY[$.*]6DA M3J(>IS1^3&6_L">!*\*Q+(>E!OA`*\9,/P)/)ZY!X+#S,^R[+'6![.S0QRX`H1H%B0(209 MP<1(9<4)R:FT%P]0XI(/NAF'?.6/I^ZXTD[<190Z])@/KJ^!$%9AU6.9"'*4IK+=`"P#,`^#GM@J.`V-B+3 M&8]@#B,*#ASC[\J%$J.YF4$.5B'6`H(,+HG?!`TA2UC,I30C%O?B$5J%#N/( MH:J]5.:3XR5)JI&&,`\[JP0W&ST.T1./(>:1R;3(Y[X0+`$.(V%Y\?,:)W>) MW"[%?;"!7HY!(;:132H[K/K2J#%/[%KF_JA%B!58Y!@58@^YM+(#3&4PK1*U MZF&ES"<%[$TAN*":,'8`LBP^G,G3BK.TU&+!BFQR&(N)(Y)LL?_[SU.^@TO'CW$M)N.2*2DP" M\?PL)!VG(I*Z.-7UF4"("$T0S)KIX(^:>]`')KRN/NL8::6-A^[J:@,LV--. M$5C7=17);87]JM-,ZR3!IU7U)&@`30(:&KZT?EM96;*X]%LO<(28"A;^K9'R M-?A/C9/3QMG)\2-SXX'5Z'^I484I] MITSB4[W>-Q5O5#%&'J5K7-PBO>=&\.3=+B-0-(69WL-=>ZZN/Z@ZFJR4SDI( MO<%5%J!4614I#_]0;S=65T=4FH8\UP[`R&LZUAM$X/>W&4=U(K'G\!OQIU:(Y_PJ=&2@A.KB**01 M=T8%%;A_)'!MP>=&-+F!^L3S>`0SI641,),PXJU7_'Z;=D)`/&AK%-3]%?/' M!-@U[S%%4PR0W6'*7X]P3-]M$R_B.2N\KAD;1"'W]WAE8HG^.\K19T):W*7U M8G]],+$8BWC23N!\O45>A+L!'>$PHM"4?98CIJ`V9U;I>0"F%-$GF=H3Y+$- M>L=M=\CC8X#Q4.R2\%FG8ZN9V#`)3"R0+:=@#[H&TWQK$<^W&%Q\MZ^UP&9#1-QVQ#?H4/0-B$JLP49*??9[ M/_`=7AHPSG[/OK0KT4N%6!_5Q#)TXF6(73B&J-A[P621W[`;*;\'4U6O))D$ MW6T%Z(/X3L7>MIB#C(1X$N)"X>=A^OLWM.7519AD1DN911_`:Q:M4M)37U#7 MWD>2(%C2K@]<5?5;BAKH"X3P:$W7Q2Y/O`@\XCS)M*DFTTPG7O2+V[L;.)9H MB(C/CW7+%[+#/BG7=EL!FLU#Z>NWZ7M*$RQ>XY.?'K5Y-=,>O%2X MR?JM)*";S3`JT5F90S--84MBEF1`E2I71:29/CN_'RF+ZNQ/ICZ'T(!.D4_^ M3*M>#&$L#ED@;W69L5X&<[#MW^Q.-X.!!OYTO!`WZQF"A>;@2/R)C%;0 M"]V"9LH<&FFY><'UX"SEHV.UEFF&2Y_].(0%S"/&4U[^_L''E,W(PO+'((BX M!*W>=XJ/6!7J!$K`<1&3:V"5-[[F7&E_:W#K@^Q>7A2NG):]R-5GPB1EEW)' M42F%CD=/'.,>^+A@E`LM&AG?>&SV0U`RZDR+?J.>45PVVVMM&HT\^^X/DSHF MA5:-1A_/;3>(:,FT9YLT&G?J%GUQPE9`%Z5N4ZY=(PUZ3Y]@?+_`?XG'VB-S M_K9_<0EM(-1(IZ)YESEZE53ZG&9KX2]>NJ$L-!:WZ>BT[:/*1:4#L]\.],$^ M%Q7*JIEW:3:3ZNC;5(Q:MF75R+\/_)+%R7WH.-LEM[>WX,TJ[F*'S,%5__:[ M7Z7F2>7NKB=`'_1S3T'S.U;>K.,NS8U4MC/+2?3!8V.EE\I5N)%''T5E%6MS MBZ^<1,<%*!FM;!%6D^F#CWJE&^45^?T%LVJ7C:D^([:7IN/DU*C!4CDM6\G1 M9T+B!&!N;UT,!XN+1?EF&-)=!-L\N_4W4F:5(GZ(IYA^,]\H'>PM#%2NQK)E MUV''K]?M)S,N*0`C[E'7Z+\!'4>+A4?PF@:55%EM=DP`W.=NVU@ZIW*/U>#6 M9V?E"VD#%V-PQ_`BGE)_%03N`_2Q=K:J,>P,\7+%YE(\]Y:`7+\23R7\]87H MLPIDI6\JE961Z:..R#/)>[K9'W7T;<7X9-YLOD&?>1;)O-FDGNSC\V+;LYF$ M_65]9[9S^F?N>""QMBU09M8'S,R8BY?$?)..&Z@J-:56'HN&3S(R",@OO+)F MC=;6?($(Y3\,)CV8=9YYX<;^0U:+*JH]NHS/[U`H5,RJS@^LPZ\/S/F_/UG( M_).W:VE,'.PCZ$26;B%IT\A4Y"=9FMM63J//:DKOP*OEWPK$8UH@`9^"4_*7 M3XB+TSX+UV=UUET?F>SQ?IUYZY._[,J%Q>\ZI]_D;XB6T:X!6O^5V#TJ5K]* M7:61K"]$G[7=A8-./+0?3)9_*2GS5U\+#W65R'6VH[($,$F;1G9TPYQ+'TLK ML^BS$H91.V`QPB0:3-KX+!S3^.[66/Z!@)^U`O'D?6Y?UEW2VX?\. MW+G.XX+$?<2OG,-QDKY@GYV`:K*U+=([P(HE(#B:9DZ.`Z0:Z'4^4 M9RJR()(AD'@/=83YGG)6F,A/S&H.K9#+YNG',-C!)5[AE-50@38QLULFA^W1 M)5AME=4V:J_GOY23K"$$OVCP!*'X9[ZWR,*O*T.?PV3MJ1O%#G_D5CCVJX@T M.O]Y4B!_9O@$M@'3>]R-?'>UM=;*7503[K;9]JG2-7HD\V@^PK"J*';7#$6J MQ#BB"R]B&5WL8(2GA(486%IH04*4?1ZT1YGZ3-3RU003AEKU$D"10J,5+'T6 MGFRX38_,EV19X[((&-BA>VQ]X^?F2;+C-:)?<3B$'ILHU]:<."W_ M0JV:<0&ZCS_\[7]02P$"'@,4````"``33$Y"ASPD_9)S```*+@0`$0`8```` M```!````I($`````8WEI9RTR,#$R,3(S,2YX;6Q55`4``X7U'%%U>`L``00E M#@``!#D!``!02P$"'@,4````"``33$Y"A:6&!,<)``!&>P``%0`8```````! M````I('=&UL550%``.%]1Q1=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`$TQ.0LQVV?I>)0``FGT"`!4`&``````` M`0```*2!\WT``&-Y:6`Q0````(`!-,3D)BY'?,5$T``.W2!``5`!@````` M``$```"D@:"C``!C>6EG+3(P,3(Q,C,Q7VQA8BYX;6Q55`4``X7U'%%U>`L` M`00E#@``!#D!``!02P$"'@,4````"``33$Y"EU;5$%XM``"V)@,`%0`8```` M```!````I(%#\0``8WEI9RTR,#$R,3(S,5]P&UL550%``.%]1Q1=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`$TQ.0DQ_48LV$```NJ4``!$`&``` M`````0```*2!\!X!`&-Y:6'-D550%``.%]1Q1=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``'$O`0`````` ` end XML 50 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended
Sep. 09, 2011
Feb. 28, 2011
Jan. 01, 2006
Dec. 31, 2012
Mar. 31, 2012
Dec. 31, 2012
Additional Paid-In Capital [Member]
Dec. 31, 2012
Additional Paid-In Capital [Member]
L.Y. Hong Kong Biotech Limited
Dec. 31, 2012
Retained Earnings [Member]
L.Y. Hong Kong Biotech Limited
Sep. 09, 2011
Patent (U.S. No. 6,475,531 B1)
L.Y. Hong Kong Biotech Limited
Feb. 28, 2011
Patent (U.S. No. 6,475,531 B1)
L.Y. Hong Kong Biotech Limited
Sep. 30, 2012
Independent Directors
Mar. 31, 2012
Independent Directors
Class of Stock [Line Items]                        
Issuance of common shares to independent directors, value                     $ 50 $ 22,222
Common stock shares issued to acquire patent   44,254,952               44,254,952    
Consideration for patents acquired 2,765,992 32,748,665             2,765,992      
Statutory reserve fund     10.00%                  
Maximum Statutory reserve fund to registered capital     50.00%                  
Statutory reserve       $ 956,633 $ 956,633              
Cancellation of issued stock for return of patent (in shares)           0 32,704,410 32,748,664        
XML 51 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)
Total
Preferred Stock Series A
Common shares
Additional paid-in capital
Statutory Reserve
Accumulated OCI
Retained Earnings
Beginning Balance at Mar. 31, 2012 $ 41,690,997 $ 22,500 $ 73,780 $ 36,879,643 $ 956,633 $ 3,341,156 $ 417,285
Beginning Balance (in shares) at Mar. 31, 2012   45 73,780,610        
Issuance of common shares to independent directors (in shares)     50,000        
Issuance of common shares to independent directors 5,000   50 4,950      
Net income for the year 2,252,710           2,252,710
Foreign currency translation adjustment (40,878)         (40,878)  
Ending Balance at Jun. 30, 2012 43,907,829 22,500 73,830 36,884,593 956,633 3,300,278 2,669,995
Ending Balance (in shares) at Jun. 30, 2012   45 73,780,610        
Net income for the year 6,170,105           6,170,105
Foreign currency translation adjustment (128,779)         (128,779)  
Ending Balance at Sep. 30, 2012 49,949,155 22,500 73,830 36,884,593 956,633 3,171,499 8,840,100
Ending Balance (in shares) at Sep. 30, 2012   45 73,780,610        
Cancellation of issued stock for return of patent     (44,255) (32,704,410)     32,746,665
Cancellation of issued stock for return of patent (in shares)     (44,255,087) 0     32,748,664
Net income for the year 4,648,852           4,648,852
Foreign currency translation adjustment 474,863         474,863  
Ending Balance at Dec. 31, 2012 $ 55,072,870 $ 22,500 $ 29,575 $ 4,180,183 $ 956,633 $ 3,646,363 $ 46,237,617
Ending Balance (in shares) at Dec. 31, 2012   45 29,575,523        
XML 52 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORY
9 Months Ended
Dec. 31, 2012
Inventory Disclosure [Abstract]  
INVENTORY

NOTE 4 - INVENTORY

 

Inventory consists of finished goods, work-in-process, and raw materials. No allowance for inventory was made for the three months and nine months ended December 31, 2012 and 2011.The components of inventories were as follows:

 

  Period Ended 
  December 31,
2012
  March 31,
2012
 
Raw materials $1,112,873  $272,873 
Work-in-progress  668,309   414,390 
Finished goods  779,870   1,291,225 
Total Inventories $2,561,052  $1,978,488 
XML 53 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Useful Lives of Property and Equipment (Detail)
9 Months Ended
Dec. 31, 2012
Buildings | Minimum
 
Property, Plant and Equipment [Line Items]  
Useful lives of property and equipment 30 years
Buildings | Maximum
 
Property, Plant and Equipment [Line Items]  
Useful lives of property and equipment 35 years
Machinery, equipment and automobiles | Minimum
 
Property, Plant and Equipment [Line Items]  
Useful lives of property and equipment 7 years
Machinery, equipment and automobiles | Maximum
 
Property, Plant and Equipment [Line Items]  
Useful lives of property and equipment 15 years
Furniture and Fixtures [Member] | Minimum
 
Property, Plant and Equipment [Line Items]  
Useful lives of property and equipment 7 years
Furniture and Fixtures [Member] | Maximum
 
Property, Plant and Equipment [Line Items]  
Useful lives of property and equipment 10 years
XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 111 170 1 false 28 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.yctgroup.com/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.yctgroup.com/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEET false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.yctgroup.com/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://www.yctgroup.com/role/StatementOfIncome CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS false false R5.htm 005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.yctgroup.com/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY false false R6.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW Sheet http://www.yctgroup.com/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW false false R7.htm 007 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsNatureOfOperations ORGANIZATION AND PRINCIPAL ACTIVITIES false false R8.htm 008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 009 - Disclosure - PREPAID ACCOUNTS Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock PREPAID ACCOUNTS false false R10.htm 010 - Disclosure - INVENTORY Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsInventoryDisclosureTextBlock INVENTORY false false R11.htm 011 - Disclosure - PLANT, PROPERTY AND EQUIPMENT, NET Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock PLANT, PROPERTY AND EQUIPMENT, NET false false R12.htm 012 - Disclosure - CONSTRUCTION IN PROGRESS Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsConstructionInProgressDisclosureTextBlock CONSTRUCTION IN PROGRESS false false R13.htm 013 - Disclosure - MAJOR CUSTOMER AND VENDOR Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsConcentrationRiskDisclosureTextBlock MAJOR CUSTOMER AND VENDOR false false R14.htm 014 - Disclosure - INTANGIBLE ASSETS, NET Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock INTANGIBLE ASSETS, NET false false R15.htm 015 - Disclosure - TAX PAYABLE Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsTaxDisclosureTextBlock TAX PAYABLE false false R16.htm 016 - Disclosure - INCOME TAXES Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock INCOME TAXES false false R17.htm 017 - Disclosure - OTHER LIABILITY Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock OTHER LIABILITY false false R18.htm 018 - Disclosure - DERIVATIVE LIABILITY AND UNREALIZED GAIN Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock DERIVATIVE LIABILITY AND UNREALIZED GAIN false false R19.htm 019 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock STOCKHOLDERS' EQUITY false false R20.htm 020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R21.htm 021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R22.htm 022 - Disclosure - INVENTORY (Tables) Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables INVENTORY (Tables) false false R23.htm 023 - Disclosure - PLANT, PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables PLANT, PROPERTY AND EQUIPMENT, NET (Tables) false false R24.htm 024 - Disclosure - INTANGIBLE ASSETS, NET (Tables) Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables INTANGIBLE ASSETS, NET (Tables) false false R25.htm 025 - Disclosure - TAX PAYABLE (Tables) Sheet http://www.yctgroup.com/role/NotesToFinancialStatementsTaxDisclosureTextBlockTables TAX PAYABLE (Tables) false false R26.htm 026 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureORGANIZATIONANDPRINCIPALACTIVITIESAdditionalInformation ORGANIZATION AND PRINCIPAL ACTIVITIES - Additional Information (Detail) false false R27.htm 027 - Disclosure - Useful Lives of Property and Equipment (Detail) Sheet http://www.yctgroup.com/role/DisclosureUsefulLivesOfPropertyAndEquipment Useful Lives of Property and Equipment (Detail) false false R28.htm 028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformation SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) false false R29.htm 029 - Disclosure - Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars (Detail) Sheet http://www.yctgroup.com/role/DisclosureExchangeRatesAdoptedToTranslateAmountsFromRMBIntoUnitedStatesDollars Exchange Rates Adopted to Translate Amounts from RMB into United States Dollars (Detail) false false R30.htm 030 - Disclosure - PREPAID ACCOUNTS - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosurePREPAIDACCOUNTSAdditionalInformation PREPAID ACCOUNTS - Additional Information (Detail) false false R31.htm 031 - Disclosure - Components of Inventories (Detail) Sheet http://www.yctgroup.com/role/DisclosureComponentsOfInventories Components of Inventories (Detail) false false R32.htm 032 - Disclosure - Components of Property and Equipment (Detail) Sheet http://www.yctgroup.com/role/DisclosureComponentsOfPropertyAndEquipment Components of Property and Equipment (Detail) false false R33.htm 033 - Disclosure - PLANT, PROPERTY AND EQUIPMENT, NET - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosurePLANTPROPERTYANDEQUIPMENTNETAdditionalInformation PLANT, PROPERTY AND EQUIPMENT, NET - Additional Information (Detail) false false R34.htm 034 - Disclosure - MAJOR CUSTOMER AND VENDOR - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureMAJORCUSTOMERANDVENDORAdditionalInformation MAJOR CUSTOMER AND VENDOR - Additional Information (Detail) false false R35.htm 035 - Disclosure - Net Land Use Right and Purchased Patent (Detail) Sheet http://www.yctgroup.com/role/DisclosureNetLandUseRightAndPurchasedPatent Net Land Use Right and Purchased Patent (Detail) false false R36.htm 036 - Disclosure - INTANGIBLE ASSETS, NET - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureINTANGIBLEASSETSNETAdditionalInformation INTANGIBLE ASSETS, NET - Additional Information (Detail) false false R37.htm 037 - Disclosure - Tax Payable (Detail) Sheet http://www.yctgroup.com/role/DisclosureTaxPayable Tax Payable (Detail) false false R38.htm 038 - Disclosure - INCOME TAXES - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureINCOMETAXESAdditionalInformation INCOME TAXES - Additional Information (Detail) false false R39.htm 039 - Disclosure - OTHER LIABILITY - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureOTHERLIABILITYAdditionalInformation OTHER LIABILITY - Additional Information (Detail) false false R40.htm 040 - Disclosure - DERIVATIVE LIABILITY AND UNREALIZED GAIN- Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureDERIVATIVELIABILITYAdditionalInformation DERIVATIVE LIABILITY AND UNREALIZED GAIN- Additional Information (Detail) false false R41.htm 041 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Detail) Sheet http://www.yctgroup.com/role/DisclosureSTOCKHOLDERSEQUITYAdditionalInformation STOCKHOLDERS' EQUITY - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_FairValueInputsOfferedQuotes had a mix of decimals attribute values: 0 2. Element us-gaap_InterestPaid had a mix of decimals attribute values: 0 2. 'Monetary' elements on report '040 - Disclosure - DERIVATIVE LIABILITY AND UNREALIZED GAIN- Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Process Flow-Through: Removing column 'Feb. 11, 2013' Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Feb. 29, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 30, 2011' Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2012' Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW cyig-20121231.xml cyig-20121231.xsd cyig-20121231_cal.xml cyig-20121231_def.xml cyig-20121231_lab.xml cyig-20121231_pre.xml true true XML 55 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
INCOME TAXES - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended 7 Months Ended 12 Months Ended 3 Months Ended
Dec. 31, 2012
Dec. 30, 2011
Dec. 31, 2012
Dec. 31, 2011
Mar. 31, 2012
Sep. 30, 2012
CHINA
Mar. 31, 2012
CHINA
Dec. 31, 2012
Shandong Spring Pharmaceutical
Income Taxes [Line Items]                
Income tax at statutory rate     25.00%   25.00% 25.00% 25.00% 25.00%
Tax difference amount caused by expenses           $ 1,106,378 $ 1,382,973  
Expense associated with the recognition of a contingent obligation     1,106,378     4,425,514 5,531,892  
Tax difference amount caused impairment loss             7,920,122  
Impairment loss         31,680,487      
Income tax provisions $ 258,827 $ 1,112,777 $ 1,585,251 $ 2,283,837        
XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Dec. 31, 2012
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

 

The consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

Principles of consolidation

Principles of consolidation

 

The consolidated financial statements include the financial statements of China YCT, Landway Nano and its wholly owned subsidiary, Shandong Spring.  All inter-company transactions and balances are eliminated in consolidation.

Use of estimates

Use of estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include: the valuation of inventory, and estimated useful lives and impairment of property and equipment and intangible assets.

Cash and cash equivalents

Cash and cash equivalents

 

For the purposes of the statement of cash flow, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Inventory

Inventory

 

Inventory is primarily composed of raw materials and packing materials for manufacturing, work in process, and finished goods. Inventories are valued at the lower of cost or market with cost determined on a weighted average basis. Management compares the cost of inventory with the market value and an allowance is made to write down the inventory to market value, if lower than cost.

Property and equipment

Property and equipment

 

Property and equipment are stated at cost. The cost of an asset is comprised of its purchase price and any direct attributable costs of bring the asset to its present working condition and locations for its intended use. Depreciation is calculated using the straight-like method over the following useful lives:

 

Building30-35 years
  
Machinery, equipment and automobiles7-15 years
  
Furniture and fixtures7-10 years

 

Expenditures for maintenance and repairs are charged to expense as incurred. Additions, renewals and betterments are capitalized.

Intangible Assets

Intangible Assets

 

(i)  Land Use Rights:

 

All land in the PRC is owned by the government and cannot be sold to any individual or company.  However, the government may grant a “land use right” for occupying, developing and using land. The Company records land use rights obtained as intangible assets at cost, which is amortized evenly over the grant period of 50 years.

 

(ii)  Patents:

 

In March 2010, the Company purchased one patent from Shandong YCT Corp.  The patent is the Company’s exclusive right to use an aglycone type and purification method of biotransformation in the gingko product manufacturing process for a period of 20 years from the patent application date.  The patent was recorded at cost when purchased, and is being amortized over the shorter of its remaining legal life, 16.5 years, or its useful life, on a straight-line basis.

 

In October 2011, two patents were transferred to the Company based on a purchase agreement signed with Jining Tianruitong Technology development Company, Limited on October 26, 2010; which are “Treatment to ischemic encephalopathy and its preparation method” (ZL200510045001.9) and “Chinese herbal medicine compound to treat renal insufficiency and its preparation” (ZL200710013301.8). The patents were recorded at cost when purchased, and are being amortized over the shorter of the remaining legal lives, 13.75 years and 14.95 years, respectively; or their useful lives, on a straight-line basis.

Revenue recognition

Revenue recognition

 

The Company’s revenue recognition policies are in compliance with Staff Accounting Bulletin (“SAB”) 104, included in the Codification as ASC 605, Revenue Recognition. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as customer deposits.

Impairment of long-lived assets

Impairment of long-lived assets

 

The Company reviews and evaluates the net carrying value of its long-lived assets at least annually, or upon the occurrence of other events or changes in circumstances that indicate that the related carrying amounts may not be recoverable. Per ASC 360-10-35-21, a long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Per ASC 360-10-35-17, an impairment loss shall be recognized only if the carrying amount of the long-lived asset (asset group) is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group).

Income taxes

Income taxes

 

The Company accounts for income tax under the asset and liability method as stipulated by ASC 740 formerly Statement of Financial Accounting Standards (”SFAS”) No. 109, “ Accounting for Income Taxes ”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred Income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company did not recognize any deferred tax amount at December 31, 2012 and March 31, 2012.

 

China YCT International, Inc. is a holding company of Shandong Spring Pharmaceutical Co., Ltd and does not have any operating activities. Although the contract for the acquisition of the US patent acquired in February 2011 from LY Research Corp. was executed by the holding company, in substance, the patent was acquired by the Company’s operating entity in China. Therefore, the patent related income or expense does not result in any US income tax liabilities.

Value-added tax

Value-added tax

 

Sales revenue represents the invoiced value of goods, net of a Value-Added Tax (“VAT”). All of the Company’s products that are sold in the PRC are subject to a Chinese value-added tax at a rate of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing their finished product.

 

The Company recorded net VAT Payable in amount of $369,944 and $225,223 as of December 31, 2012 and March 31, 2012, respectively.

Research and development

Research and development

 

Research and development costs relate to the Company’s developing its intellectual property. Research and development costs are expensed as incurred. The costs of material and equipment that are acquired or constructed for research and development activities and have alternative future uses are classified as plant and equipment and are depreciated over their estimated useful lives.

 

The research and development expense for the three months ended December 31, 2012 and 2011 was $723,790 and $183,693, respectively.

 

The research and development expense for the nine months ended December 31, 2012 and 2011 was $1,272,490 and $577,514, respectively.

Advertising costs

Advertising costs

 

Advertising costs for newspaper and television are expensed as incurred.

 

The Company incurred advertising costs of $158,750 and $157,712 for the three months ended December 31, 2012 and 2011, respectively.

 

The Company incurred advertising costs of $759,866 and $390,452 for the nine months ended December 31, 2012 and 2011, respectively.

Mailing and handling costs

Mailing and handling costs

 

The Company accounts for mailing and handling fees in accordance with the FASB ASC 605-45 (Emerging Issues Task Force ( EITF ) Issue No . 00-10 , Accounting for Shipping and Handling Fees and Costs ). The Company includes shipping and handling fees billed to customers in net revenues. Amounts incurred by the Company for freight are included in cost of goods sold.

 

For the three months ended December 31, 2012 and 2011, the Company incurred $218,820 and $1,475 mailing and handling costs, respectively.

 

For the nine months ended December 31, 2012 and 2011, the Company incurred $765,413 and $662,629 mailing and handling costs, respectively.

Stock Based Compensation

Stock Based Compensation

 

The Company measures compensation expense for its non-employee stock-based compensation under FASB ASC 718.  The fair value of the stock issued is used to measure the transaction, as this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense.

Net income (loss) per share ("EPS")

Net income (loss) per share (“EPS”)

 

Basic EPS excludes dilution and is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock (convertible preferred stock, forward contracts, warrants to purchase common stock, contingently issuable shares, common stock options and warrants and their equivalents using the treasury stock method) were exercised or converted into common stock.

 

There are nil and 31,610,679 common stock equivalents available for dilution purposes as of December 31, 2012 and 2011, respectively.

Risks and uncertainties

Risks and uncertainties

 

The Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in the North America and Western Europe. The risks include political, economic and legal, and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

For certain of the Company’s financial instruments, including cash and cash equivalents, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

As of December 31, 2012, the Company did not identify any financial instruments that are required to be presented on the balance sheet at fair value other than those whose carrying amounts approximate fair value due to their short maturities.

Foreign currency translation

Foreign currency translation

 

The accounts of the Company’s Chinese subsidiary are maintained in the RMB and the accounts related to the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification (“ASC”) Topic 830 “Foreign Currency Matters,” with the RMB as the functional currency for the Chinese subsidiary. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders’ equity is translated at historical rates and statement of income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, “Comprehensive Income.” Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statements of income.

 

Translation adjustments resulting from this process amounted to $3,646,363 and $3,341,156 as of December 31, 2012 and March 31, 2012, respectively.

 

The following exchange rates were adopted to translate the amounts from RMB into United States dollars (“USD$”) for the respective periods:

 

  December 31,
2012
  March 31,
2012
  December 31,
2011
 
Quarter End RMB Exchange Rate (RMB/USD$)  6.2855   6.2943   6.3009 
Quarterly Average RMB Exchange Rate (RMB/USD$)  6.2992   6.3933   6.3403
Recent accounting pronouncements

Recent accounting pronouncements

 

In July 2012, FASB issued an amendment to the FASB Codification Topic 350 – Testing Indefinite-Lived Intangible Assets for Impairment. The objective of the amendments in this Update is to reduce the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-lived asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles – Goodwill and Other – General Intangibles Other than Goodwill. The more likely-than-not threshold is defined as having a likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company decided to adopt the amendment for the year starting with April 1, 2013. The Company does not expect the adoption of this pronouncement to have a significant impact on its financial condition or results of operations.